<SEC-DOCUMENT>0000897101-23-000192.txt : 20230509
<SEC-HEADER>0000897101-23-000192.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160603
ACCESSION NUMBER:		0000897101-23-000192
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Electromed, Inc.
		CENTRAL INDEX KEY:			0001488917
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411732920
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34839
		FILM NUMBER:		23901917

	BUSINESS ADDRESS:	
		STREET 1:		500 SIXTH AVENUE NW
		CITY:			NEW PRAGUE
		STATE:			MN
		ZIP:			56071
		BUSINESS PHONE:		952-758-9299

	MAIL ADDRESS:	
		STREET 1:		500 SIXTH AVENUE NW
		CITY:			NEW PRAGUE
		STATE:			MN
		ZIP:			56071
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>elmd230506_10q.htm
<DESCRIPTION>FORM 10Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:elmd="http://electromed.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_elmd_electromed.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20220701_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001488917 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNi0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_D%2D%2D\XBRL JOB\2023\Q2\04 APRIL\AFPI\iXBRL__Electromed, Inc__03%2D31%2D2023__230506__10Q\In Process\XFR\3\a230506__10q.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityCentralIndexKey">0001488917</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:CurrentFiscalYearEndDate">--06-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:IncomeTaxReceivable" contextRef="AsOf2022-06-30" id="xdx2ixbrl0063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2021-07-012022-03-31" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="elmd:LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="From2022-07-01to2023-03-31" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-012022-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-05-26_srt_BoardOfDirectorsChairmanMember" id="xdx2ixbrl0804" decimals="INF" unitRef="Shares">3000000</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-07-01to2023-03-31" id="xdx2ixbrl0849" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0850" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0870" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y2M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl0888" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y4M24D</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="elmd-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_InternationalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">elmd:InternationalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_InternationalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">elmd:InternationalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_InstitutionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_InstitutionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_InstitutionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_InstitutionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_InternationalOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_InternationalOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_InternationalOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_InternationalOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_CommercialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_CommercialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_CommercialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_CommercialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicaidMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-30_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CapitalStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elmd:CapitalStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AuthorizedSharesUndesignatedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elmd:AuthorizedSharesUndesignatedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_us-gaap_EmployeeStockOptionMember_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488917</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="text-align: center; margin-top: 0; margin-bottom: 0; margin-right: 0"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%; margin-right: 0">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"><span style="font-size: 12pt">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.1pt; text-align: center"><span style="font-size: 12pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b>&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"><span style="font-size: 14pt">Washington,
D.C. 20549</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"><span style="font-size: 14pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 33%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 37%">&#160;</td>
  <td style="width: 30%">&#160;</td></tr>
</table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center">&#160;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"><span style="font-size: 14pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20220701__20230331_zPRnY27Uhkac"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 33%">&#160;</td>
  <td style="border-top: Black 1pt solid; width: 37%">&#160;</td>
  <td style="width: 30%">&#160;</td></tr>
</table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="font: 11pt Times New Roman, Times, Serif; padding-left: 242.35pt; text-align: center"></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Mark One)</span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-left: 10pt">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span id="xdx_90A_edei--DocumentQuarterlyReport_c20220701__20230331_zuIyMB7NW611"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9745;</ix:nonNumeric></span></td>
    <td style="width: 78%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
        THE SECURITIES EXCHANGE ACT OF 1934</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0">For the quarterly period ended <span id="xdx_905_edei--DocumentPeriodEndDate_c20220701__20230331_zgAfH4EW6az5"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2023</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 167.05pt">&#160;</p></td>
    <td style="width: 11%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_edei--DocumentTransitionReport_c20220701__20230331_zJfO3R3qn1Vd"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></td>
    <td style="border-bottom: black 1pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
        THE SECURITIES EXCHANGE ACT OF 1934</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; .</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153.35pt">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No.:
        <span id="xdx_901_edei--EntityFileNumber_c20220701__20230331_z4luwt2pomF6"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityFileNumber">001-34839</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 169.35pt; text-align: center"></p></td>
    <td>&#160;</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-size: 14pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20220701__20230331_zqZkjS0Umj2b"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityRegistrantName">Electromed,
    Inc.</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Exact Name of Registrant as Specified in its Charter)</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-size: 12pt"><b>&#160;<span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20220701__20230331_zDgBYEL8ejW7"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Minnesota</ix:nonNumeric></span> </b></span></td>
    <td style="width: 4%"><span style="font-size: 12pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20220701__20230331_zz3I7eRRpOMg"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">41-1732920</ix:nonNumeric></span> </b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td>&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(I.R.S. Employer Identification No.)</span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><span style="font-size: 12pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220701__20230331_z4whRb2DNwL4"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityAddressAddressLine1">500
        Sixth Avenue NW</ix:nonNumeric></span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><span style="font-size: 12pt"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20220701__20230331_zrxiqndKHLLg"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityAddressCityOrTown">New
        Prague</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20220701__20230331_z2eWT9gbi6xj"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Minnesota</ix:nonNumeric> </span></b>&#160;</span></p></td>
    <td><span style="font-size: 12pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><span style="font-size: 12pt"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20220701__20230331_z5Pqo9Fp8AZh"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityAddressPostalZipCode">56071</ix:nonNumeric></span></b>&#160;</span></p></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Zip Code)</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 80%; text-align: center"><span style="font-size: 12pt"><b>(<span id="xdx_90E_edei--CityAreaCode_c20220701__20230331_zYnxjxPYbXif"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:CityAreaCode">952</ix:nonNumeric></span>)
    <span id="xdx_904_edei--LocalPhoneNumber_c20220701__20230331_z2PkPfuTtq67"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:LocalPhoneNumber">758-9299</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-left: 63.6pt; text-align: center"><span style="font-size: 8pt">(Registrant&#8217;s telephone number, including area code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_904_edei--Security12bTitle_c20220701__20230331_zNbETVpH10r3"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span> </b></span></td>
    <td style="width: 2%"><span style="font-size: 12pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-size: 12pt"><b>&#160; <span id="xdx_900_edei--TradingSymbol_c20220701__20230331_zzMYOV2IHUS4"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:TradingSymbol">ELMD</ix:nonNumeric></span> </b></span></td>
    <td style="width: 2%"><span style="font-size: 12pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-size: 12pt"><b>&#160; <span id="xdx_90B_edei--SecurityExchangeName_c20220701__20230331_zfVUFEYdE562"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE
    American LLC</ix:nonNumeric></span> </b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Title of each class)</span></td>
    <td>&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Trading Symbol(s))</span></td>
    <td>&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">(Name of each exchange on which registered)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20220701__20230331_zWqXnouK5C63"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9745; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_908_edei--EntityInteractiveDataCurrent_c20220701__20230331_zP8MX6L5A9d2"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9745; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; width: 47%; padding-left: 0.625in"><span style="font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; width: 53%; padding-left: 84.4pt"><span style="font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-left: 84.4pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-left: 0.625in"><span style="font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20220701__20230331_z4mqtQAvx6mk"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#9745;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.4pt">Smaller reporting company <span id="xdx_90F_edei--EntitySmallBusiness_c20220701__20230331_zkiZIKXH3PS9"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9745;</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.4pt">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.4pt">Emerging growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220701__20230331_zbdjqdBME9yl"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.4pt">&#160;</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_908_edei--EntityShellCompany_c20220701__20230331_zO4vF0zqw8C7"><ix:nonNumeric contextRef="From2022-07-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9745;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were <span id="xdx_90B_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20230505_zwPYRbYfzGX5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-05-05" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,561,100</ix:nonFraction></span> shares of Electromed, Inc. common stock,
par value $0.01 per share, outstanding as of the close of business on May 5, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt"></p>

<!-- Field: Rule-Page --><div style="text-align: center; margin-top: 0; margin-bottom: 0; margin-right: 0"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%; margin-right: 0">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&#160;</p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 3 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">Electromed, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: center"><b>Index to Quarterly Report
on Form 10-Q</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 94%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-decoration: underline; width: 5%; text-align: right"><span style="text-decoration: underline">Page</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><a href="#a001_v1"><b>PART I &#8211; FINANCIAL INFORMATION</b></a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a002_v1">Item 1. Financial Statements</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">1</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a003_v1">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">11</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a004_v1">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">17</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a005_v1">Item 4. Controls and Procedures</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><a href="#a006_v1"><b>PART II &#8211; OTHER INFORMATION</b></a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a007_v1">Item 1. Legal Proceedings</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a008_v1">Item 1A. Risk Factors</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a009_v1">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a010_v1">Item 3. Defaults Upon Senior Securities</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a011_v1">Item 4. Mine Safety Disclosures</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a012_v1">Item 5. Other Information</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">19</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 0.25in"><a href="#a013_v1">Item 6. Exhibits</a></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom">19</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 453.5pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 2; Value: 3 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.7pt; text-align: center"><span id="a001_v1"></span>PART I &#8211; FINANCIAL
INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.7pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt"><b>Item 1.</b></td><td><span id="a002_v1"></span><b>Financial Statements.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">Electromed, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center"><b>Condensed Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_z9fnXp2UEuv1" summary="xdx: Statement - Condensed Balance Sheets (Unaudited)" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230331_zl5HxhPTIIif" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220630_zpfRpZg5iPAk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Unaudited)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AssetsAbstract_iB_z5qElOvlVf2c" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zwZC3gwcmO47" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzKuN_z0Xq9P9NJFi2" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,776,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,153,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzKuN_z6hslhg6DMNk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts receivable (net of allowances for doubtful accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230331_zWINFoMKhqJc" title="Accounts receivable, allowance for doubtful accounts"><span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20220630_zkhGf2y5zea6"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,345,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,052,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ContractWithCustomerAssetNetCurrent_i02I_maACzKuN_z5ea0cei2ev3" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Contract assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--InventoryNet_i02I_maACzKuN_zkrJFOewEXT3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventories</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,451,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,178,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzKuN_z2GKgUwLtsR5" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,808,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,870,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReceivable_i02I_maACzKuN_zjQiW98v5L97" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax receivable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReceivable" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0063">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AssetsCurrent_i01TI_mtACzKuN_maAzvtl_zvMMHUaewGWi" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,169,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,539,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzvtl_zIzEEgdCBf99" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,502,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,568,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzvtl_zGKf2hozSji8" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finite-life intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsNoncurrent_i01I_maAzvtl_zIQTSC60Mqaj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maAzvtl_zdg8oBAJdJA7" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,506,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,538,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--Assets_i01TI_mtAzvtl_zRF4SeWzePDk" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,841,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,364,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zMbNOvk7VMul" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Shareholders' Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zwdlav0zH6Z" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maLCzrL7_zUd8dEvKSncf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,289,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzrL7_zx89O1nACumb" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accrued compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,082,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,742,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_i02I_maLCzrL7_zoFnQMeY0wU9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Income tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ProductWarrantyAccrual_i02I_maLCzrL7_zRMVVhzqdUm4" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Warranty reserve</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,256,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzrL7_zNaSmebmOsM7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other accrued liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,713,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzrL7_maLzG4t_zzviZDeRDVv4" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,417,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,150,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesOtherThanLongtermDebtNoncurrent_i01I_maLzG4t_zKAJuE2Iu9l4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other long-term liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--Liabilities_i01TI_mtLzG4t_maLASEzEvH_zNLIYgqfk17k" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,447,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,191,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CommitmentsAndContingencies_i01I_zZiDUI244t5e" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zAHBtZQGxcLi" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shareholders' Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CommonStockValue_i02I_maSEzzwJ_zsS4NfipO4Se" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230331_zidMzExTer8j" title="Common stock, par value (in dollars per share)"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220630_zbx5KjUzuUyc" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value per share,
    <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_zHLcYoXdJpfc" title="Common stock, authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220630_zQVSieXCTWf5" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zEpE8tFg2j47" title="Common stock, outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zIpNSlaYfSta" title="Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,556,600</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20220630_zAu1GnmwdQhe" title="Common stock, outstanding"><span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20220630_zAQbvS8oHEt4" title="Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,475,438</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, as of March 31, 2023 and June 30, 2022,
    respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEzzwJ_zuDBOw29vQyc" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,548,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,308,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzzwJ_zaKUp7Rv56fb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Retained earnings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,760,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,780,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockholdersEquity_i01TI_mtSEzzwJ_maLASEzEvH_zP3gxVG0divg" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total shareholders' equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,394,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,173,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzEvH_zaMkEhKrB9r1" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and shareholders' equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,841,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,364,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-right: 0">See Notes to Condensed Financial Statements (Unaudited).</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt"></p></td>
    </tr>
</table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">Electromed, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.6pt; text-align: center"><b>Condensed Statements of Operations
(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.6pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.6pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zRBSHDW1E8y2" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 7.5pt; font-weight: bold">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_497_20230101__20230331_zVpYnbZCZ9gd" style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49F_20220101__20220331_zDErMq1xagK3" style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 7.5pt; font-weight: bold">&#160;</td><td style="font-size: 7.5pt; font-weight: bold">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20220701__20230331_zDGQ4gOr71sd" style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49A_20210701__20220331_zM3mQzv630nb" style="font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 7.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months
    Ended</span></td><td style="font-size: 7.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine Months
    Ended</span></td><td style="font-size: 7.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31,</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31,</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--Revenues_maCzCzi_z2wLj1mKSmtl" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 48%; font-size: 9pt; text-align: left"><span style="font-size: 10pt">Net revenues</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,068,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 9pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,141,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,455,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,390,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--CostOfRevenue_msCzCzi_zfmffxlSioOd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">Cost of revenues</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,012,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,398,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,386,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,066,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--GrossProfit_iT_mtCzCzi_maCzlbB_ztmPBvj3oHEk" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Gross
    profit</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,056,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,743,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,069,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,324,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zbr4evOBhQ5b" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">Operating expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--SellingGeneralAndAdministrativeExpense_maCzI7L_zxpZ6ZcDlaF" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Selling, general and administrative</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,694,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,544,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,937,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,806,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_maCzI7L_z3IjNJeTwWB1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Research
    and development</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">618,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_iT_mtCzI7L_msCzlbB_zK8MtYCrFli1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.25in; padding-bottom: 1pt"><span style="font-size: 10pt">Total
    operating expenses</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,860,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,880,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,555,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,847,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtCzlbB_maCzsMS_zB5Yh6Nk3SFk" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Operating
    income</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,196,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">863,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,514,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,477,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--InterestIncomeExpenseNet_maCzsMS_zJsKahexHSx" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left; padding-left: 0in; padding-bottom: 1pt"><span style="font-size: 10pt">Interest
    income, net</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzsMS_maCzskB_zBieZKp4oJo1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Net income
    before income taxes</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,222,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,551,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,498,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_msCzskB_zmzzDrkWrQQ8" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; text-align: left; padding-left: 0in; padding-bottom: 1pt"><span style="font-size: 10pt">Income
    tax expense</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,000</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtCzskB_zwnMnRQXEGD8" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="font-size: 10pt">Net
    income</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,922,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--EarningsPerShareBasicAbstract_iB_zmhUjwqJQhf2" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt"><span style="font-size: 10pt">Income per share:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zRl6wmBtsSEd" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Basic</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.13</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.23</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zQvcLRrrRyc4" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Diluted</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.12</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.07</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.22</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zxBJKodaOAWl" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">Weighted-average common shares outstanding:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_zqNf9iAruSt7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Basic</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,461,531</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,454,504</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,449,623</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,485,856</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 9pt; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_zQNOl5PjLJN3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Diluted</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,710,106</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,744,535</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,694,407</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,762,963</ix:nonFraction></span></td><td style="font-size: 9pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.6pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.6pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-right: 0">See Notes to Condensed Financial Statements (Unaudited).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">Electromed, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"><b>Condensed Statements of Cash
Flows (Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zD6ffkDQqBxc" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49A_20220701__20230331_z6PW6E1tusgk" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_497_20210701__20220331_z2S77yykK9Ti" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended March 31,</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 7.5pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-size: 7.5pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zDHDKtCt0NC6" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Cash Flows From Operating Activities</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_maCzscs_maNCPBUzh5Q_z8qWr8US7T87" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Net income</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,922,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zz8XNSlltFVe" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Adjustments to reconcile net income to net
    cash provided by operating activities:</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--Depreciation_maCzscs_maNCPBUzh5Q_zZm2gNjYnJ7d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Depreciation</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_maNCPBUzh5Q_z1HwMZ9nEcrh" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Amortization of finite-life intangible assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--ShareBasedCompensation_maNCPBUzh5Q_zHMwo76gPFa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Share-based compensation expense</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_maNCPBUzh5Q_zODYhIxDyFcj" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Deferred income taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zjvMrkBvJFP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsReceivable_iN_di_msNCPBUzh5Q_zgHT59PFMDRe" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.375in"><span style="font-size: 10pt">Accounts receivable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,582,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInContractWithCustomerAsset_iN_di_msNCPBUzh5Q_zKp4km3qUTLe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.375in"><span style="font-size: 10pt">Contract assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInInventories_iN_di_msNCPBUzh5Q_zQCkPxRQ8DQ" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.375in"><span style="font-size: 10pt">Inventories</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_iN_di_msNCPBUzh5Q_ztFKQXCpKIp" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.375in"><span style="font-size: 10pt">Prepaid expenses and other assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">105,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_maNCPBUzh5Q_zNppPJXlTI9h" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.375in"><span style="font-size: 10pt">Income tax receivable, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">270,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">443,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_maNCPBUzh5Q_zUqKtCz2jio" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.375in"><span style="font-size: 10pt">Accounts payable and accrued liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--AccruedCompensation_iN_di_msNCPBUzh5Q_z1LPGQhJddC1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.375in; padding-bottom: 1pt"><span style="font-size: 10pt">Accrued compensation</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="elmd:AccruedCompensation" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="elmd:AccruedCompensation" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzh5Q_maCCERCzL7s_z3L8d6128DEe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.5in; padding-bottom: 1pt"><span style="font-size: 10pt">Net
    cash provided by operating activities</span></td><td style="padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zucVui0nZzEg" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Cash Flows From Investing Activities</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_iN_di_msNCPBUzOBh_zCEAeME4yKBg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Expenditures for property and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_406_eus-gaap--PaymentsToAcquireIntangibleAssets_iN_di_msNCPBUzOBh_zMLIi9VPqIa6" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Expenditures for finite-life
    intangible assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUzOBh_maCCERCzL7s_zGHWGfP7LG23" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.5in; padding-bottom: 1pt"><span style="font-size: 10pt">Net
    cash used in investing activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,066,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z7UBz6h4GJr9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Cash Flows From Financing Activities</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_maNCPBUzrN1_zuToEpkwOXIg" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Issuance of common stock upon exercise of
    options</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_msNCPBUzrN1_zJjxbgiEaKp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Taxes paid on net share settlement of stock
    option exercises</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_400_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_msNCPBUzrN1_zaOqALz29oE2" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Repurchase of common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">962,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzrN1_maCCERCzL7s_zXiUt55psh8f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.5in; padding-bottom: 1pt"><span style="font-size: 10pt">Net
    cash used in financing activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">418,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,032,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzL7s_zLayVNpMuNhl" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.5in"><span style="font-size: 10pt">Net decrease in cash</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,377,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,045,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAbstract_iB_z7zzU39k81al" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Cash and cash equivalents</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z1Vvv4fRwB5" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.125in; padding-bottom: 1pt"><span style="font-size: 10pt">Beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,153,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,889,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zd7joQfyObx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 2.5pt"><span style="font-size: 10pt">End of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,776,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,844,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z3Jq88mbgRXk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Supplemental Disclosures of Cash Flow Information</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--IncomeTaxesPaid_zZekJtD8mbW9" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Cash paid for income taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zny9gRHPFhC9" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Supplemental Disclosures of Noncash Investing and Financing Activities</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--PropertyAndEquipmentAcquisitionsInAccountsPayable_i01_z2qfDUSuRzF5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Property and equipment acquisitions in accounts
    payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--IntangibleAssetAcquisitionsInAccountsPayable_i01_zuFFK3qOM05l" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Intangible asset acquisitions in accounts
    payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:IntangibleAssetAcquisitionsInAccountsPayable" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:IntangibleAssetAcquisitionsInAccountsPayable" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_i01_z8Vz2hIGUs0l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Lease assets obtained in exchange for new
    operating lease liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--DemonstrationEquipmentReturnedToInventory_i01_zSDurBc8sch1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Demonstration equipment returned to inventory</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:DemonstrationEquipmentReturnedToInventory" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:DemonstrationEquipmentReturnedToInventory" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See Notes to Condensed Financial Statements (Unaudited).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">Electromed, Inc.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"><b>Condensed Statements of Shareholders&#8217;
Equity (Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zykMT3p6svF2" summary="xdx: Statement - Condensed Statements of Shareholders&apos; Equity (Unaudited)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zGgIw2ys4fmk" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zPxDJn0zvY2d" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z2kZQldjT9o5" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_zj7xKEBjGNXd" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Retained</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shareholders&#8217;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">in Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Earnings</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_43C_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zZZT5aPrpxs9" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 35%; padding-left: 0.25in; text-indent: -0.25in">Balance at June 30, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwDno5B0clB" title="Balance at beginning (in shares)" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,533,209</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,409,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,922,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,416,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20210701__20210930_eus-gaap--NetIncomeLoss_zklVkl7fQBJ6" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_434_c20210701__20210930_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zdd8OgQaYRq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Issuance of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3hXJJ3szmyf" title="Issuance of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20210701__20210930_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zpGKpYr0GNs5" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Issuance of common stock upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXjua14xcXx6" title="Issuance of common stock upon exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20210701__20210930_eus-gaap--IncomeTaxesPaidNet_zVstQnCroGjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Taxes paid on stock options exercised on a net basis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_43E_c20210701__20210930_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zH6L3LjYDSo2" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20211001__20211231_eus-gaap--StockholdersEquity_iS_zXZilt7I0gt2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.25in">Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znm19DxFovX9" style="border-top: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,569,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="border-top: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="border-top: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,594,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="border-top: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,361,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="border-top: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,041,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20211001__20211231_eus-gaap--NetIncomeLoss_zAcOK2hwnUj8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20211001__20211231_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zpw4nGuBP0T" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Issuance of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFrNeoSmUaA2" title="Issuance of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20211001__20211231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zANfmm2ITnVb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Issuance of common stock upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM0fNEsJQpel" title="Issuance of common stock upon exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20211001__20211231_eus-gaap--IncomeTaxesPaidNet_zOPtByHzMd5b" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Taxes paid on stock options exercised on a net basis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_438_c20211001__20211231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zMj8XHeQYlze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20211001__20211231_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_zSfXopc7j5C1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 1pt">Repurchase of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_984_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_iN_pid_di_uShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7KTWmWaMsk6" title="Repurchase of common stock (in shares)" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,687</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">662,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_438_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zKuCsyk84H78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 1pt">Balance at December 31, 2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfUWLB1DwOSj" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,533,339</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,865,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,537,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,487,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 10pt; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20220101__20220331_eus-gaap--NetIncomeLoss_z1zuuAa9b2bh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20220101__20220331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ztonIVYsYg4i" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20220101__20220331_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_zndhMbCsUhua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 1pt">Repurchase of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_iN_pid_di_uShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znwSTxxR4Mf2" title="Repurchase of common stock (in shares)" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,551</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_433_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zsDCmgUdLVKg" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.25in; text-indent: -0.25in; padding-bottom: 2.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_986_eus-gaap--CommonStockSharesOutstanding_iE_pid_uShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqGJpYbtwU54" title="Balance at ending (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,508,788</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,042,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,883,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,010,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zeCcK6OsW10g" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKUCBBfXtpi6" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zvTCPKozGcc8" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_zCaDaGHxWPcd" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Retained</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shareholders&#8217;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">in Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Earnings</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_43F_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zQCZehZjPFFl" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 35%; padding-left: 0.125in; text-indent: -0.125in">Balance at June 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOjDSMxrdwqe" title="Balance at beginning (in shares)" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,475,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,308,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,780,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,173,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20220701__20220930_eus-gaap--NetIncomeLoss_zPxlMdOYywRa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20220701__20220930_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zmmka3XSLzUc" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpgQhVxX2rl7" title="Issuance of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20220701__20220930_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zPQPaAD01X6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Forfeiture of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSFjRNWl5vbb" title="Forfeiture of restricted stock (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">14,166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20220701__20220930_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zoZpZwKrfZk4" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of common stock upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT9Yo440jnRc" title="Issuance of common stock upon exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20220701__20220930_eus-gaap--IncomeTaxesPaidNet_z858gaStMwT9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Taxes paid on stock options exercised on a net basis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_437_c20220701__20220930_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zvWCtrmj7Mhk" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20220701__20220930_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_zE2qBM8hKkGe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repurchase of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_iN_pid_di_uShares_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlPfw5h0HT81" title="Repurchase of common stock (in shares)" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,568</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_43E_c20221001__20221231_eus-gaap--StockholdersEquity_iS_ztRsrqR2bdX1" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Balance at September 30, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBuRURKZzVMl" title="Balance at beginning (in shares)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,485,864</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,343,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,716,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,144,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20221001__20221231_eus-gaap--NetIncomeLoss_zwNPIu9AVNLg" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 35%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20221001__20221231_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_z6Ak1nNKmqU3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8H5dGqm7Akc" title="Issuance of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20221001__20221231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zr9vmqjHc376" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of common stock upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlqjyuJ8RGod" title="Issuance of common stock upon exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20221001__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z1Xa2HMmIPR" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20221001__20221231_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_zJY5xUfMP2ih" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Repurchase of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_iN_pid_di_uShares_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpVFZwwbCBab" title="Repurchase of common stock (in shares)" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_431_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zNrkVcK9WBY" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Balance at December 31, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z91AFfLY6M64" title="Balance at beginning (in shares)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,514,164</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,580,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,685,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,350,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="font-size: 10pt; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_43F_c20230101__20230331_eus-gaap--NetIncomeLoss_z7twDcw1obR5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20230101__20230331_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zpVAEyr7VCr6" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of common stock upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQ9SplWunFc" title="Issuance of common stock upon exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8211;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20230101__20230331_eus-gaap--IncomeTaxesPaidNet_zvDu0JNE6yrg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Taxes paid on stock options exercised on a net basis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_430_c20230101__20230331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zToMnLEeSXY4" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8211;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_43E_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zzCoXNa77YLl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iE_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52qO0GdmGug" title="Balance at ending (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,556,600</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,548,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,760,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,394,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See Notes to Condensed Financial Statements (Unaudited).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Electromed, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Notes to Condensed
Financial Statements <br />
(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 192.55pt; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zgZLgdNGfwwb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Note 1. <span id="xdx_82A_zmOQbaN18oHj">Interim Financial Reporting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Nature of business: </b>Electromed, Inc.
(the &#8220;Company&#8221;) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest
Wall Oscillation (&#8220;HFCWO&#8221;) therapy in pulmonary care for patients of all ages. The Company markets its products in
the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The
Company also sells internationally, primarily through distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">International sales were $<span id="xdx_90B_eus-gaap--Revenues_c20220701__20230331__srt--StatementGeographicalAxis__custom--InternationalMember_zRHEOsdnclIk" title="Net revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012023-03-31_custom_InternationalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--Revenues_c20210701__20220331__srt--StatementGeographicalAxis__custom--InternationalMember_zRbLV67T5KQ7" title="Net revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-07-012022-03-31_custom_InternationalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,000</ix:nonFraction></span>
for the nine months ended March 31, 2023 and 2022, respectively. Since its inception, the Company has operated in a single industry
segment: developing, manufacturing and marketing medical equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Impacts of COVID-19 on the Company&#8217;s
business:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The potential impact of the COVID-19 pandemic
and its effects on our operational and financial performance will depend in large part on future developments, which cannot be
reasonably estimated at this time. For a more detailed discussion, see &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; in Part I, Item 2 of this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Basis of presentation: </b>The accompanying
unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities
and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments
consisting of normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results
of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may
be achieved for the full year. The financial statements and related notes do not include all information and footnotes required
by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the
Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (&#8220;fiscal 2022&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">A summary of the Company&#8217;s significant accounting
policies follows:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zAIyugA5IAf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86C_zwAGO7ZjAZg2">Use of estimates.</span> </b>Management uses estimates
and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies
that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements
include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation
and warranty reserve.</p>

</ix:nonNumeric><p id="xdx_85E_zLK3gLpTtQ18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z8p7JCUBTdi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86A_zanynNVgxi8d">Net income per common share.</span> </b>Net income
is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using
the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not
vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock
options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive.
Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were
<span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zYrwOWEESbOd" title="Common stock equivalents excluded from calculation of diluted earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,992</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOv4v84jj4D8" title="Common stock equivalents excluded from calculation of diluted earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,435</ix:nonFraction></span> for the three months ended March 31, 2023 and 2022, respectively, and were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zxrV5XaDJ7zl" title="Common stock equivalents excluded from calculation of diluted earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,140</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210701__20220331_zAV5NKvK0i5k" title="Common stock equivalents excluded from calculation of diluted earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">112,427</ix:nonFraction></span> for the nine
months ended March 31, 2023 and 2022, respectively.</p>

</ix:nonNumeric><p id="xdx_856_zi0rugzd0seg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz7WRCTqxvWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_861_z2NH1iOxi8ca">Recently Issued Accounting Standards</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">In June 2016, the Financial Accounting Board issued
Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;&#8220;Financial Instruments -- Credit Losses: Measurement of Credit
Losses on Financial Instruments&#8221;,&#160;which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11,
and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including
trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It
is effective for interim and annual reporting periods in fiscal years beginning after December 15, 2022, with early adoption permitted.
The adoption of the standard is not expected to have a significant impact on the Company&#8217;s consolidated results of operations
and financial condition.</p>

</ix:nonNumeric><p id="xdx_851_zkD3LR7Vi3Hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_818_zkbAPx0sajoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="xdx_23B_zl4Gfc0o0Eqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_zGdbEaDPmYOg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Note 2. <span id="xdx_825_zveAcxBhmPA3">Revenues</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Revenue is measured based on consideration specified
in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the
transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all
customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer,
as further described below under <i>Performance obligations and transaction price</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Individual promised goods
and services in a contract are considered a performance obligation and accounted for separately if the individual good or service
is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available
to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes
multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated
standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance
obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs
under Accounting Standards Codification (&#8220;ASC&#8221;) 340-40, &#8220;Other Assets and Deferred Costs&#8221; (&#8220;ASC 340&#8221;),
or other applicable guidance are met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The Company includes shipping and handling
fees in net revenues. Shipping and handling costs associated with the shipment of the Company&#8217;s SmartVest&#174; Airway Clearance
System (&#8220;SmartVest System&#8221;) after control has transferred to a customer are accounted for as a fulfillment cost and
are included in cost of revenues in the Condensed Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The timing of revenue recognition, billings and
cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under <i>Accounts receivable</i>
and <i>Contract assets</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLoifyJ7Myvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Disaggregation of revenues.</b> <span id="xdx_8B8_zbNN7XPeu6Id">In the following
table, net revenues are disaggregated by market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 48%; text-align: left"><span style="font-size: 10pt">Home care</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z86jOQNiggka" title="Revenue" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,971,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zl1BpvekjHsi" title="Revenue" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,033,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zqQkL2R3djz8" title="Revenue" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,335,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVsh5wh4Vq08" title="Revenue" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,721,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Institutional</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zRmkAT5v63h5" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_InstitutionalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_z5lgkT0U2RD5" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_InstitutionalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">392,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zDZJvfPHT1F7" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_InstitutionalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,420,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zlYFcN92AIYa" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_InstitutionalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Home care distributor</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zWdaUbftJc3l" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareDistributorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zFnnTkVGaiT5" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareDistributorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zGLv1pAPQV54" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareDistributorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,391,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zzaPj6BkKZci" title="Revenue" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareDistributorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,063,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">International</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zIYA14yIQGEc" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_InternationalOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zXfHm6g8UJQc" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_InternationalOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zaF7SL27pK04" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_InternationalOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zCqWlakdq6r5" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_InternationalOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zd5l41CsTMj5" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,068,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331_zng3LTz2GCJ3" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,141,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zVPoLccoxd35" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,455,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331_zd3XEnTcWzD3" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,390,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">In the following table, net home care revenue is
disaggregated by payer type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 47%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zH1XYS8w9Lya" title="Revenue" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_CommercialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,787,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zsz8iLiK1zK4" title="Revenue" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_CommercialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,358,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zfBVNpoRjc0g" title="Revenue" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_CommercialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,706,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zMhoG4GeGNl8" title="Revenue" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_CommercialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,738,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zVwjODUXwiNe" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,822,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEBT6kF79IFa" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,027,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_z3dEZQq2uMa3" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,434,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zH9W63PDezOh" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,603,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicaid</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zmH6PG4boQd4" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicaidMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z4eiQKE6bJ9i" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicaidMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zOmfmtBqPkpj" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicaidMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">618,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zfB4N5oepocj" title="Revenue" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicaidMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zlyJTJjKAMrc" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zDDGrVnM1117" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zEpSNMrXMyy8" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zO9SoJimqs8j" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_OtherMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z4T44Pxld2Vb" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,971,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zXvOELmvjwC9" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,033,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zMeVRJ4XZgi1" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012023-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,335,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zvyDOZHiqHPf" title="Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012022-03-31_custom_HomeCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,721,000</ix:nonFraction></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A7_zLc5pPW1XhL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;<span style="font-size: 9pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Revenues in the Company&#8217;s home care, home
care distributor, and international markets are recognized at a point in time when control passes to the customer upon product
shipment or delivery. Revenues in the Company&#8217;s institutional market include revenue recognized at a point in time upon shipment
or delivery as well as revenue recognized over time under operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Performance obligations and transaction price.</b>
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account
under ASC 606, &#8220;Revenue From Contracts With Customers&#8221; (&#8220;ASC 606&#8221;). A contract&#8217;s transaction price
is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue
when, or as, the performance obligation is satisfied. The Company&#8217;s performance obligations and the timing or method of revenue
recognition in each of the Company&#8217;s markets are discussed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Home care market</i>.</b> In the Company&#8217;s
home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised
of three main components &#8211; a generator, a vest and a connecting hose &#8211; that are sold together as an integrated unit.
Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.</p>

<ix:exclude><p id="xdx_232_zg2MmQtnRbY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company makes available to its home care
patients limited post-sale services that are not material in the context of the contracts, either individually or taken together,
and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed
when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation:
the SmartVest System.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Home care patients generally will rely on third-party
payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs
to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers&#8217; reimbursement programs fall
into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright
sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest
System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or
(iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues
to use the SmartVest System.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Regardless of the type of transaction, provided
criteria for an enforceable contract are met, it is the Company&#8217;s long- standing business practice to regard all home care
agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government
or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature
installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly
less than expected if the contract is terminated due to changes in the patient&#8217;s status, including insurance coverage, hospitalization,
death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System,
the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies.
As a result, the Company&#8217;s product sales qualify for point in time revenue recognition. Control transfers to the patient,
and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks
and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further
discussed under <i>Accounts receivable</i> and <i>Contract assets</i> below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company&#8217;s contractually stated transaction
prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government
programs. The transaction price for the Company&#8217;s products may be further impacted by variable consideration. ASC 606 requires
the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value
of payments to be received from insurance payers based on historical experience and other available information, subject to the
constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include
(i) capped installment payments, which are subject to the third-party payer&#8217;s termination due to changes in insurance coverage,
death or the patient&#8217;s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility
amounts for deductibles, coinsurance, copays and other similar payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Although estimates may be made on a contract-by-contract
basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable
consideration for portfolios of contracts. The Company&#8217;s estimates of variable consideration consist of amounts it may receive
from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the
payment duration, changes to a patient&#8217;s insurance status, changes in an insurance allowable, claims in appeals with Medicare
and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical
information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has
with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue
recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The
Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize
the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative
revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration
is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of
cumulative revenue under the contract will not occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">For example, for contracts in which the Company
believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is
unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery
experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for
populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving
at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to
payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes
in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in
estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration
are generally not subject to the risk of significant revenue reversal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">For each type of variable consideration discussed
above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For
that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company often receives payment from third-party
payers for SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant
financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer
or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental
purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a
short period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Home care distributors.</i></b> Sales
to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based
rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor&#8217;s
purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within
the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases
in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively
defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount
is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to
the distributor, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Institutional market.</i></b> The Company&#8217;s
institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales
to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received
directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions
and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product
is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions
fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 18pt"><span>&#9679;</span></td><td>Outright sale &#8211; Under these transactions, the Company sells its products for a prescribed
or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and
payment is made within normal credit terms, usually within thirty days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 18pt">&#9679;</td><td><span style="font-size: 10pt">Wrap usage agreements &#8211; Under these transactions, the Company
provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These
agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned
to the Company, where it can be refurbished and used again at a later date. Revenue for the consumable wraps is recognized when
control transfers to the customer.</span></td></tr></table>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>International market.</i></b>
Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not
subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery
to the distributor, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Product warranty.</b> The Company offers warranties
on its products. These warranties are assurance-type warranties not sold on a standalone basis or are otherwise considered immaterial
in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates
the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product
is sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Accounts receivable.
</b>The Company&#8217;s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors.
Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid
and private insurance companies. Accounts receivable are carried at amounts estimated to be received from patients under reimbursement
arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines
the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s
financial condition and credit history. Receivables are written off when deemed uncollectible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Contract assets. </b>Contract
assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final
determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the
Company is dependent on a future event such as the patient meeting a deductible prior to the Company&#8217;s claim being processed
by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the
Company&#8217;s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive
payment is unconditional.</p>

<ix:exclude><p id="xdx_23E_zReyY7Vac8Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock"><p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zWMBUzxObaea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Contract balances.</b> <span id="xdx_8BA_zTWSoVb7jQr1">The following table
provides information about contract assets from contracts with customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br />
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br />
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Contract assets, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20220701__20230331_zojnsWRs8uDl" title="Contract assets  beginning" style="width: 10%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20210701__20220630_zSJp3oDx3Dfg" title="Contract assets, beginning" style="width: 10%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reclassification of contract assets to accounts receivable </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230331_zulTzlgwvoyb" title="Reclassification of contract assets to accounts receivable" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,107,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20210701__20220630_zcO5mEItPTre" title="Reclassification of contract assets to accounts receivable" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">833,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Contract assets recognized</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230331_zV7nM92BK2Tc" title="Contract assets recognized" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,372,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210701__20220630_zzmnkmPVAHWe" title="Contract assets recognized" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">784,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Increase (decrease) as a result of changes
    in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230331_zYT9RjztCYFj" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20210701__20220630_z60A9HmVzs8j" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Contract assets, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230331_z7TEg7dvyzI2" title="Contract assets, ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20210701__20220630_znjbSdw5tqM8" title="Contract assets, ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zLXTeaCb1Itj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Incremental costs to
obtain a contract. </b>Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs
that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin
on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment
or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred.
These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations.</p>

</ix:nonNumeric><p id="xdx_818_zy811JwXO87e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zrBG6lEHYaP1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 3. <span id="xdx_82C_z3esTlzgoW3c">Inventories</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ztm6QJuufMLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><span id="xdx_8BA_zGkVMdu5kD5d">The components of inventory were as follows</span>: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 9.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20230331_zAjqevD72dCk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220630_zFezRGXTIGY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">June
    30, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherInventorySupplies_iI_maINzW5z_maINzrcq_zsHRxqUaYAHi" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Parts inventory</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherInventorySupplies" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,908,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherInventorySupplies" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,672,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_maINzW5z_maINzrcq_z76eOK0OCXTd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_maINzW5z_maINzrcq_zg3MoyojxDv" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Finished goods</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--OtherInventoryInTransit_iI_maINzW5z_maINzrcq_zjROX6X1J8Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Estimated inventory to be returned</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--InventoryValuationReserves_iNI_di_msINzW5z_msINzrcq_zPO8mebFeD1c" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: Reserve for obsolescence</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iI_zICO24i8OXdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,451,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,178,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zuT5X7Q4dgM4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;&#160;</p>

</ix:nonNumeric><p id="xdx_818_zZdlA5YpQeI4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ProductWarrantyDisclosureTextBlock"><p id="xdx_806_eus-gaap--ProductWarrantyDisclosureTextBlock_zPYKjjjq8wCb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 4. <span id="xdx_825_zm7ErBxP5qcd">Warranty Reserve</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The Company provides a lifetime warranty on
its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales
to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability
in the amount of such costs at the time the product is shipped. Factors that affect the Company&#8217;s warranty reserve include
the number of units shipped, historical and anticipated rates of warranty claims, the product&#8217;s useful life and cost per
claim. The Company periodically assesses the adequacy of its recorded warranty reserve and adjusts the amounts as necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_z81p7xYdAUEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><span id="xdx_8BF_zFHwYYqtavx3">Changes in the Company&#8217;s warranty
reserve were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br />
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br />
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Warranty reserve, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230331_znWEmS9LRTn5" title="Warranty reserve, beginning" style="width: 10%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,256,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ProductWarrantyAccrual_iS_c20210701__20220630_zEzcXwsVIr97" title="Warranty reserve, beginning" style="width: 10%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Accrual for products sold </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230331_zVZjpbza45Rl" title="Accrual for products sold" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20210701__20220630_z1R1172ED1Id" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><span style="font-size: 10pt">Expenditures and costs
    incurred for warranty claims</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230331_z6CI4SCelsP1" title="Expenditures and costs incurred for warranty claims" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProductWarrantyAccrualPayments" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20210701__20220630_zFvsEIt3Zcuj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProductWarrantyAccrualPayments" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Warranty reserve, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230331_z3trpH4UvIl1" title="Warranty reserve, ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ProductWarrantyAccrual_iE_c20210701__20220630_zhP5TRijSnI" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,256,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zqlmEh3g1yFj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_818_zpIWwg0rQoa6" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zEhE5mRpJIb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 5. <span id="xdx_828_zGxgpa1ouBr5">Income Taxes</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense was estimated at $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20230331_zfPhFpPGuhpk" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20220701__20230331_zJllbYLgbAS5" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,000</ix:nonFraction></span>, and the effective tax rate was <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20230331_z6WC12it3x5e" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.0</ix:nonFraction></span>% and <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220701__20230331_zMdO0rdEw2q3" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.4</ix:nonFraction></span>% for the three and nine months ended March 31, 2023, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2023 includes a discrete current tax benefit of $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20230101__20230331_zBBLtSTZxxa7" title="Discrete current tax benefit - non-qualified stock options exercised"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220701__20230331_zIix4EjDTQd7" title="Discrete current tax benefit - non-qualified stock options exercised"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,000</ix:nonFraction></span>, respectively, related to the exercise of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense was estimated at $<span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20220331_zp7JYiGqIw9b" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,000</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210701__20220331_zg53vWkVMix9" title="Income tax expense"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,000</ix:nonFraction></span>, and the effective tax rate was <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20220331_ztjOKQWFZP98" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25.8</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210701__20220331_zbSmcCmTpQH" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.1</ix:nonFraction></span>% for the three and nine months ended March 31, 2022, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2022 includes a discrete current tax benefit of $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220101__20220331_zuYpzyve2tO1" title="Discrete current tax benefit - non-qualified stock options exercised"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20210701__20220331_zA0vJnA3nYIi" title="Discrete current tax benefit - non-qualified stock options exercised"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span>, respectively, related to the exercise of stock options and other items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is subject to U.S. federal and state
income tax in multiple jurisdictions. With limited exceptions, years prior to the Company&#8217;s fiscal year ended June 30, 2019
are no longer open to U.S. federal, state or local examinations by taxing authorities. The Company is not under any current income
tax examinations by any federal, state or local taxing authority. If any issues addressed in the Company&#8217;s tax audits are
resolved in a manner not consistent with management&#8217;s expectations, the Company could be required to adjust its provision
for income taxes in the period such resolution occurs.</p>

</ix:nonNumeric><p id="xdx_81B_zGUdduVoIXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zlvGew50A74k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 6. <span id="xdx_822_zTtz57LMREOd">Financing Arrangements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has a credit facility that provides
for a $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3o5E1zjdVMl" title="Maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> revolving line of credit. There was <span id="xdx_90E_eus-gaap--LinesOfCreditCurrent_iI_do_c20230330__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5wvx3Wh5dIl"><span id="xdx_90F_eus-gaap--LinesOfCreditCurrent_iI_do_c20220630__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zxWjK3EgGFad"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2023-03-30_us-gaap_RevolvingCreditFacilityMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2022-06-30_us-gaap_RevolvingCreditFacilityMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> outstanding principal balance on the line of credit as of March 31, 2023
or June 30, 2022. Interest on borrowings under the line of credit, if any, accrues at the prime rate (<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVCKA0YkE9S2" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.00</ix:nonFraction></span>% at March 31, 2023)
less <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220701__20230331_z1rgPYZCMzPj" title="Basis spread on rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span>% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $<span id="xdx_903_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zndZE983dFja" title="Available borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span>
or <span id="xdx_90C_ecustom--BorrowingCapacityOfEligibleAccountsReceivablePercent_iI_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zy7VPEka9iq" title="Available borrowing capacity"><ix:nonFraction name="elmd:BorrowingCapacityOfEligibleAccountsReceivablePercent" contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">57.00</ix:nonFraction></span>% of eligible accounts receivable and the line of credit expires on <span id="xdx_90F_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20220701__20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zqNBIpjNNYse" title="Line of credit facility, expiration date"><ix:nonNumeric contextRef="From2022-07-012023-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:datemonthdayyearen" name="us-gaap:LineOfCreditFacilityExpirationDate1">December 18, 2023</ix:nonNumeric></span>, if not renewed before such date.
At March 31, 2023, the maximum $<span id="xdx_901_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zlVkWyUABNTc" title="Available borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> was eligible for borrowing. Payment obligations under the line of credit, if any, are
secured by a security interest in substantially all of the tangible and intangible assets of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The documents governing
the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not
less than $<span id="xdx_90E_ecustom--DebtInstrumentCovenantComplianceAmount_iI_uUSD_c20230331_zPrxef3Pynal" title="Minimum tangible net worth to be maintained"><ix:nonFraction name="elmd:DebtInstrumentCovenantComplianceAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,125,000</ix:nonFraction></span> and restrictions on the Company&#8217;s ability to incur certain additional indebtedness or pay dividends.</p>

</ix:nonNumeric><p id="xdx_81D_z353Vsas4dNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKSISVZhDhK4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 7. <span id="xdx_82B_z3i7lHEFjEBl">Common Stock</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Authorized
shares:</b>&#160;The Company&#8217;s Articles of Incorporation, as amended, have established&#160;<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--CapitalStockMember_ztolrmB4gg33" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31_custom_CapitalStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction>&#160;</span>authorized shares
of capital stock consisting of&#160;<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaR19zCmm53e" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000,000</ix:nonFraction>&#160;</span>shares of common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuodLQLa7cf1" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>&#160;per share, and&#160;<span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--AuthorizedSharesUndesignatedStockMember_zzJEq38i96E7" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31_custom_AuthorizedSharesUndesignatedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span>&#160;shares
of undesignated stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On
May 26, 2021, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved a stock repurchase authorization. Under
the authorization, the Company was originally able to repurchase up to $<span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_dxL_uShares_c20220526__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zw2RweSZoxpg" title="Common stock, authorized::XDX::3000000"><span style="-sec-ix-hidden: xdx2ixbrl0804">3.0</span></span>&#160;million&#160;of shares of common stock through
May 26, 2022. On May 26, 2022, the Board removed the date limitation. As of March 31, 2023, a total of&#160;<span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_uShares_c20220701__20230331_zthAU97Py7ik" title="Number of share repurchased"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">239,995</ix:nonFraction></span>&#160;shares
have been repurchased and retired under this authorization for a total cost of $<span id="xdx_902_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_c20220701__20230331_z2HmskETELY5" title="Repurchase of common stock"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,725,000</ix:nonFraction></span>, or $11.36&#160;per share. Repurchased
shares have been retired and constitute authorized but unissued shares.</p>

</ix:nonNumeric><p id="xdx_810_zdmml4dbmEP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zd2od0puKq63" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 8. <span id="xdx_82C_zRc74D7oLLlb">Share-Based Compensation</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s share-based compensation
plans are described in Note 8 to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for fiscal
2022. Share-based compensation expense was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220701__20230331_zxgLmDIDtxd" title="Share-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210701__20220331_zPhPRUGcDif" title="Share-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,000</ix:nonFraction></span> for the nine months ended March 31, 2023 and 2022, respectively.
This expense is included in selling, general and administrative expense in the Condensed Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock Options</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2LBMDxTSnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zexP6TkyzPf">Stock option transactions during
the nine months ended March 31, 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 8pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"><span style="font-size: 10pt"><b>Number
                                         of Shares</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average
                                         </b><br /> <b>Exercise Price per</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;<b>Share</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; padding-left: 0in"><span style="font-size: 10pt">Outstanding at June 30, 2022</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220701__20231231_zUk1cNxQRlW2" title="Options outstanding, beginning | shares" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">502,084</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220701__20230331_zDELv2zhVc43" title="Options outstanding, beginning | $ / shares" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.82</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20230331_zJHxA8gC1nq3" title="Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104,325</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_zHX7AlfopaAi" title="Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.93</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Exercised</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20220701__20230331_z6E2KoU14aPb" title="Exercised" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,351</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_pid_uUSDPShares_c20220701__20230331_zq3XCSIew0Qe" title="Exercised" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="elmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.82</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Cancelled or Forfeited   </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220701__20230331_zkgUtP23WzE1" title="Cancelled or Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,930</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_ziij5IOI2Yb8" title="Cancelled or Forfeited" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.19</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Outstanding at March 31, 2023   </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20230331_zZdbeVZbk0Al" title="Options outstanding, ending | shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">468,128</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220701__20230331_zUnEMAzPClf8" title="Options outstanding, ending | shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.96</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zTLxbcxo00x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zcGECJZlGvs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zbTnC3vjZCPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span id="xdx_8BB_zljBe1zRuSH1">The following assumptions were
used to estimate the fair value of stock options granted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended <br /> March 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended <br /> June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230331_zNriTIRbfnY8" title="Risk free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.88</ix:nonFraction></span> - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230331_z8PojxQwFNx9" title="Risk free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.23</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210701__20220630_zBzqgbMF8p78" title="Risk free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.89</ix:nonFraction></span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210701__20220630_zdGFnuw9iSwl" title="Risk free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.52</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 69%; text-align: left">Expected term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220701__20230331_zyCtIt7J3IO5" title="Expected term (years)::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0849">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210701__20220630_z89Kw50kH0z2" title="::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0850">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230331_z5ONt5OVEGx" title="Expected volatility Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53</ix:nonFraction></span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230331_zy6VX3coaKK3" title="Expected volatility Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-07-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">54</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210701__20220630_za2Zw3fbfi9d" title="Expected volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">55</ix:nonFraction></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210701__20220630_zCtfkkiMUtik" title="Expected volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A5_zstQvYouApKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The intrinsic value of an option is the amount
by which the fair value of the underlying stock exceeds its exercise price. At March 31 2023, the weighted average remaining contractual
term for all outstanding stock options was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5OwNa2skHy3" title="Weighted average contractual term outstanding stock options"><ix:nonNumeric contextRef="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">5.9</ix:nonNumeric></span> years and the aggregate intrinsic value of the options was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZT0TcgXtlw8" title="Options outstanding, intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,802,672</ix:nonFraction></span>. Outstanding
at March 31, 2023 were 468,128 stock options issued to employees, of which <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS3eSgcyRN1f" title="Outstanding exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">339,342</ix:nonFraction></span> were vested and exercisable and had an aggregate
intrinsic value of $<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6cDS4h9agHf" title="Options exercisable, intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,762,445</ix:nonFraction></span>. As of March 31, 2023, $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyGnMEFw0eNj" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,218</ix:nonFraction></span> of total unrecognized compensation expense related to stock options
is expected to be recognized over a weighted-average period of approximately <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEV2b3K2kx8" title="Weighted average period::XDX::P2Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0870">2.0</span></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Restricted Stock</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">During the nine months ended March 31, 2023,
the Company issued restricted stock awards to employees totaling <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zeCJFOlGXgt" title="Restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,400</ix:nonFraction></span> shares of common stock, with a weighted average vesting
term of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zTKOlXxVgeOi" title="Vesting period"><ix:nonNumeric contextRef="From2022-07-012023-03-31_us-gaap_EmployeeStockOptionMember_custom_EmployeeMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">2.7</ix:nonNumeric></span> years and a weighted average fair value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHGiuODpzcp7" title="Fair value on grant date"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.92</ix:nonFraction></span> per share, and to directors totaling <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zgJ4XkRlfM1b" title="Restricted stock - vested (shares)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,000</ix:nonFraction></span> shares of common stock,
with a vesting term of six months and a weighted average fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zaSHdLknxUj9" title="Weight average fair value -vested  restricted stock (per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.86</ix:nonFraction></span> per share. There were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zCZ6paYeNclg" title="Restricted stock - unvested (shares)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,818</ix:nonFraction></span> shares of unvested restricted
stock with a weighted average fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_uUSDPShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zknYMC09m1Ce" title="Weight average fair value - unvested restricted stock (per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.32</ix:nonFraction></span> per share outstanding as of March 31, 2023. As of March 31, 2023, $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs0U8Ka9X555" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,063</ix:nonFraction></span> of
total unrecognized compensation expense related to restricted stock awards is expected to be recognized over a weighted-average
period of approximately <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJswSXZSEDAb" title="Weighted average period::XDX::P1Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0888">1.3</span></span> years.</p>

</ix:nonNumeric><p id="xdx_811_zeDPXpfOI0uk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_ztNQUvbbFyO1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 9.<span id="xdx_82D_zrjbfofoIPJa"> Commitments and Contingencies</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The Company is occasionally involved in claims
and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate
the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other
disposition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">On September 8, 2021, a state court putative
class action lawsuit was filed in Minnesota against the Company asserting injury resulting from the previously announced data breach
that impacted the Company&#8217;s customer protected health information and employee personal information and seeking compensatory
damages, equitable relief, and attorneys&#8217; fees and costs. On October 6, 2021, the proceeding was removed to the District
of Minnesota. The Company believes the plaintiff was not injured as a result of the data privacy incident and, as a result, the
claims are without merit. <span style="background-color: white">Accordingly, on November 11, 2021, the Company moved to dismiss
the complaint in its entirety. Prior to the hearing on the motion to dismiss, the parties agreed in principle to settle the case.&#160;The
parties have executed a settlement agreement and submitted a motion to settle the class action in the near future. During January
2023, the settlement was preliminarily approved. The hearing for final approval is scheduled for June 5, 2023. If the court does
not grant the approval for settlement, the Company will continue to vigorously defend the lawsuit. At this time, the Company is
unable to determine the ultimate outcome or potential exposure to loss, if any.</span></p>

</ix:nonNumeric><p id="xdx_814_zEIQsD0ErEP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt">Item 2.</td><td><span id="a003_v1"></span>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Financial
Statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and our audited financial
statements and related notes thereto included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended June
30, 2022 (&#8220;fiscal 2022&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Overview</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 17.95pt">Electromed, Inc. (&#8220;we,&#8221;
&#8220;our,&#8221; &#8220;us,&#8221; &#8220;Electromed&#8221; or the &#8220;Company&#8221;) develops and provides innovative airway
clearance products applying High Frequency Chest Wall Oscillation (&#8220;HFCWO&#8221;) technologies in pulmonary care for patients
of all ages.</p>

<p id="xdx_239_zVZ1mdXYvbKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">We manufacture, market and sell products that provide HFCWO, including
the SmartVest&#174; Airway Clearance System (&#8220;SmartVest System&#8221;) that includes our newest generation SmartVest&#160;Clearway&#174;
Airway Clearance System (&#8220;Clearway&#8221;), previous generations SmartVest SQL&#174; and SV2100, and related products, to patients
with compromised pulmonary function. The SmartVest Clearway, which received 510(k) clearance from the U.S. Food and Drug Administration
in December 2022, offers a state-of-the-art patient experience with a simple touch screen user interface, remote monitoring of data, and
is the lightest HFCWO generator on the market. Clearway also includes SmartVest Connect&#8482; wireless technology, which allows data
connection between physicians and patients to track therapy performance and collaborate in treatment decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Our products are sold in both the
home health care market and the institutional market for use by patients in hospitals, which we refer to as &#8220;institutional sales.&#8221;
Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, bronchiectasis
and repeated episodes of pneumonia. Additionally, we offer our products to a patient population that includes neuromuscular disorders
such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis (&#8220;ALS&#8221;), the combination of emphysema and chronic
bronchitis commonly known as chronic obstructive pulmonary disease (&#8220;COPD&#8221;), and patients with post-surgical complications
or who are ventilator dependent or have other conditions involving excess secretion and impaired mucus transport.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The SmartVest System is often eligible
for reimbursement from major private insurance providers, health maintenance organizations (&#8220;HMOs&#8221;), state Medicaid systems,
and the federal Medicare system, which we believe is an important consideration for patients considering an HFCWO course of therapy. For
domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code (E0483) for HFCWO devices if the patient
has cystic fibrosis, bronchiectasis (including chronic bronchitis or COPD that has resulted in a diagnosis of bronchiectasis), or any
one of certain enumerated neuromuscular diseases, and can demonstrate that another less expensive physical or mechanical treatment did
not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting
their coverage policies and payment amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Critical Accounting Estimates</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">For a description of our
critical accounting policies, estimates and assumptions used in the preparation of our financial statements, including the unaudited
Condensed Financial Statements in this Quarterly Report on Form 10-Q, see Note 1 to our unaudited Condensed Financial Statements
included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Part II, Item 7, and Note 1 to our audited financial statements
included in Part II, Item 8, of our Annual Report on Form 10-K for fiscal 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">Some of our accounting
policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial statements.
Such judgments are subject to an inherent degree of uncertainty and are based upon our historical experience, known trends in our
industry, terms of existing contracts, other information from outside sources, as appropriate and other factors. Therefore, management
discusses the development, selection and disclosures with the audit committee. Among other factors, these judgements are based
upon our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources,
as appropriate. We believe the critical accounting policies that require the most significant estimates, assumptions and judgments
in the preparation of our financial statements, including the unaudited Condensed Financial Statements contained in this Quarterly
Report on Form 10-Q, include: revenue recognition and the estimation of variable consideration, inventory valuation, share-based
compensation and warranty reserve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Impacts of <span style="font-size: 10.5pt">COVID-19</span>
on Our Business and Operations</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">In March 2020, the World
Health Organization designated COVID-19 as a global pandemic, and the U.S. Department of Health and Human Services designated COVID-19
as a public health emergency (&#8220;PHE&#8221;). In response to the COVID-19 pandemic and the U.S. federal government&#8217;s
declaration of a PHE, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) implemented a number of temporary rule
changes and waivers to allow prescribers to best treat patients during the period of the PHE. These waivers became effective on
March 1, 2020. Clinical indications and documentation typically required will not be enforced for respiratory-related products,
including the SmartVest System (solely with respect to Medicare patients). The minimum documentation now requires a valid order
and documentation of a respiratory-related diagnosis. Face-to-face and in-person requirements for respiratory devices are being
waived while the waiver is in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">On January 30, 2023, the
Biden administration announced that the COVID-19 national and PHE declarations will end on May 11, 2023 (the &#8220;PHE End Date&#8221;).
Without further action from the U.S. federal government, we expect the CMS waiver will terminate no later than the PHE End Date
and we may experience a one-time delay in some percentage of our Medicare net revenue as we expect our average Medicare patient
referral to approval timeframe will extend to pre-COVID-19 timeframes and referrals with diagnoses not covered pre-COVID-19 may
be cancelled or need to be submitted to CMS for an appeal. We are executing our plans to attempt to mitigate the potential effects
on our future net revenue resulting from the likely termination of the CMS waiver by hiring additional employees to increase capacity
and minimize the average timeframe to convert a Medicare patient referral to approval and re-educating clinicians on Medicare requirements
for reimbursement of HFCWO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 0.5in"><b><i>Impacts of Certain Macro-Economic
Conditions and the Supply Chain on Our Business and Operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">We observed increased lead
times for certain components in our supply chain and increased material costs and shipping rates during the second half of fiscal
2022 and into the nine months ended March 31, 2023. The changes to our supply chain lead times resulted in a temporary interruption
that impacted product availability for certain customers beginning in September 2022 and continuing through March 2023. We anticipate
that these increased lead times and temporary interruption of supply have the potential to continue through the fourth quarter
of our fiscal year ending June 30, 2023 (&#8220;fiscal 2023&#8221;). If we are unable to procure components to meet our demand
or if we extend delivery lead-times to our customers, there may be an adverse impact to our revenue and, longer term, the potential
of market share losses. We are taking actions to expedite components and to identify and qualify alternate suppliers for certain
components to minimize any impact to our revenue and customer deliveries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">We expect that material costs and shipping
rates will remain elevated during the fourth quarter of fiscal 2023 and the first half of our fiscal year ending June 30, 2024 <span style="font-size: 8pt">&#160;</span>relating
to supply chain availability and inflationary trends in electronic components and may extend to other components. In certain instances,
we have purchased key electronic materials in advance to ensure adequate future supply and mitigate the risk of potential supply chain
disruptions. It is possible that these macro-economic conditions could have a greater adverse impact on our supply chain in the future,
including impacts associated with preventative and precautionary measures taken by other businesses and applicable governments. A reduction
or further interruption in any of our manufacturing processes could have a material adverse effect on our business. Any significant increases
to our raw material or shipping costs could reduce our gross margins.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 17.95pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Results of Operations</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Net Revenues</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Net revenues for the
three and nine months ended March 31, 2023 and 2022 are summarized in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended <br />
March 31,</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.05pt; text-align: center; text-indent: -18.4pt"><b>Nine
Months Ended</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: center; text-indent: -18.7pt"><b>March
31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 12%; text-align: left; padding-left: 10pt">Home care</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,971,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,033,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,938,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">21.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">31,335,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">27,721,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,614,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">13.0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Institutional</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,174,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-left: 10pt">Home care distributor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.7</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,391,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,063,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.9</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">International</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">156,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">196,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(40,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">)</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20.4</td><td style="padding-bottom: 1pt; text-align: left">%)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">309,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">432,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(123,000</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">)</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28.5</td><td style="padding-bottom: 1pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,068,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,141,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,927,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.0</td><td style="text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,455,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,390,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,065,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.4</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>Home care revenue</i></b><i>.
</i>Home care revenue increased by $1,938,000, or 21.5%, for the three months ended March 31, 2023 compared to the same period in the prior year.  For the nine months ended March 31, 2023, home care revenue was $31,335,000, representing an increase of $3,614,000, or 13.0%, compared to the same period in the prior year.  The increase was primarily due to an increase in referrals and approvals. The increase in referrals was due to an increase in direct sales representatives as well as positive market momentum from the introduction of our newest generation SmartVest Clearway during the quarter and was partially offset by a temporary interruption in supply chain and associated operations in the nine months ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The CMS waiver continues to benefit the non-commercial Medicare portion of our home care revenue by increasing the number of referrals and the approval percentage for non-covered diagnoses. We believe that our ongoing sales team execution, along with the continued return to pre-COVID-19 levels of patient face-to-face engagement with physicians and clinic access for our sales team and the recent introduction of our newest generation SmartVest Clearway, has the potential to mitigate much of the impact of the potential CMS waiver expiration.  If we are unsuccessful in mitigating the impact of the CMS waiver expiration, we may experience a decrease in our historical year over year growth rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt"><b><i>Home care distributor
revenue</i></b><i>. </i>Home care distributor revenue decreased by $19,000, or 3.7%, for the three months ended March 31, 2023
compared to the same period in the prior year. For the nine months ended March 31, 2023, home care distributor revenue was $1,391,000,
an increase of $328,000, or 30.9%, compared to the same period in the prior year. Home care distributor sales are affected by the
timing of distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis. The year-to-date
revenue increase was due to increased demand from one of our primary home care distribution partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>Institutional revenue.
</i></b>Institutional revenue was $440,000, an increase of $48,000, or 12.2%, for the three months ended March 31, 2023 compared
to the same period in the prior year. For the nine months ended March 31, 2023, institutional revenue was $1,420,000, an increase
of $246,000, or 21.0%, compared to the same period in the prior year. The increase in the current year periods was primarily due
to increased consumable sales to institutional customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>International revenue</i></b><i>.
</i>International revenue was $156,000, a decrease of $40,000, or 20.4%, for the three months ended March 31, 2023 compared to
the same period in the prior year. For the nine months ended March 31, 2023, international revenue was $309,000, a decrease of
$123,000, or 28.5%, compared to the same period in the prior year. International sales are affected by the timing of distributor
purchases that can cause significant fluctuations in reported revenue on a quarterly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Gross profit</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Gross profit increased to $9,056,000, or 75.0% of net revenues, for the three months ended March 31, 2023, from $7,743,000, or 76.4% of net revenues, in the same period in the prior year. Gross profit increased to $26,069,000, or 75.7% of net revenues, for the nine months ended March 31, 2023, from $23,324,000, or 76.7% of net revenues, in the same period in the prior year. The decrease in gross profit as a percentage of net revenues compared to the same period in the prior year was primarily due to increased material costs and component broker fees incurred to accelerate the ramp of supply for the Clearway product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Operating expenses</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><i>Selling, general and
administrative expenses. </i>Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $7,694,000 and $22,937,000
for the three and nine months ended March 31, 2023, respectively, representing increases of $1,150,000 and $3,131,000, or 17.6%
and 15.8%, respectively, compared to the same periods in the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 20.5pt">Payroll and compensation-related
expenses were $5,037,000 and $14,920,000 for the three and nine months ended March 31, 2023, respectively, representing increases
of $739,000 and $2,030,000, or 17.2% and 15.7%, respectively, compared to the same periods in the prior year. The increase in the
current year periods was primarily due to salaries and incentive compensation related to the higher average number of sales, sales
support, marketing, and reimbursement personnel to process higher patient referrals. We have also continued to provide regular
merit-based increases for our employees and are regularly benchmarking our compensation ranges for new and existing employees to
ensure we can hire and retain the talent needed to drive growth in our business. Field sales employees totaled 57 as of March 31,
2023, 48 of which were direct sales representatives, compared to 51 field sales employees and 42 direct sales representatives as
of March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 20.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Travel, meals and entertainment
expenses were $658,000 and $2,290,000 for the three and nine months ended March 31, 2023, respectively, representing increases
of $20,000 and $390,000, or 3.1% and 20.5%, respectively, compared to the same periods in the prior year. The increase in the current
year periods was due to a higher average number of direct sales representatives as well as increases in airfare, lodging and inflationary
expenses for our annual sales meeting in August 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Total discretionary marketing
expenses were $212,000 and $581,000 for the three and nine months ended March 31, 2023, respectively, representing decreases of
$29,000 and $24,000, or 12.0% and 4.0%, respectively, compared to the same periods in the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Professional fees were
$1,388,000 and $3,850,000 for the three and nine months ended March 31, 2023, respectively, representing increases of $382,000
and $646,000, or 38.0% and 20.2%, respectively, compared to the same periods in the prior year. Professional fees are primarily
for services related to legal costs, shareowner services and reporting requirements, information technology technical support and
consulting fees. The increase in the three months ended March 31, 2023 was primarily due to higher legal and consulting costs related
to the termination of the PHE and recruiting costs for multiple senior leadership positions, including a new Chief Executive Officer.
The additional increase in the nine months ended March 31, 2023 was primarily due to nonrecurring legal compliance fees of approximately
$400,000 for a reimbursement-related project offset by a reduction in expenses related to shareholder activism incurred during
the prior year, which concluded with a cooperation agreement that became effective in September 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><i>Research and development
expenses</i>. Research and development (&#8220;R&amp;D&#8221;) expenses were $166,000 and $618,000 for the three and nine months
ended March 31, 2023, respectively, representing decreases of $170,000 and $423,000, or 50.6% and 40.6%, respectively, compared
to the same periods in the prior year. The decreases in R&amp;D expenses to 1.4% and 1.8% of revenue for the three and nine months
ended March 31, 2023, respectively were due to the completion of the Clearway product development process, resulting in the full
launch to the U.S. home care market in March 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.85pt; text-indent: 0.25in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Interest income, net</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Net interest income for the three and nine months ended March 31, 2023 was $26,000 and $37,000, respectively, compared to $6,000 and $21,000, respectively, for the same periods in the prior year. These increases were due to a higher yield in our interest-bearing cash accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt; text-indent: 0.25in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Income tax expense</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 16pt">Income tax expense was estimated
at $147,000 and $418,000, and the effective tax rate was 14.7% and 16.4%, for the three and nine months ended March 31, 2023, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2023 includes a discrete tax benefit of $176,000 and
$219,000, respectively, related to the exercise of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 16pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 16pt">Income tax expense was estimated
at $224,000 and $576,000, and the effective tax rate was 25.8% and 23.1%, for the three and nine months ended March 31, 2022, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2022 includes a discrete tax benefit of $22,000 and
$43,000, respectively, related to the exercise of stock options and other items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 16pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Net income</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Net income for the three and nine
months ended March 31, 2023 was $1,075,000 and $2,133,000, respectively, compared to $645,000 and $1,922,000 for the same periods in
the prior year. The increases in net income were driven primarily by revenue growth and a decrease in R&amp;Dexpenses but partially
offset by increased SG&amp;A expenses related to our sales and reimbursement investments to drive revenue growth as well as
increased material costs and broker fees incurred to ramp up supply for the Clearway product.<span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Liquidity and Capital Resources</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Cash Flows and Sources of Liquidity</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Cash Flows from Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">For the nine months ended
March 31, 2023, net cash provided by operating activities was $316,000. Cash flows provided by operating activities consisted of
net income of $2,133,000, non-cash expenses of $960,000, and a decrease in prepaid expenses and other assets of $105,000. These
cash flows from operating activities were offset by an increase in accounts receivable of $1,293,000, a decrease in accrued compensation
of $660,000, an increase in income tax receivable of $270,000, an increase in inventory of $264,000, an increase in contract assets
of $284,000, and a decrease in accounts payable and other accrued liabilities of $111,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Cash Flows from Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">For the nine months
ended March 31, 2023, cash used in investing activities was $1,275,000. Cash used in investing activities consisted of $1,221,000
primarily related to our enterprise resource planning infrastructure investments and $54,000 in expenditures for intangible asset
costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Cash Flows from Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">For the nine months ended
March 31, 2023, cash used in financing activities was $418,000. Cash used in financing activities consisted primarily of $305,000
for taxes paid on net share settlement of stock option exercises and $153,000 used for our share repurchase program partially offset
by cash received for stock option exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Adequacy of Capital Resources</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Our primary working capital
requirements relate to adding employees to our sales force and support functions, continuing infrastructure investments, and supporting
general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course
of business. Based on our current operational performance, we believe our working capital of $28,752,000 and available borrowings
under our existing credit facility will provide adequate liquidity during fiscal 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Our credit facility provides
us with a revolving line of credit. Interest on borrowings on the line of credit accrues at the prime rate (8.0% at March 31, 2023)
less 1.00% and is payable monthly. There was no outstanding principal balance on the line of credit as of March 31, 2023 or June
30, 2022. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible
accounts receivable, and the line of credit expires on December 18, 2023, if not renewed. As of March 31, 2023, the maximum $2,500,000
was available under the line of credit. Payment obligations under the line of credit are secured by a security interest in substantially
all of our tangible and intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">The documents governing
our line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than
$10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">Any failure to comply with
these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating
the maturity of our indebtedness, preventing access to additional funds under the line of credit, requiring prepayment of outstanding
indebtedness, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit
is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue
operations as planned. If we are unable to repay such indebtedness, the lender could foreclose on these assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">For the nine months ended March
31, 2023 and 2022, we spent $1,221,000 and $980,000, respectively, on property and equipment. We currently expect to finance planned
equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt
if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">While the impact of macro-economic
factors such as inflation are difficult to predict, we believe our cash, cash equivalents and cash flows from operations will be
sufficient to meet our working capital, capital expenditure, operational cash requirements&#160;for fiscal 2023 and the foreseeable
future.&#160; We will continue to evaluate our projected expenditures relative to our available cash and evaluate financing alternatives
in order to satisfy our working capital and other cash requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Information Regarding Forward-Looking Statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Statements contained in
this Quarterly Report on Form 10-Q that are not statements of historical fact should be considered forward-looking statements within
the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward- looking statements include, but are not limited to,
statements regarding: the expected impact of the COVID-19 pandemic on our business; our business strategy, including our intended
level of investment in R&amp;D and marketing activities; our expectations with respect to earnings, gross margins and sales growth,
industry relationships, marketing strategies and international sales; estimated sizes of markets into which our products are or
may be sold; our business strengths and competitive advantages; our ability to grow additional sales distribution channels; our
intent to retain any earnings for use in operations rather than paying dividends; our expectation that our products will continue
to qualify for reimbursement and payment under government and private insurance programs; our intellectual property plans and practices;
the expected impact of applicable regulations on our business; our beliefs about our manufacturing processes; our expectations
and beliefs with respect to our employees and our relationships with them; our belief that our current facilities are adequate
to support our growth plans; our expectations with respect to ongoing compliance with the terms of our credit facility; our expectations
regarding the ongoing availability of credit and our ability to renew our line of credit; enhancements to our products and services;
expected excise tax exemption for the SmartVest System; and our anticipated revenues, expenses, capital requirements and liquidity.
Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221;
&#8220;project,&#8221; &#8220;goal,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not
the exclusive means of identifying such statements. Although we believe these forward-looking statements are reasonable, they involve
risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements
involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry&#8217;s actual
results, levels of activity, performance or achievements to be materially different from the information expressed or implied by
the forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">Factors that could cause
actual results to differ from those discussed in the forward-looking statements include, but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 17.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">ability to obtain reimbursement from Medicare, Medicaid, or private insurance
payers for our products including the potential adverse impact of an expiration of the CMS waiver for certain respiratory diseases;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">component or raw material shortages, changes to lead times or significant
price increases;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">business disruption from the anticipated implementation of a new enterprise
resource planning software system;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">adverse changes to state and federal health care regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">our ability to maintain regulatory compliance and to gain future regulatory
approvals and clearances;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">entry of new competitors including new drug or pharmaceutical discoveries;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">adverse economic and business conditions or intense competition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify"><span style="background-color: white">the risks associated with our planned
sales force expansion;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify"><span style="background-color: white">wage and component price inflation;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">technical problems with our research and products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">the duration, extent and severity of the COVID-19 pandemic, including its
effects on our business, operations and employees as well as its impact on our customers and distribution channels and on economies
and markets more generally;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">the risks associated with cyberattacks, data breaches, computer viruses
and other similar security threats;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">changes affecting the medical device industry;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify"><span style="background-color: white">our ability to develop new sales channels
for our products such as the home care distributor channel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">adverse international health care regulation impacting current international
business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify"><span style="background-color: white">our ability to renew our line of credit
or obtain additional credit as necessary; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 17.9pt"><span>&#9679;</span></td><td style="text-align: justify">our ability to protect and expand our intellectual property portfolio.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">This list of factors is
not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect
on us and our results of operations. Therefore, you should consider these risk factors with caution and form your own critical
and independent conclusions about the likely effect of these risk factors on our future performance. Forward-looking statements
speak only as of the date on which the statements are made, and we undertake no obligation, and expressly disclaim any such obligation,
to update any forward-looking statement for any reason other than as required by law, even if new information becomes available
or other events occur in the future. You should carefully review the disclosures and the risk factors described in this and other
documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;), including our Annual Report
on Form 10-K for fiscal 2022. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified
in their entirety by the cautionary statements set forth herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt">Item 3.</td><td><span id="a004_v1"></span>Quantitative and Qualitative Disclosures About Market Risk.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">As a smaller reporting company, we are not required
to provide disclosure pursuant to this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt">Item 4.</td><td><span id="a005_v1"></span>Controls and Procedures.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">Our principal executive
officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules
13a-15(e) and 15d-15(e) of the Exchange Act, as of the end of the period subject to this Quarterly Report on Form 10-Q. Based on
this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
were effective as of the date of such evaluation to provide reasonable assurance that information required to be disclosed by the
Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the
time periods specified by the SEC&#8217;s rules and forms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Changes to Internal Control Over Financial Reporting</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">There were no changes
in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt; text-indent: 17.95pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.7pt; text-align: center"><span id="a006_v1"></span>PART II &#8211; OTHER INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.7pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 1.</b></td><td><b><span id="a007_v1"></span>Legal Proceedings.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 17.95pt">The disclosure regarding
legal proceedings set forth in Note 9 to our unaudited Condensed Financial Statements in Part I, Item 1 of this Quarterly Report
on Form 10-Q is incorporated herein by reference. Occasionally, we may be party to legal actions, proceedings, or claims in the
ordinary course of business, including claims based on assertions of patent and trademark infringement. Corresponding costs are
accrued when it is probable that loss will be incurred and the amount can be precisely or reasonably estimated. We are not aware
of any undisclosed actual or threatened litigation that would have a material adverse effect on our financial condition or results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt; text-indent: 17.95pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><span id="a008_v1"></span>Item 1A. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">As a smaller reporting company, we are not required
to provide disclosure pursuant to this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"><span id="a009_v1"></span></td><td style="width: 74.35pt">Item 2.</td><td>Unregistered Sales of Equity Securities and Use of Proceeds.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">On May 26, 2021, our Board of
Directors (the &#8220;Board&#8221;) approved a stock repurchase authorization. Under the authorization, we were originally able
to repurchase up to $3.0 million of outstanding shares of our common stock through May 26, 2022. On May 26, 2022, the Board removed
the date limitation. The shares of our common stock may be repurchased under the authorization on the open market or in privately
negotiated transactions subject to applicable securities laws and regulations. The following table sets forth information concerning
purchases of shares of our common stock for three months ended March 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Number of <br />
Shares Purchased</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average<br /> Price Paid<br /> per Share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Number of Shares <br />
Purchased as Part of <br />
Publicly Announced <br />
Plans or Programs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Approximate Dollar <br />
Value of Shares that <br />
May Yet be Purchased <br />
Under the Plans or <br />
Programs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 31%; text-align: left"><span style="font-size: 10pt">January 1 &#8211; January 31, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-size: 11pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">275,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">February 1 &#8211; February 28, 2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">-</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">275,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">March 1 &#8211; March 31, 2023</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="text-align: right">275,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"><span id="a010_v1"></span></td><td style="width: 74.35pt">Item 3.</td><td>Defaults Upon Senior Securities.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"><span id="a011_v1"></span></td><td style="width: 74.3pt">Item 4.</td><td>Mine Safety Disclosures.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt">Item 5.</td><td><span id="a012_v1"></span>Other Information.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 74.3pt">Item 6.</td><td><span id="a013_v1"></span>Exhibits.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 10%; text-align: center">
        <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"><b>Exhibit</b>&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"><b>Number</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 65%; text-align: center; vertical-align: bottom">
        <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Description</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 22%; text-align: center; vertical-align: bottom">
        <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><b>Method of Filing</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710115001220/elmd153168_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">3.1</span></a></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710115001220/elmd153168_ex3-1.htm" style="-sec-extract: exhibit">Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 4.35pt; text-align: center"><span style="font-size: 10pt">Incorporated by Reference</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 4.35pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710120000781/elmd201479_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">3.2</span></a></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710120000781/elmd201479_ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 4.35pt; text-align: center"><span style="font-size: 10pt">Incorporated by Reference</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 4.35pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710123000086/elmd230175_ex10-1.htm" style="-sec-extract: exhibit">10.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710123000086/elmd230175_ex10-1.htm" style="-sec-extract: exhibit">Letter Agreement with Kathleen S. Skarvan, dated February 14, 2023 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed February 14, 2023)*</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center"><span style="font-size: 10pt">Incorporated by Reference</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center"><span style="font-size: 10pt"><a href="elmd230506_ex31-1.htm">31.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="elmd230506_ex31-1.htm">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center"><span style="font-size: 10pt">Filed Electronically</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center"><span style="font-size: 10pt"><a href="elmd230506_ex31-2.htm">31.2</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="elmd230506_ex31-2.htm">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center"><span style="font-size: 10pt">Filed Electronically</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center"><span style="font-size: 10pt"><a href="elmd230506_ex32-1.htm">32.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="elmd230506_ex32-1.htm">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 8.3pt; text-align: center"><span style="font-size: 10pt">Furnished Electronically</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 8.3pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center"><span style="font-size: 10pt"><a href="elmd230506_ex32-2.htm">32.2</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="elmd230506_ex32-2.htm">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="padding-left: 8.3pt; text-align: center"><span style="font-size: 10pt">Furnished Electronically</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 15.5pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 8.3pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 16.7pt; text-align: center"><span style="font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Financial statements from the Quarterly Report on Form 10-Q for the period ended March 31, 2023, formatted in inline XBRL: (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Cash Flows, (iv) Condensed Statements of Shareholders&#8217; Equity, and (v) Notes to Condensed Financial Statements</span></td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center"><span style="font-size: 10pt">Filed Electronically</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 16.7pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 16.7pt; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL Document)</span></td>
    <td>&#160;</td>
    <td style="padding-left: 18.05pt; text-align: center"><span style="font-size: 10pt">Filed Electronically</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt">* Management compensatory contract or arrangement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt">&#160;</p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.95pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-indent: 17.95pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">ELECTROMED, INC.</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Date:&#160;
                    &#160;&#160;&#160;May 9, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</td>
    <td style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">/s/ Kathleen
        S. Skarvan  </span></p></td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 44%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 50%"><span style="font-size: 10pt">Kathleen S. Skarvan, President and Chief Executive Officer (duly authorized
    officer)</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Date: &#160;&#160;&#160;&#160;May
                    9, 2023&#160;</span></p>

</td>
    <td style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">/s/ Bradley
        M. Nagel </span></p></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Bradley M. Nagel, Chief Financial Officer (principal financial officer and principal accounting
    officer)</span></td></tr>
</table>




























<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>elmd230506_ex31-1.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><b>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Certification Pursuant to Section&nbsp;302
of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Kathleen S. Skarvan, certify that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD><FONT STYLE="font-size: 10pt">I have reviewed this report on Form 10-Q of Electromed, Inc.; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of
directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Date:&#9;May 9, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">/s/ Kathleen S. Skarvan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Kathleen S. Skarvan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>elmd230506_ex31-2.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Certification Pursuant to Section&nbsp;302
of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Bradley M. Nagel, certify that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD><FONT STYLE="font-size: 10pt">I have reviewed this report on Form 10-Q of Electromed, Inc.; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of
directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Date:&#9;May 9, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">/s/ Bradley M. Nagel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Bradley M. Nagel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>elmd230506_ex32-1.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 32.1&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In connection with the Quarterly Report
of Electromed, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Kathleen S. Skarvan, President and Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#9;May 9, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kathleen S. Skarvan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kathleen S. Skarvan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>elmd230506_ex32-2.htm
<DESCRIPTION>CERTIFICATION PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In connection with the Quarterly Report
of Electromed, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Bradley M. Nagel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect;1350,
as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#9;May 9, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bradley M. Nagel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley M. Nagel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <div style="border-bottom: Gray 3pt solid; margin-top: 12pt; margin-bottom: 6pt; margin-right: 0"><p style="margin: 0pt 0 0pt 0pt">&#160;</p></div>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>elmd-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9aM5s7xRiXhun8uCaHNMOayFObPtxpd9qelBvm1+bak6HyklarAboiRhcoBGwbwO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:elmd="http://electromed.com/20230331" elementFormDefault="qualified" targetNamespace="http://electromed.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://electromed.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
	  <link:definition>00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/InterimFinancialReporting" id="InterimFinancialReporting">
	  <link:definition>00000007 - Disclosure - Interim Financial Reporting</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/Revenues" id="Revenues">
	  <link:definition>00000008 - Disclosure - Revenues</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/Inventories" id="Inventories">
	  <link:definition>00000009 - Disclosure - Inventories</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/WarrantyReserve" id="WarrantyReserve">
	  <link:definition>00000010 - Disclosure - Warranty Reserve</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000011 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/FinancingArrangements" id="FinancingArrangements">
	  <link:definition>00000012 - Disclosure - Financing Arrangements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/CommonStock" id="CommonStock">
	  <link:definition>00000013 - Disclosure - Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/Share-basedCompensation" id="Share-basedCompensation">
	  <link:definition>00000014 - Disclosure - Share-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/InterimFinancialReportingPolicies" id="InterimFinancialReportingPolicies">
	  <link:definition>00000016 - Disclosure - Interim Financial Reporting (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/RevenuesTables" id="RevenuesTables">
	  <link:definition>00000017 - Disclosure - Revenues (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000018 - Disclosure - Inventories (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/WarrantyReserveTables" id="WarrantyReserveTables">
	  <link:definition>00000019 - Disclosure - Warranty Reserve (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/Share-basedCompensationTables" id="Share-basedCompensationTables">
	  <link:definition>00000020 - Disclosure - Share-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" id="InterimFinancialReportingDetailsNarrative">
	  <link:definition>00000021 - Disclosure - Interim Financial Reporting (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" id="InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails">
	  <link:definition>00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" id="FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails">
	  <link:definition>00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" id="ComponentsOfInventoryWereAsFollowsDetails">
	  <link:definition>00000024 - Disclosure - The components of inventory were as follows (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" id="ChangesInCompanysWarrantyReserveWereAsFollowsDetails">
	  <link:definition>00000025 - Disclosure - Changes in the Company&#8217;s warranty reserve were as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/FinancingArrangementsDetailsNarrative" id="FinancingArrangementsDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Financing Arrangements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/CommonStockDetailsNarrative" id="CommonStockDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" id="StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails">
	  <link:definition>00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" id="FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails">
	  <link:definition>00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://electromed.com/role/Share-basedCompensationDetailsNarrative" id="Share-basedCompensationDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Share-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="elmd-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="elmd-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="elmd-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="elmd-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="elmd_InternationalMember" name="InternationalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_HomeCareMember" name="HomeCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_InstitutionalMember" name="InstitutionalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_HomeCareDistributorMember" name="HomeCareDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_InternationalOneMember" name="InternationalOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_CommercialMember" name="CommercialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_MedicareMember" name="MedicareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_MedicaidMember" name="MedicaidMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_CapitalStockMember" name="CapitalStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_AuthorizedSharesUndesignatedStockMember" name="AuthorizedSharesUndesignatedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_EmployeeMember" name="EmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" name="PropertyAndEquipmentAcquisitionsInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_IntangibleAssetAcquisitionsInAccountsPayable" name="IntangibleAssetAcquisitionsInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" name="LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_DemonstrationEquipmentReturnedToInventory" name="DemonstrationEquipmentReturnedToInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_PayerTypeAxis" name="PayerTypeAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="elmd_PayerTypeDomain" name="PayerTypeDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" name="BorrowingCapacityOfEligibleAccountsReceivablePercent" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_DebtInstrumentCovenantComplianceAmount" name="DebtInstrumentCovenantComplianceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>elmd-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://electromed.com/role/Cover" xlink:href="elmd-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheets" xlink:href="elmd-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheetsParenthetical" xlink:href="elmd-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfOperations" xlink:href="elmd-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfCashFlows" xlink:href="elmd-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:href="elmd-20230331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReporting" xlink:href="elmd-20230331.xsd#InterimFinancialReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Revenues" xlink:href="elmd-20230331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Inventories" xlink:href="elmd-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserve" xlink:href="elmd-20230331.xsd#WarrantyReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxes" xlink:href="elmd-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangements" xlink:href="elmd-20230331.xsd#FinancingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStock" xlink:href="elmd-20230331.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensation" xlink:href="elmd-20230331.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommitmentsAndContingencies" xlink:href="elmd-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:href="elmd-20230331.xsd#InterimFinancialReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/RevenuesTables" xlink:href="elmd-20230331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InventoriesTables" xlink:href="elmd-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserveTables" xlink:href="elmd-20230331.xsd#WarrantyReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationTables" xlink:href="elmd-20230331.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:href="elmd-20230331.xsd#InterimFinancialReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:href="elmd-20230331.xsd#InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:href="elmd-20230331.xsd#FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ComponentsOfInventoryWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:href="elmd-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:href="elmd-20230331.xsd#FinancingArrangementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStockDetailsNarrative" xlink:href="elmd-20230331.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:href="elmd-20230331.xsd#StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:href="elmd-20230331.xsd#FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:href="elmd-20230331.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="loc_us-gaapIncomeTaxReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapIncomeTaxReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerAsset" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AccruedCompensation" xlink:label="loc_elmdAccruedCompensation" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_elmdAccruedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Statements of Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReporting" xlink:title="00000007 - Disclosure - Interim Financial Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Revenues" xlink:title="00000008 - Disclosure - Revenues" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Inventories" xlink:title="00000009 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserve" xlink:title="00000010 - Disclosure - Warranty Reserve" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxes" xlink:title="00000011 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangements" xlink:title="00000012 - Disclosure - Financing Arrangements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStock" xlink:title="00000013 - Disclosure - Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensation" xlink:title="00000014 - Disclosure - Share-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:title="00000016 - Disclosure - Interim Financial Reporting (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/RevenuesTables" xlink:title="00000017 - Disclosure - Revenues (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/InventoriesTables" xlink:title="00000018 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserveTables" xlink:title="00000019 - Disclosure - Warranty Reserve (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationTables" xlink:title="00000020 - Disclosure - Share-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:title="00000021 - Disclosure - Interim Financial Reporting (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:title="00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:title="00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:title="00000024 - Disclosure - The components of inventory were as follows (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:title="00000025 - Disclosure - Changes in the Company&#8217;s warranty reserve were as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000026 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:title="00000027 - Disclosure - Financing Arrangements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStockDetailsNarrative" xlink:title="00000028 - Disclosure - Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:title="00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000031 - Disclosure - Share-Based Compensation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>elmd-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://electromed.com/role/Cover" xlink:href="elmd-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheets" xlink:href="elmd-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheetsParenthetical" xlink:href="elmd-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfOperations" xlink:href="elmd-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfCashFlows" xlink:href="elmd-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:href="elmd-20230331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReporting" xlink:href="elmd-20230331.xsd#InterimFinancialReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Revenues" xlink:href="elmd-20230331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Inventories" xlink:href="elmd-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserve" xlink:href="elmd-20230331.xsd#WarrantyReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxes" xlink:href="elmd-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangements" xlink:href="elmd-20230331.xsd#FinancingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStock" xlink:href="elmd-20230331.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensation" xlink:href="elmd-20230331.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommitmentsAndContingencies" xlink:href="elmd-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:href="elmd-20230331.xsd#InterimFinancialReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/RevenuesTables" xlink:href="elmd-20230331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InventoriesTables" xlink:href="elmd-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserveTables" xlink:href="elmd-20230331.xsd#WarrantyReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationTables" xlink:href="elmd-20230331.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:href="elmd-20230331.xsd#InterimFinancialReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:href="elmd-20230331.xsd#InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:href="elmd-20230331.xsd#FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ComponentsOfInventoryWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:href="elmd-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:href="elmd-20230331.xsd#FinancingArrangementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStockDetailsNarrative" xlink:href="elmd-20230331.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:href="elmd-20230331.xsd#StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:href="elmd-20230331.xsd#FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:href="elmd-20230331.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReporting" xlink:title="00000007 - Disclosure - Interim Financial Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Revenues" xlink:title="00000008 - Disclosure - Revenues" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Inventories" xlink:title="00000009 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserve" xlink:title="00000010 - Disclosure - Warranty Reserve" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxes" xlink:title="00000011 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangements" xlink:title="00000012 - Disclosure - Financing Arrangements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStock" xlink:title="00000013 - Disclosure - Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensation" xlink:title="00000014 - Disclosure - Share-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:title="00000016 - Disclosure - Interim Financial Reporting (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/RevenuesTables" xlink:title="00000017 - Disclosure - Revenues (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/InventoriesTables" xlink:title="00000018 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserveTables" xlink:title="00000019 - Disclosure - Warranty Reserve (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationTables" xlink:title="00000020 - Disclosure - Share-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:title="00000021 - Disclosure - Interim Financial Reporting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalMember" xlink:label="loc_elmdInternationalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_elmdInternationalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:title="00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareMember" xlink:label="loc_elmdHomeCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdHomeCareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InstitutionalMember" xlink:label="loc_elmdInstitutionalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdInstitutionalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareDistributorMember" xlink:label="loc_elmdHomeCareDistributorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdHomeCareDistributorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalOneMember" xlink:label="loc_elmdInternationalOneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdInternationalOneMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeAxis" xlink:label="loc_elmdPayerTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_elmdPayerTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeDomain" xlink:label="loc_elmdPayerTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_elmdPayerTypeAxis" xlink:to="loc_elmdPayerTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeDomain" xlink:label="loc_elmdPayerTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_elmdPayerTypeAxis" xlink:to="loc_elmdPayerTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CommercialMember" xlink:label="loc_elmdCommercialMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdCommercialMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicareMember" xlink:label="loc_elmdMedicareMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdMedicareMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicaidMember" xlink:label="loc_elmdMedicaidMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdMedicaidMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_OtherMember" xlink:label="loc_elmdOtherMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdOtherMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_370" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:title="00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:title="00000024 - Disclosure - The components of inventory were as follows (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:title="00000025 - Disclosure - Changes in the Company&#8217;s warranty reserve were as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000026 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:title="00000027 - Disclosure - Financing Arrangements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:label="loc_elmdBorrowingCapacityOfEligibleAccountsReceivablePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_elmdBorrowingCapacityOfEligibleAccountsReceivablePercent_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_DebtInstrumentCovenantComplianceAmount" xlink:label="loc_elmdDebtInstrumentCovenantComplianceAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_elmdDebtInstrumentCovenantComplianceAmount_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStockDetailsNarrative" xlink:title="00000028 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CapitalStockMember" xlink:label="loc_elmdCapitalStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_elmdCapitalStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AuthorizedSharesUndesignatedStockMember" xlink:label="loc_elmdAuthorizedSharesUndesignatedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_elmdAuthorizedSharesUndesignatedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:title="00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000031 - Disclosure - Share-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_EmployeeMember" xlink:label="loc_elmdEmployeeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_elmdEmployeeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>elmd-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalMember" xlink:label="elmd_InternationalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InternationalMember" xlink:to="elmd_InternationalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_InternationalMember_lbl" xml:lang="en-US">International [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareMember" xlink:label="elmd_HomeCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_HomeCareMember" xlink:to="elmd_HomeCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_HomeCareMember_lbl" xml:lang="en-US">Home Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InstitutionalMember" xlink:label="elmd_InstitutionalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InstitutionalMember" xlink:to="elmd_InstitutionalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_InstitutionalMember_lbl" xml:lang="en-US">Institutional [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareDistributorMember" xlink:label="elmd_HomeCareDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_HomeCareDistributorMember" xlink:to="elmd_HomeCareDistributorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_HomeCareDistributorMember_lbl" xml:lang="en-US">Home Care Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalOneMember" xlink:label="elmd_InternationalOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InternationalOneMember" xlink:to="elmd_InternationalOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_InternationalOneMember_lbl" xml:lang="en-US">International One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeAxis" xlink:label="elmd_PayerTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_PayerTypeAxis" xlink:to="elmd_PayerTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_PayerTypeAxis_lbl" xml:lang="en-US">Payer Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CommercialMember" xlink:label="elmd_CommercialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_CommercialMember" xlink:to="elmd_CommercialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_CommercialMember_lbl" xml:lang="en-US">Commercial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicareMember" xlink:label="elmd_MedicareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_MedicareMember" xlink:to="elmd_MedicareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_MedicareMember_lbl" xml:lang="en-US">Medicare [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicaidMember" xlink:label="elmd_MedicaidMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_MedicaidMember" xlink:to="elmd_MedicaidMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_MedicaidMember_lbl" xml:lang="en-US">Medicaid [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_OtherMember" xlink:label="elmd_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_OtherMember" xlink:to="elmd_OtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_OtherMember_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CapitalStockMember" xlink:label="elmd_CapitalStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_CapitalStockMember" xlink:to="elmd_CapitalStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_CapitalStockMember_lbl" xml:lang="en-US">Capital Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AuthorizedSharesUndesignatedStockMember" xlink:label="elmd_AuthorizedSharesUndesignatedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_AuthorizedSharesUndesignatedStockMember" xlink:to="elmd_AuthorizedSharesUndesignatedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_AuthorizedSharesUndesignatedStockMember_lbl" xml:lang="en-US">Authorized Shares Undesignated Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_EmployeeMember" xlink:label="elmd_EmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_EmployeeMember" xlink:to="elmd_EmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable (net of allowances for doubtful accounts of $45,000)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xml:lang="en-US">Income tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-life intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrual_lbl" xml:lang="en-US">Warranty reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:to="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Shareholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,556,600 and 8,475,438 shares issued and outstanding, as of March 31, 2023 and June 30, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained earnings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net income before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Income per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of finite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Contract assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Income tax receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AccruedCompensation" xlink:label="elmd_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_AccruedCompensation" xlink:to="elmd_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="elmd_AccruedCompensation_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Expenditures for property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditures for finite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Taxes paid on net share settlement of stock option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Disclosures of Noncash Investing and Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" xlink:label="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" xlink:to="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable_lbl" xml:lang="en-US">Property and equipment acquisitions in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_IntangibleAssetAcquisitionsInAccountsPayable" xlink:label="elmd_IntangibleAssetAcquisitionsInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_IntangibleAssetAcquisitionsInAccountsPayable" xlink:to="elmd_IntangibleAssetAcquisitionsInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_IntangibleAssetAcquisitionsInAccountsPayable_lbl" xml:lang="en-US">Intangible asset acquisitions in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:to="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_lbl" xml:lang="en-US">Lease assets obtained in exchange for new operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_DemonstrationEquipmentReturnedToInventory" xlink:label="elmd_DemonstrationEquipmentReturnedToInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_DemonstrationEquipmentReturnedToInventory" xlink:to="elmd_DemonstrationEquipmentReturnedToInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_DemonstrationEquipmentReturnedToInventory_lbl" xml:lang="en-US">Demonstration equipment returned to inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes paid on stock options exercised on a net basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Forfeiture of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Forfeiture of restricted stock (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance at ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Interim Financial Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAndProductWarrantiesAbstract" xlink:label="us-gaap_GuaranteesAndProductWarrantiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesAndProductWarrantiesAbstract" xlink:to="us-gaap_GuaranteesAndProductWarrantiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteesAndProductWarrantiesAbstract_lbl" xml:lang="en-US">Guarantees and Product Warranties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="us-gaap_ProductWarrantyDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock_lbl" xml:lang="en-US">Warranty Reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Financing Arrangements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net income per common share.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">In the following table, net revenues are disaggregated by market:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">The following table provides information about contract assets from contracts with customers:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">The components of inventory were as follows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_lbl" xml:lang="en-US">Changes in the Company&#8217;s warranty reserve were as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock option transactions during the nine months ended March 31, 2023 are summarized as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The following assumptions were used to estimate the fair value of stock options granted:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_2_lbl" xml:lang="en-US">Contract assets, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:to="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_lbl" xml:lang="en-US">Reclassification of contract assets to accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract assets recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xml:lang="en-US">Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_3_lbl" xml:lang="en-US">Contract assets, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInventorySupplies_lbl" xml:lang="en-US">Parts inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="us-gaap_OtherInventoryInTransit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryInTransit" xlink:to="us-gaap_OtherInventoryInTransit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInventoryInTransit_lbl" xml:lang="en-US">Estimated inventory to be returned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Less: Reserve for obsolescence</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ProductWarrantyAccrual_2_lbl" xml:lang="en-US">Warranty reserve, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:label="us-gaap_ProductWarrantyAccrualWarrantiesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="us-gaap_ProductWarrantyAccrualWarrantiesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualWarrantiesIssued_lbl" xml:lang="en-US">Accrual for products sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments" xlink:label="us-gaap_ProductWarrantyAccrualPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualPayments" xlink:to="us-gaap_ProductWarrantyAccrualPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProductWarrantyAccrualPayments_lbl" xml:lang="en-US">Expenditures and costs incurred for warranty claims</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ProductWarrantyAccrual_3_lbl" xml:lang="en-US">Warranty reserve, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Discrete current tax benefit - non-qualified stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line of Credit, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Basis spread on rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US">Available borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:label="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:to="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_lbl" xml:lang="en-US">Available borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Line of credit facility, expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_DebtInstrumentCovenantComplianceAmount" xlink:label="elmd_DebtInstrumentCovenantComplianceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_DebtInstrumentCovenantComplianceAmount" xlink:to="elmd_DebtInstrumentCovenantComplianceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_DebtInstrumentCovenantComplianceAmount_lbl" xml:lang="en-US">Minimum tangible net worth to be maintained</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2_lbl" xml:lang="en-US">Number of share repurchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Repurchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning | shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Options outstanding, beginning | $ / shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" xlink:label="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" xlink:to="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled or Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Cancelled or Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending | shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Options outstanding, ending | shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average contractual term outstanding stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Outstanding exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value on grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Restricted stock - vested (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weight average fair value -vested restricted stock (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted stock - unvested (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weight average fair value - unvested restricted stock (per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InternationalMember" xlink:to="elmd_InternationalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_InternationalMember_doc" xml:lang="en-US">This member stands for international member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_HomeCareMember" xlink:to="elmd_HomeCareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_HomeCareMember_doc" xml:lang="en-US">This member stands for home care member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InstitutionalMember" xlink:to="elmd_InstitutionalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_InstitutionalMember_doc" xml:lang="en-US">This member stands for institutional member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_HomeCareDistributorMember" xlink:to="elmd_HomeCareDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_HomeCareDistributorMember_doc" xml:lang="en-US">This member stands for home care distributor member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_InternationalOneMember" xlink:to="elmd_InternationalOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_InternationalOneMember_doc" xml:lang="en-US">This member stands for international one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_PayerTypeAxis" xlink:to="elmd_PayerTypeAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_PayerTypeAxis_doc" xml:lang="en-US">This member stands for paper type axis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_CommercialMember" xlink:to="elmd_CommercialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_CommercialMember_doc" xml:lang="en-US">This member stands for commercial member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_MedicareMember" xlink:to="elmd_MedicareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_MedicareMember_doc" xml:lang="en-US">This member stands for medicare member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_MedicaidMember" xlink:to="elmd_MedicaidMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_MedicaidMember_doc" xml:lang="en-US">This member stands for medicaid member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_OtherMember" xlink:to="elmd_OtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_OtherMember_doc" xml:lang="en-US">This member stands for other member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:to="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_doc" xml:lang="en-US">This element represent borrowing capacity of eligible accounts receivable percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_DebtInstrumentCovenantComplianceAmount" xlink:to="elmd_DebtInstrumentCovenantComplianceAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_DebtInstrumentCovenantComplianceAmount_doc" xml:lang="en-US">This element represent debt instrument covenant compliance amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_CapitalStockMember" xlink:to="elmd_CapitalStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_CapitalStockMember_doc" xml:lang="en-US">This member stands for capital stock member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_AuthorizedSharesUndesignatedStockMember" xlink:to="elmd_AuthorizedSharesUndesignatedStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_AuthorizedSharesUndesignatedStockMember_doc" xml:lang="en-US">This member stands for authorized shares undesignated stock member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" xlink:to="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_doc" xml:lang="en-US">This element represent share based compensation arrangement by share based payment award options grants in period weighted average exercise date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_EmployeeMember" xlink:to="elmd_EmployeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_EmployeeMember_doc" xml:lang="en-US">This member stands for employee member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_AccruedCompensation" xlink:to="elmd_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_AccruedCompensation_doc" xml:lang="en-US">This element represent accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" xlink:to="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable_doc" xml:lang="en-US">This element represent property and equipment acquisitions in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_IntangibleAssetAcquisitionsInAccountsPayable" xlink:to="elmd_IntangibleAssetAcquisitionsInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_IntangibleAssetAcquisitionsInAccountsPayable_doc" xml:lang="en-US">This element represent intangible asset acquisitions in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:to="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_doc" xml:lang="en-US">This element represent lease assets obtained in exchange for new operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_DemonstrationEquipmentReturnedToInventory" xlink:to="elmd_DemonstrationEquipmentReturnedToInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="elmd_DemonstrationEquipmentReturnedToInventory_doc" xml:lang="en-US">This element represent demonstration equipment returned to inventory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_AccruedCompensation" xlink:to="elmd_AccruedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_AccruedCompensation_3_lbl" xml:lang="en-US">Accrued Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory Valuation Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualPayments" xlink:to="us-gaap_ProductWarrantyAccrualPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualPayments_2_lbl" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:to="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent_3_lbl" xml:lang="en-US">Borrowing Capacity of Eligible Accounts Receivable Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>elmd-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://electromed.com/role/Cover" xlink:href="elmd-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheets" xlink:href="elmd-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/BalanceSheetsParenthetical" xlink:href="elmd-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfOperations" xlink:href="elmd-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfCashFlows" xlink:href="elmd-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:href="elmd-20230331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReporting" xlink:href="elmd-20230331.xsd#InterimFinancialReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Revenues" xlink:href="elmd-20230331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Inventories" xlink:href="elmd-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserve" xlink:href="elmd-20230331.xsd#WarrantyReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxes" xlink:href="elmd-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangements" xlink:href="elmd-20230331.xsd#FinancingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStock" xlink:href="elmd-20230331.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensation" xlink:href="elmd-20230331.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommitmentsAndContingencies" xlink:href="elmd-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:href="elmd-20230331.xsd#InterimFinancialReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/RevenuesTables" xlink:href="elmd-20230331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InventoriesTables" xlink:href="elmd-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/WarrantyReserveTables" xlink:href="elmd-20230331.xsd#WarrantyReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationTables" xlink:href="elmd-20230331.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:href="elmd-20230331.xsd#InterimFinancialReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:href="elmd-20230331.xsd#InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:href="elmd-20230331.xsd#FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ComponentsOfInventoryWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:href="elmd-20230331.xsd#ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:href="elmd-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:href="elmd-20230331.xsd#FinancingArrangementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/CommonStockDetailsNarrative" xlink:href="elmd-20230331.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:href="elmd-20230331.xsd#StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:href="elmd-20230331.xsd#FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:href="elmd-20230331.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="loc_us-gaapIncomeTaxReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AccruedCompensation" xlink:label="loc_elmdAccruedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_elmdAccruedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable" xlink:label="loc_elmdPropertyAndEquipmentAcquisitionsInAccountsPayable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_elmdPropertyAndEquipmentAcquisitionsInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_IntangibleAssetAcquisitionsInAccountsPayable" xlink:label="loc_elmdIntangibleAssetAcquisitionsInAccountsPayable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_elmdIntangibleAssetAcquisitionsInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_elmdLeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_elmdLeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_DemonstrationEquipmentReturnedToInventory" xlink:label="loc_elmdDemonstrationEquipmentReturnedToInventory" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_elmdDemonstrationEquipmentReturnedToInventory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReporting" xlink:title="00000007 - Disclosure - Interim Financial Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Revenues" xlink:title="00000008 - Disclosure - Revenues">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Inventories" xlink:title="00000009 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserve" xlink:title="00000010 - Disclosure - Warranty Reserve">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAndProductWarrantiesAbstract" xlink:label="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock" xlink:label="loc_us-gaapProductWarrantyDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapProductWarrantyDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxes" xlink:title="00000011 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangements" xlink:title="00000012 - Disclosure - Financing Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStock" xlink:title="00000013 - Disclosure - Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensation" xlink:title="00000014 - Disclosure - Share-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingPolicies" xlink:title="00000016 - Disclosure - Interim Financial Reporting (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/RevenuesTables" xlink:title="00000017 - Disclosure - Revenues (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/InventoriesTables" xlink:title="00000018 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/WarrantyReserveTables" xlink:title="00000019 - Disclosure - Warranty Reserve (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAndProductWarrantiesAbstract" xlink:label="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:label="loc_us-gaapScheduleOfProductWarrantyLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationTables" xlink:title="00000020 - Disclosure - Share-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/InterimFinancialReportingDetailsNarrative" xlink:title="00000021 - Disclosure - Interim Financial Reporting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalMember" xlink:label="loc_elmdInternationalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_elmdInternationalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails" xlink:title="00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareMember" xlink:label="loc_elmdHomeCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdHomeCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InstitutionalMember" xlink:label="loc_elmdInstitutionalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdInstitutionalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_HomeCareDistributorMember" xlink:label="loc_elmdHomeCareDistributorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdHomeCareDistributorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_InternationalOneMember" xlink:label="loc_elmdInternationalOneMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_elmdInternationalOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeAxis" xlink:label="loc_elmdPayerTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_elmdPayerTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_PayerTypeDomain" xlink:label="loc_elmdPayerTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elmdPayerTypeAxis" xlink:to="loc_elmdPayerTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CommercialMember" xlink:label="loc_elmdCommercialMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdCommercialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicareMember" xlink:label="loc_elmdMedicareMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdMedicareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_MedicaidMember" xlink:label="loc_elmdMedicaidMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdMedicaidMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_OtherMember" xlink:label="loc_elmdOtherMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_elmdPayerTypeDomain" xlink:to="loc_elmdOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails" xlink:title="00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaapContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" xlink:title="00000024 - Disclosure - The components of inventory were as follows (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies" xlink:label="loc_us-gaapOtherInventorySupplies" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapOtherInventorySupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaapOtherInventoryInTransit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapOtherInventoryInTransit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" xlink:title="00000025 - Disclosure - Changes in the Company&#8217;s warranty reserve were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAndProductWarrantiesAbstract" xlink:label="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:label="loc_us-gaapProductWarrantyAccrualWarrantiesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments" xlink:label="loc_us-gaapProductWarrantyAccrualPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapProductWarrantyAccrualPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteesAndProductWarrantiesAbstract" xlink:to="loc_us-gaapProductWarrantyAccrual_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000026 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/FinancingArrangementsDetailsNarrative" xlink:title="00000027 - Disclosure - Financing Arrangements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVariableRateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:label="loc_elmdBorrowingCapacityOfEligibleAccountsReceivablePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_elmdBorrowingCapacityOfEligibleAccountsReceivablePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_DebtInstrumentCovenantComplianceAmount" xlink:label="loc_elmdDebtInstrumentCovenantComplianceAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_elmdDebtInstrumentCovenantComplianceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/CommonStockDetailsNarrative" xlink:title="00000028 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_CapitalStockMember" xlink:label="loc_elmdCapitalStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_elmdCapitalStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_AuthorizedSharesUndesignatedStockMember" xlink:label="loc_elmdAuthorizedSharesUndesignatedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_elmdAuthorizedSharesUndesignatedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails" xlink:title="00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" xlink:label="loc_elmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_elmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://electromed.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000031 - Disclosure - Share-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="elmd-20230331.xsd#elmd_EmployeeMember" xlink:label="loc_elmdEmployeeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_elmdEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849264575296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Electromed,
    Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001488917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1732920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500
        Sixth Avenue NW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
        Prague<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">56071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">758-9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,561,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849263331664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,776,000<span></span>
</td>
<td class="nump">$ 8,153,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowances for doubtful accounts of $45,000)</a></td>
<td class="nump">22,345,000<span></span>
</td>
<td class="nump">21,052,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">570,000<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,451,000<span></span>
</td>
<td class="nump">3,178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,808,000<span></span>
</td>
<td class="nump">1,870,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income tax receivable</a></td>
<td class="nump">219,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,169,000<span></span>
</td>
<td class="nump">34,539,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,502,000<span></span>
</td>
<td class="nump">4,568,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-life intangible assets, net</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">599,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">1,506,000<span></span>
</td>
<td class="nump">1,538,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,841,000<span></span>
</td>
<td class="nump">41,364,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,289,000<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,082,000<span></span>
</td>
<td class="nump">2,742,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Warranty reserve</a></td>
<td class="nump">1,333,000<span></span>
</td>
<td class="nump">1,256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,713,000<span></span>
</td>
<td class="nump">1,840,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,417,000<span></span>
</td>
<td class="nump">7,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,447,000<span></span>
</td>
<td class="nump">7,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,556,600 and 8,475,438 shares issued and outstanding, as of March 31, 2023 and June 30, 2022, respectively</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">18,548,000<span></span>
</td>
<td class="nump">18,308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">17,760,000<span></span>
</td>
<td class="nump">15,780,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,394,000<span></span>
</td>
<td class="nump">34,173,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 42,841,000<span></span>
</td>
<td class="nump">$ 41,364,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849265633440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">8,556,600<span></span>
</td>
<td class="nump">8,475,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">8,556,600<span></span>
</td>
<td class="nump">8,475,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849264352448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="nump">$ 12,068,000<span></span>
</td>
<td class="nump">$ 10,141,000<span></span>
</td>
<td class="nump">$ 34,455,000<span></span>
</td>
<td class="nump">$ 30,390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">3,012,000<span></span>
</td>
<td class="nump">2,398,000<span></span>
</td>
<td class="nump">8,386,000<span></span>
</td>
<td class="nump">7,066,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,056,000<span></span>
</td>
<td class="nump">7,743,000<span></span>
</td>
<td class="nump">26,069,000<span></span>
</td>
<td class="nump">23,324,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,694,000<span></span>
</td>
<td class="nump">6,544,000<span></span>
</td>
<td class="nump">22,937,000<span></span>
</td>
<td class="nump">19,806,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">166,000<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
<td class="nump">1,041,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,860,000<span></span>
</td>
<td class="nump">6,880,000<span></span>
</td>
<td class="nump">23,555,000<span></span>
</td>
<td class="nump">20,847,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,196,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="nump">2,514,000<span></span>
</td>
<td class="nump">2,477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">1,222,000<span></span>
</td>
<td class="nump">869,000<span></span>
</td>
<td class="nump">2,551,000<span></span>
</td>
<td class="nump">2,498,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
<td class="nump">418,000<span></span>
</td>
<td class="nump">576,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,075,000<span></span>
</td>
<td class="nump">$ 645,000<span></span>
</td>
<td class="nump">$ 2,133,000<span></span>
</td>
<td class="nump">$ 1,922,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">8,461,531<span></span>
</td>
<td class="nump">8,454,504<span></span>
</td>
<td class="nump">8,449,623<span></span>
</td>
<td class="nump">8,485,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">8,710,106<span></span>
</td>
<td class="nump">8,744,535<span></span>
</td>
<td class="nump">8,694,407<span></span>
</td>
<td class="nump">8,762,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849266392160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,133,000<span></span>
</td>
<td class="nump">$ 1,922,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of finite-life intangible assets</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">506,000<span></span>
</td>
<td class="nump">703,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,293,000)<span></span>
</td>
<td class="num">(2,582,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contract assets</a></td>
<td class="num">(284,000)<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(264,000)<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="num">(519,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Income tax receivable, net</a></td>
<td class="num">(270,000)<span></span>
</td>
<td class="num">(443,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(111,000)<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_AccruedCompensation', window );">Accrued compensation</a></td>
<td class="num">(660,000)<span></span>
</td>
<td class="num">(173,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">316,000<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Expenditures for property and equipment</a></td>
<td class="num">(1,221,000)<span></span>
</td>
<td class="num">(980,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for finite-life intangible assets</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,275,000)<span></span>
</td>
<td class="num">(1,066,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on net share settlement of stock option exercises</a></td>
<td class="num">(305,000)<span></span>
</td>
<td class="num">(70,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(153,000)<span></span>
</td>
<td class="num">(962,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(418,000)<span></span>
</td>
<td class="num">(1,032,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(1,377,000)<span></span>
</td>
<td class="num">(2,045,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">8,153,000<span></span>
</td>
<td class="nump">11,889,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">6,776,000<span></span>
</td>
<td class="nump">9,844,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">655,000<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable', window );">Property and equipment acquisitions in accounts payable</a></td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_IntangibleAssetAcquisitionsInAccountsPayable', window );">Intangible asset acquisitions in accounts payable</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities', window );">Lease assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_DemonstrationEquipmentReturnedToInventory', window );">Demonstration equipment returned to inventory</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_DemonstrationEquipmentReturnedToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent demonstration equipment returned to inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_DemonstrationEquipmentReturnedToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_IntangibleAssetAcquisitionsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent intangible asset acquisitions in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_IntangibleAssetAcquisitionsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent lease assets obtained in exchange for new operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent property and equipment acquisitions in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849264776160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Shareholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">$ 17,409,000<span></span>
</td>
<td class="nump">$ 14,922,000<span></span>
</td>
<td class="nump">$ 32,416,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Jun. 30, 2021</a></td>
<td class="nump">8,533,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
<td class="nump">25,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">10,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid on stock options exercised on a net basis</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(64,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(64,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">17,594,000<span></span>
</td>
<td class="nump">15,361,000<span></span>
</td>
<td class="nump">33,041,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Sep. 30, 2021</a></td>
<td class="nump">8,569,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">17,409,000<span></span>
</td>
<td class="nump">14,922,000<span></span>
</td>
<td class="nump">32,416,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Jun. 30, 2021</a></td>
<td class="nump">8,533,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(962,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,042,000<span></span>
</td>
<td class="nump">15,883,000<span></span>
</td>
<td class="nump">34,010,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Mar. 31, 2022</a></td>
<td class="nump">8,508,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">17,594,000<span></span>
</td>
<td class="nump">15,361,000<span></span>
</td>
<td class="nump">33,041,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Sep. 30, 2021</a></td>
<td class="nump">8,569,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">838,000<span></span>
</td>
<td class="nump">838,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid on stock options exercised on a net basis</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(662,000)<span></span>
</td>
<td class="num">(663,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="num">(55,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">17,865,000<span></span>
</td>
<td class="nump">15,537,000<span></span>
</td>
<td class="nump">33,487,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">8,533,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">645,000<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">326,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(299,000)<span></span>
</td>
<td class="num">(299,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="num">(24,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,042,000<span></span>
</td>
<td class="nump">15,883,000<span></span>
</td>
<td class="nump">34,010,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Mar. 31, 2022</a></td>
<td class="nump">8,508,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,308,000<span></span>
</td>
<td class="nump">15,780,000<span></span>
</td>
<td class="nump">$ 34,173,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Jun. 30, 2022</a></td>
<td class="nump">8,475,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,475,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
<td class="nump">27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">11,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid on stock options exercised on a net basis</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(145,000)<span></span>
</td>
<td class="num">(145,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="num">(14,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Forfeiture of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Forfeiture of restricted stock (in shares)</a></td>
<td class="num">(14,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,343,000<span></span>
</td>
<td class="nump">15,716,000<span></span>
</td>
<td class="nump">34,144,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Sep. 30, 2022</a></td>
<td class="nump">8,485,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,308,000<span></span>
</td>
<td class="nump">15,780,000<span></span>
</td>
<td class="nump">$ 34,173,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Jun. 30, 2022</a></td>
<td class="nump">8,475,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,475,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (153,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(239,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">18,548,000<span></span>
</td>
<td class="nump">17,760,000<span></span>
</td>
<td class="nump">$ 36,394,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Mar. 31, 2023</a></td>
<td class="nump">8,556,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,556,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,343,000<span></span>
</td>
<td class="nump">15,716,000<span></span>
</td>
<td class="nump">$ 34,144,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Sep. 30, 2022</a></td>
<td class="nump">8,485,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">977,000<span></span>
</td>
<td class="nump">977,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">18,580,000<span></span>
</td>
<td class="nump">16,685,000<span></span>
</td>
<td class="nump">35,350,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">8,514,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,075,000<span></span>
</td>
<td class="nump">1,075,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">42,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid on stock options exercised on a net basis</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(245,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(245,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 18,548,000<span></span>
</td>
<td class="nump">$ 17,760,000<span></span>
</td>
<td class="nump">$ 36,394,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Mar. 31, 2023</a></td>
<td class="nump">8,556,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,556,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269353936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Interim Financial Reporting</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zgZLgdNGfwwb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Note 1. <span id="xdx_82A_zmOQbaN18oHj">Interim Financial Reporting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Nature of business: </b>Electromed, Inc.
(the &#8220;Company&#8221;) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest
Wall Oscillation (&#8220;HFCWO&#8221;) therapy in pulmonary care for patients of all ages. The Company markets its products in
the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The
Company also sells internationally, primarily through distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">International sales were $<span id="xdx_90B_eus-gaap--Revenues_c20220701__20230331__srt--StatementGeographicalAxis__custom--InternationalMember_zRHEOsdnclIk" title="Net revenues">309,000</span> and $<span id="xdx_903_eus-gaap--Revenues_c20210701__20220331__srt--StatementGeographicalAxis__custom--InternationalMember_zRbLV67T5KQ7" title="Net revenues">432,000</span>
for the nine months ended March 31, 2023 and 2022, respectively. Since its inception, the Company has operated in a single industry
segment: developing, manufacturing and marketing medical equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Impacts of COVID-19 on the Company&#8217;s
business:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The potential impact of the COVID-19 pandemic
and its effects on our operational and financial performance will depend in large part on future developments, which cannot be
reasonably estimated at this time. For a more detailed discussion, see &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; in Part I, Item 2 of this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Basis of presentation: </b>The accompanying
unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities
and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments
consisting of normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results
of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may
be achieved for the full year. The financial statements and related notes do not include all information and footnotes required
by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the
Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (&#8220;fiscal 2022&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">A summary of the Company&#8217;s significant accounting
policies follows:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zAIyugA5IAf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86C_zwAGO7ZjAZg2">Use of estimates.</span> </b>Management uses estimates
and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies
that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements
include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation
and warranty reserve.</p>

<p id="xdx_85E_zLK3gLpTtQ18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z8p7JCUBTdi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86A_zanynNVgxi8d">Net income per common share.</span> </b>Net income
is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using
the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not
vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock
options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive.
Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were
<span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zYrwOWEESbOd" title="Common stock equivalents excluded from calculation of diluted earnings per share">179,992</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOv4v84jj4D8" title="Common stock equivalents excluded from calculation of diluted earnings per share">102,435</span> for the three months ended March 31, 2023 and 2022, respectively, and were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zxrV5XaDJ7zl" title="Common stock equivalents excluded from calculation of diluted earnings per share">200,140</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210701__20220331_zAV5NKvK0i5k" title="Common stock equivalents excluded from calculation of diluted earnings per share">112,427</span> for the nine
months ended March 31, 2023 and 2022, respectively.</p>

<p id="xdx_856_zi0rugzd0seg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz7WRCTqxvWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_861_z2NH1iOxi8ca">Recently Issued Accounting Standards</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">In June 2016, the Financial Accounting Board issued
Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;&#8220;Financial Instruments -- Credit Losses: Measurement of Credit
Losses on Financial Instruments&#8221;,&#160;which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11,
and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including
trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It
is effective for interim and annual reporting periods in fiscal years beginning after December 15, 2022, with early adoption permitted.
The adoption of the standard is not expected to have a significant impact on the Company&#8217;s consolidated results of operations
and financial condition.</p>

<p id="xdx_851_zkD3LR7Vi3Hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269378896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_zGdbEaDPmYOg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Note 2. <span id="xdx_825_zveAcxBhmPA3">Revenues</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Revenue is measured based on consideration specified
in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the
transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all
customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer,
as further described below under <i>Performance obligations and transaction price</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Individual promised goods
and services in a contract are considered a performance obligation and accounted for separately if the individual good or service
is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available
to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes
multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated
standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance
obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs
under Accounting Standards Codification (&#8220;ASC&#8221;) 340-40, &#8220;Other Assets and Deferred Costs&#8221; (&#8220;ASC 340&#8221;),
or other applicable guidance are met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The Company includes shipping and handling
fees in net revenues. Shipping and handling costs associated with the shipment of the Company&#8217;s SmartVest&#174; Airway Clearance
System (&#8220;SmartVest System&#8221;) after control has transferred to a customer are accounted for as a fulfillment cost and
are included in cost of revenues in the Condensed Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The timing of revenue recognition, billings and
cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under <i>Accounts receivable</i>
and <i>Contract assets</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLoifyJ7Myvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Disaggregation of revenues.</b> <span id="xdx_8B8_zbNN7XPeu6Id">In the following
table, net revenues are disaggregated by market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 48%; text-align: left"><span style="font-size: 10pt">Home care</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z86jOQNiggka" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">10,971,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zl1BpvekjHsi" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">9,033,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zqQkL2R3djz8" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">31,335,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVsh5wh4Vq08" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">27,721,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Institutional</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zRmkAT5v63h5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">440,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_z5lgkT0U2RD5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">392,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zDZJvfPHT1F7" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,420,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zlYFcN92AIYa" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,174,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Home care distributor</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zWdaUbftJc3l" style="text-align: right" title="Revenue"><span style="font-size: 10pt">501,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zFnnTkVGaiT5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">520,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zGLv1pAPQV54" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,391,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zzaPj6BkKZci" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,063,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">International</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zIYA14yIQGEc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">156,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zXfHm6g8UJQc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">196,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zaF7SL27pK04" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">309,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zCqWlakdq6r5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">432,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zd5l41CsTMj5" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">12,068,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331_zng3LTz2GCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">10,141,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zVPoLccoxd35" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">34,455,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331_zd3XEnTcWzD3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">30,390,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">In the following table, net home care revenue is
disaggregated by payer type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 47%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zH1XYS8w9Lya" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,787,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zsz8iLiK1zK4" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,358,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zfBVNpoRjc0g" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,706,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zMhoG4GeGNl8" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,738,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zVwjODUXwiNe" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,822,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEBT6kF79IFa" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,027,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_z3dEZQq2uMa3" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,434,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zH9W63PDezOh" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,603,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicaid</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zmH6PG4boQd4" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z4eiQKE6bJ9i" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zOmfmtBqPkpj" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zfB4N5oepocj" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">790,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zlyJTJjKAMrc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zDDGrVnM1117" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">275,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zEpSNMrXMyy8" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">577,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zO9SoJimqs8j" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">590,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z4T44Pxld2Vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,971,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zXvOELmvjwC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,033,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zMeVRJ4XZgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,335,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zvyDOZHiqHPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,721,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8A7_zLc5pPW1XhL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;<span style="font-size: 9pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Revenues in the Company&#8217;s home care, home
care distributor, and international markets are recognized at a point in time when control passes to the customer upon product
shipment or delivery. Revenues in the Company&#8217;s institutional market include revenue recognized at a point in time upon shipment
or delivery as well as revenue recognized over time under operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Performance obligations and transaction price.</b>
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account
under ASC 606, &#8220;Revenue From Contracts With Customers&#8221; (&#8220;ASC 606&#8221;). A contract&#8217;s transaction price
is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue
when, or as, the performance obligation is satisfied. The Company&#8217;s performance obligations and the timing or method of revenue
recognition in each of the Company&#8217;s markets are discussed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Home care market</i>.</b> In the Company&#8217;s
home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised
of three main components &#8211; a generator, a vest and a connecting hose &#8211; that are sold together as an integrated unit.
Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company makes available to its home care
patients limited post-sale services that are not material in the context of the contracts, either individually or taken together,
and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed
when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation:
the SmartVest System.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Home care patients generally will rely on third-party
payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs
to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers&#8217; reimbursement programs fall
into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright
sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest
System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or
(iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues
to use the SmartVest System.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Regardless of the type of transaction, provided
criteria for an enforceable contract are met, it is the Company&#8217;s long- standing business practice to regard all home care
agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government
or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature
installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly
less than expected if the contract is terminated due to changes in the patient&#8217;s status, including insurance coverage, hospitalization,
death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System,
the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies.
As a result, the Company&#8217;s product sales qualify for point in time revenue recognition. Control transfers to the patient,
and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks
and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further
discussed under <i>Accounts receivable</i> and <i>Contract assets</i> below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company&#8217;s contractually stated transaction
prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government
programs. The transaction price for the Company&#8217;s products may be further impacted by variable consideration. ASC 606 requires
the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value
of payments to be received from insurance payers based on historical experience and other available information, subject to the
constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include
(i) capped installment payments, which are subject to the third-party payer&#8217;s termination due to changes in insurance coverage,
death or the patient&#8217;s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility
amounts for deductibles, coinsurance, copays and other similar payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Although estimates may be made on a contract-by-contract
basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable
consideration for portfolios of contracts. The Company&#8217;s estimates of variable consideration consist of amounts it may receive
from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the
payment duration, changes to a patient&#8217;s insurance status, changes in an insurance allowable, claims in appeals with Medicare
and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical
information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has
with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue
recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The
Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize
the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative
revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration
is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of
cumulative revenue under the contract will not occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">For example, for contracts in which the Company
believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is
unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery
experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for
populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving
at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to
payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes
in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in
estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration
are generally not subject to the risk of significant revenue reversal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">For each type of variable consideration discussed
above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For
that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company often receives payment from third-party
payers for SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant
financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer
or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental
purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a
short period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Home care distributors.</i></b> Sales
to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based
rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor&#8217;s
purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within
the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases
in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively
defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount
is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to
the distributor, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Institutional market.</i></b> The Company&#8217;s
institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales
to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received
directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions
and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product
is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions
fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt"><span>&#9679;</span></td><td>Outright sale &#8211; Under these transactions, the Company sells its products for a prescribed
or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and
payment is made within normal credit terms, usually within thirty days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">&#9679;</td><td><span style="font-size: 10pt">Wrap usage agreements &#8211; Under these transactions, the Company
provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These
agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned
to the Company, where it can be refurbished and used again at a later date. Revenue for the consumable wraps is recognized when
control transfers to the customer.</span></td></tr></table>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>International market.</i></b>
Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not
subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery
to the distributor, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Product warranty.</b> The Company offers warranties
on its products. These warranties are assurance-type warranties not sold on a standalone basis or are otherwise considered immaterial
in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates
the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product
is sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Accounts receivable.
</b>The Company&#8217;s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors.
Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid
and private insurance companies. Accounts receivable are carried at amounts estimated to be received from patients under reimbursement
arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines
the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s
financial condition and credit history. Receivables are written off when deemed uncollectible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Contract assets. </b>Contract
assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final
determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the
Company is dependent on a future event such as the patient meeting a deductible prior to the Company&#8217;s claim being processed
by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the
Company&#8217;s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive
payment is unconditional.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zWMBUzxObaea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Contract balances.</b> <span id="xdx_8BA_zTWSoVb7jQr1">The following table
provides information about contract assets from contracts with customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br/>
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br/>
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Contract assets, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20220701__20230331_zojnsWRs8uDl" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets  beginning"><span style="font-size: 10pt">286,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20210701__20220630_zSJp3oDx3Dfg" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets, beginning"><span style="font-size: 10pt">393,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reclassification of contract assets to accounts receivable </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230331_zulTzlgwvoyb" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"><span style="font-size: 10pt">(1,107,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20210701__20220630_zcO5mEItPTre" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"><span style="font-size: 10pt">(833,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Contract assets recognized</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230331_zV7nM92BK2Tc" style="font-size: 10pt; text-align: right" title="Contract assets recognized"><span style="font-size: 10pt">1,372,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210701__20220630_zzmnkmPVAHWe" style="font-size: 10pt; text-align: right" title="Contract assets recognized"><span style="font-size: 10pt">784,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Increase (decrease) as a result of changes
    in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230331_zYT9RjztCYFj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"><span style="font-size: 10pt">19,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20210701__20220630_z60A9HmVzs8j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"><span style="font-size: 10pt">(58,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Contract assets, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230331_z7TEg7dvyzI2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"><span style="font-size: 10pt">570,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20210701__20220630_znjbSdw5tqM8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"><span style="font-size: 10pt">286,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8AA_zLXTeaCb1Itj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>Incremental costs to
obtain a contract. </b>Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs
that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin
on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment
or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred.
These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849263322880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zrBG6lEHYaP1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 3. <span id="xdx_82C_z3esTlzgoW3c">Inventories</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ztm6QJuufMLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><span id="xdx_8BA_zGkVMdu5kD5d">The components of inventory were as follows</span>: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 9.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20230331_zAjqevD72dCk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220630_zFezRGXTIGY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">June
    30, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherInventorySupplies_iI_maINzW5z_maINzrcq_zsHRxqUaYAHi" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Parts inventory</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">2,908,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">2,672,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_maINzW5z_maINzrcq_z76eOK0OCXTd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">213,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_maINzW5z_maINzrcq_zg3MoyojxDv" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Finished goods</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">280,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">469,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--OtherInventoryInTransit_iI_maINzW5z_maINzrcq_zjROX6X1J8Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Estimated inventory to be returned</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">263,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">228,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--InventoryValuationReserves_iNI_di_msINzW5z_msINzrcq_zPO8mebFeD1c" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: Reserve for obsolescence</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(213,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(291,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iI_zICO24i8OXdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,451,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,178,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8A9_zuT5X7Q4dgM4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849270891264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesAndProductWarrantiesAbstract', window );"><strong>Guarantees and Product Warranties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p id="xdx_806_eus-gaap--ProductWarrantyDisclosureTextBlock_zPYKjjjq8wCb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 4. <span id="xdx_825_zm7ErBxP5qcd">Warranty Reserve</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The Company provides a lifetime warranty on
its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales
to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability
in the amount of such costs at the time the product is shipped. Factors that affect the Company&#8217;s warranty reserve include
the number of units shipped, historical and anticipated rates of warranty claims, the product&#8217;s useful life and cost per
claim. The Company periodically assesses the adequacy of its recorded warranty reserve and adjusts the amounts as necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_z81p7xYdAUEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><span id="xdx_8BF_zFHwYYqtavx3">Changes in the Company&#8217;s warranty
reserve were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br/>
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br/>
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Warranty reserve, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230331_znWEmS9LRTn5" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"><span style="font-size: 10pt">1,256,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ProductWarrantyAccrual_iS_c20210701__20220630_zEzcXwsVIr97" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"><span style="font-size: 10pt">940,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Accrual for products sold </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230331_zVZjpbza45Rl" style="font-size: 10pt; text-align: right" title="Accrual for products sold"><span style="font-size: 10pt">290,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20210701__20220630_z1R1172ED1Id" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">494,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><span style="font-size: 10pt">Expenditures and costs
    incurred for warranty claims</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230331_z6CI4SCelsP1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expenditures and costs incurred for warranty claims"><span style="font-size: 10pt">(213,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20210701__20220630_zFvsEIt3Zcuj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(178,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Warranty reserve, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230331_z3trpH4UvIl1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Warranty reserve, ending"><span style="font-size: 10pt">1,333,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ProductWarrantyAccrual_iE_c20210701__20220630_zhP5TRijSnI" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt">1,256,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8AF_zqlmEh3g1yFj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAndProductWarrantiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAndProductWarrantiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269663200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zEhE5mRpJIb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 5. <span id="xdx_828_zGxgpa1ouBr5">Income Taxes</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense was estimated at $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20230331_zfPhFpPGuhpk" title="Income tax expense">147,000</span>
and $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20220701__20230331_zJllbYLgbAS5" title="Income tax expense">418,000</span>, and the effective tax rate was <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20230331_z6WC12it3x5e" title="Effective tax rate">12.0</span>% and <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220701__20230331_zMdO0rdEw2q3" title="Effective tax rate">16.4</span>% for the three and nine months ended March 31, 2023, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2023 includes a discrete current tax benefit of $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20230101__20230331_zBBLtSTZxxa7" title="Discrete current tax benefit - non-qualified stock options exercised">176,000</span>
and $<span id="xdx_902_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220701__20230331_zIix4EjDTQd7" title="Discrete current tax benefit - non-qualified stock options exercised">219,000</span>, respectively, related to the exercise of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense was estimated at $<span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20220331_zp7JYiGqIw9b" title="Income tax expense">224,000</span>
and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210701__20220331_zg53vWkVMix9" title="Income tax expense">576,000</span>, and the effective tax rate was <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20220331_ztjOKQWFZP98" title="Effective tax rate">25.8</span>% and <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210701__20220331_zbSmcCmTpQH" title="Effective tax rate">23.1</span>% for the three and nine months ended March 31, 2022, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2022 includes a discrete current tax benefit of $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220101__20220331_zuYpzyve2tO1" title="Discrete current tax benefit - non-qualified stock options exercised">22,000</span>
and $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20210701__20220331_zA0vJnA3nYIi" title="Discrete current tax benefit - non-qualified stock options exercised">43,000</span>, respectively, related to the exercise of stock options and other items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is subject to U.S. federal and state
income tax in multiple jurisdictions. With limited exceptions, years prior to the Company&#8217;s fiscal year ended June 30, 2019
are no longer open to U.S. federal, state or local examinations by taxing authorities. The Company is not under any current income
tax examinations by any federal, state or local taxing authority. If any issues addressed in the Company&#8217;s tax audits are
resolved in a manner not consistent with management&#8217;s expectations, the Company could be required to adjust its provision
for income taxes in the period such resolution occurs.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269385200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing Arrangements</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zlvGew50A74k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 6. <span id="xdx_822_zTtz57LMREOd">Financing Arrangements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has a credit facility that provides
for a $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3o5E1zjdVMl" title="Maximum borrowing capacity">2,500,000</span> revolving line of credit. There was <span id="xdx_90E_eus-gaap--LinesOfCreditCurrent_iI_do_c20230330__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5wvx3Wh5dIl"><span id="xdx_90F_eus-gaap--LinesOfCreditCurrent_iI_do_c20220630__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zxWjK3EgGFad">no</span></span> outstanding principal balance on the line of credit as of March 31, 2023
or June 30, 2022. Interest on borrowings under the line of credit, if any, accrues at the prime rate (<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVCKA0YkE9S2" title="Interest rate">8.00</span>% at March 31, 2023)
less <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220701__20230331_z1rgPYZCMzPj" title="Basis spread on rate">1.00</span>% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $<span id="xdx_903_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zndZE983dFja" title="Available borrowing capacity">2,500,000</span>
or <span id="xdx_90C_ecustom--BorrowingCapacityOfEligibleAccountsReceivablePercent_iI_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zy7VPEka9iq" title="Available borrowing capacity">57.00</span>% of eligible accounts receivable and the line of credit expires on <span id="xdx_90F_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20220701__20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zqNBIpjNNYse" title="Line of credit facility, expiration date">December 18, 2023</span>, if not renewed before such date.
At March 31, 2023, the maximum $<span id="xdx_901_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zlVkWyUABNTc" title="Available borrowing capacity">2,500,000</span> was eligible for borrowing. Payment obligations under the line of credit, if any, are
secured by a security interest in substantially all of the tangible and intangible assets of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The documents governing
the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not
less than $<span id="xdx_90E_ecustom--DebtInstrumentCovenantComplianceAmount_iI_uUSD_c20230331_zPrxef3Pynal" title="Minimum tangible net worth to be maintained">10,125,000</span> and restrictions on the Company&#8217;s ability to incur certain additional indebtedness or pay dividends.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849270962064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKSISVZhDhK4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 7. <span id="xdx_82B_z3i7lHEFjEBl">Common Stock</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Authorized
shares:</b>&#160;The Company&#8217;s Articles of Incorporation, as amended, have established&#160;<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--CapitalStockMember_ztolrmB4gg33" title="Common stock, authorized">15,000,000&#160;</span>authorized shares
of capital stock consisting of&#160;<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaR19zCmm53e" title="Common stock, authorized">13,000,000&#160;</span>shares of common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuodLQLa7cf1" title="Common stock, par value (in dollars per share)">0.01</span>&#160;per share, and&#160;<span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--AuthorizedSharesUndesignatedStockMember_zzJEq38i96E7" title="Common stock, authorized">2,000,000</span>&#160;shares
of undesignated stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On
May 26, 2021, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved a stock repurchase authorization. Under
the authorization, the Company was originally able to repurchase up to $<span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_dxL_uShares_c20220526__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zw2RweSZoxpg" title="Common stock, authorized::XDX::3000000"><span style="-sec-ix-hidden: xdx2ixbrl0804">3.0</span></span>&#160;million&#160;of shares of common stock through
May 26, 2022. On May 26, 2022, the Board removed the date limitation. As of March 31, 2023, a total of&#160;<span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_uShares_c20220701__20230331_zthAU97Py7ik" title="Number of share repurchased">239,995</span>&#160;shares
have been repurchased and retired under this authorization for a total cost of $<span id="xdx_902_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_c20220701__20230331_z2HmskETELY5" title="Repurchase of common stock">2,725,000</span>, or $11.36&#160;per share. Repurchased
shares have been retired and constitute authorized but unissued shares.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849270910768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zd2od0puKq63" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 8. <span id="xdx_82C_zRc74D7oLLlb">Share-Based Compensation</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s share-based compensation
plans are described in Note 8 to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for fiscal
2022. Share-based compensation expense was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220701__20230331_zxgLmDIDtxd" title="Share-based compensation expense">506,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210701__20220331_zPhPRUGcDif" title="Share-based compensation expense">703,000</span> for the nine months ended March 31, 2023 and 2022, respectively.
This expense is included in selling, general and administrative expense in the Condensed Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock Options</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2LBMDxTSnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zexP6TkyzPf">Stock option transactions during
the nine months ended March 31, 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 8pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"><span style="font-size: 10pt"><b>Number
                                         of Shares</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average
                                         </b><br/> <b>Exercise Price per</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;<b>Share</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; padding-left: 0in"><span style="font-size: 10pt">Outstanding at June 30, 2022</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220701__20231231_zUk1cNxQRlW2" style="width: 10%; text-align: right" title="Options outstanding, beginning | shares"><span style="font-size: 10pt">502,084</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220701__20230331_zDELv2zhVc43" style="width: 10%; text-align: right" title="Options outstanding, beginning | $ / shares"><span style="font-size: 10pt">5.82</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20230331_zJHxA8gC1nq3" style="text-align: right" title="Granted"><span style="font-size: 10pt">104,325</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_zHX7AlfopaAi" style="text-align: right" title="Granted"><span style="font-size: 10pt">9.93</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Exercised</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20220701__20230331_z6E2KoU14aPb" style="text-align: right" title="Exercised"><span style="font-size: 10pt">(90,351</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_pid_uUSDPShares_c20220701__20230331_zq3XCSIew0Qe" style="text-align: right" title="Exercised"><span style="font-size: 10pt">1.82</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Cancelled or Forfeited   </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220701__20230331_zkgUtP23WzE1" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited"><span style="font-size: 10pt">(47,930</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_ziij5IOI2Yb8" style="text-align: right" title="Cancelled or Forfeited"><span style="font-size: 10pt">11.19</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Outstanding at March 31, 2023   </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20230331_zZdbeVZbk0Al" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending | shares"><span style="font-size: 10pt">468,128</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220701__20230331_zUnEMAzPClf8" style="text-align: right" title="Options outstanding, ending | shares"><span style="font-size: 10pt">6.96</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8AA_zTLxbcxo00x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"/>





<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zbTnC3vjZCPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span id="xdx_8BB_zljBe1zRuSH1">The following assumptions were
used to estimate the fair value of stock options granted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended <br/> March 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended <br/> June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230331_zNriTIRbfnY8" title="Risk free interest rate - minimum">2.88</span> - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230331_z8PojxQwFNx9" title="Risk free interest rate - maximum">4.23</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210701__20220630_zBzqgbMF8p78" title="Risk free interest rate - minimum">0.89</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210701__20220630_zdGFnuw9iSwl" title="Risk free interest rate - maximum">2.52</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 69%; text-align: left">Expected term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220701__20230331_zyCtIt7J3IO5" title="Expected term (years)::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0849">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210701__20220630_z89Kw50kH0z2" title="::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0850">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230331_z5ONt5OVEGx" title="Expected volatility Minimum">53</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230331_zy6VX3coaKK3" title="Expected volatility Maximum">54</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210701__20220630_za2Zw3fbfi9d" title="Expected volatility - minimum">55</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210701__20220630_zCtfkkiMUtik" title="Expected volatility - maximum">64</span>%</span></td><td style="text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A5_zstQvYouApKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The intrinsic value of an option is the amount
by which the fair value of the underlying stock exceeds its exercise price. At March 31 2023, the weighted average remaining contractual
term for all outstanding stock options was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5OwNa2skHy3" title="Weighted average contractual term outstanding stock options">5.9</span> years and the aggregate intrinsic value of the options was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZT0TcgXtlw8" title="Options outstanding, intrinsic value">1,802,672</span>. Outstanding
at March 31, 2023 were 468,128 stock options issued to employees, of which <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS3eSgcyRN1f" title="Outstanding exercisable">339,342</span> were vested and exercisable and had an aggregate
intrinsic value of $<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6cDS4h9agHf" title="Options exercisable, intrinsic value">1,762,445</span>. As of March 31, 2023, $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyGnMEFw0eNj" title="Unrecognized compensation expense">328,218</span> of total unrecognized compensation expense related to stock options
is expected to be recognized over a weighted-average period of approximately <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEV2b3K2kx8" title="Weighted average period::XDX::P2Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0870">2.0</span></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Restricted Stock</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">During the nine months ended March 31, 2023,
the Company issued restricted stock awards to employees totaling <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zeCJFOlGXgt" title="Restricted stock issued">32,400</span> shares of common stock, with a weighted average vesting
term of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zTKOlXxVgeOi" title="Vesting period">2.7</span> years and a weighted average fair value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHGiuODpzcp7" title="Fair value on grant date">9.92</span> per share, and to directors totaling <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zgJ4XkRlfM1b" title="Restricted stock - vested (shares)">21,000</span> shares of common stock,
with a vesting term of six months and a weighted average fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zaSHdLknxUj9" title="Weight average fair value -vested  restricted stock (per share)">9.86</span> per share. There were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zCZ6paYeNclg" title="Restricted stock - unvested (shares)">57,818</span> shares of unvested restricted
stock with a weighted average fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_uUSDPShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zknYMC09m1Ce" title="Weight average fair value - unvested restricted stock (per share)">10.32</span> per share outstanding as of March 31, 2023. As of March 31, 2023, $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs0U8Ka9X555" title="Unrecognized compensation expense">244,063</span> of
total unrecognized compensation expense related to restricted stock awards is expected to be recognized over a weighted-average
period of approximately <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJswSXZSEDAb" title="Weighted average period::XDX::P1Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0888">1.3</span></span> years.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269552048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_ztNQUvbbFyO1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Note 9.<span id="xdx_82D_zrjbfofoIPJa"> Commitments and Contingencies</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The Company is occasionally involved in claims
and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate
the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other
disposition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">On September 8, 2021, a state court putative
class action lawsuit was filed in Minnesota against the Company asserting injury resulting from the previously announced data breach
that impacted the Company&#8217;s customer protected health information and employee personal information and seeking compensatory
damages, equitable relief, and attorneys&#8217; fees and costs. On October 6, 2021, the proceeding was removed to the District
of Minnesota. The Company believes the plaintiff was not injured as a result of the data privacy incident and, as a result, the
claims are without merit. <span style="background-color: white">Accordingly, on November 11, 2021, the Company moved to dismiss
the complaint in its entirety. Prior to the hearing on the motion to dismiss, the parties agreed in principle to settle the case.&#160;The
parties have executed a settlement agreement and submitted a motion to settle the class action in the near future. During January
2023, the settlement was preliminarily approved. The hearing for final approval is scheduled for June 5, 2023. If the court does
not grant the approval for settlement, the Company will continue to vigorously defend the lawsuit. At this time, the Company is
unable to determine the ultimate outcome or potential exposure to loss, if any.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849266186480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Reporting (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates.</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zAIyugA5IAf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86C_zwAGO7ZjAZg2">Use of estimates.</span> </b>Management uses estimates
and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies
that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements
include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation
and warranty reserve.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income per common share.</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z8p7JCUBTdi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_86A_zanynNVgxi8d">Net income per common share.</span> </b>Net income
is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using
the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not
vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock
options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive.
Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were
<span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zYrwOWEESbOd" title="Common stock equivalents excluded from calculation of diluted earnings per share">179,992</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOv4v84jj4D8" title="Common stock equivalents excluded from calculation of diluted earnings per share">102,435</span> for the three months ended March 31, 2023 and 2022, respectively, and were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zxrV5XaDJ7zl" title="Common stock equivalents excluded from calculation of diluted earnings per share">200,140</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210701__20220331_zAV5NKvK0i5k" title="Common stock equivalents excluded from calculation of diluted earnings per share">112,427</span> for the nine
months ended March 31, 2023 and 2022, respectively.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz7WRCTqxvWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b><span id="xdx_861_z2NH1iOxi8ca">Recently Issued Accounting Standards</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">In June 2016, the Financial Accounting Board issued
Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;&#8220;Financial Instruments -- Credit Losses: Measurement of Credit
Losses on Financial Instruments&#8221;,&#160;which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11,
and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including
trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It
is effective for interim and annual reporting periods in fiscal years beginning after December 15, 2022, with early adoption permitted.
The adoption of the standard is not expected to have a significant impact on the Company&#8217;s consolidated results of operations
and financial condition.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849270791872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">In the following table, net revenues are disaggregated by market:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLoifyJ7Myvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Disaggregation of revenues.</b> <span id="xdx_8B8_zbNN7XPeu6Id">In the following
table, net revenues are disaggregated by market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 48%; text-align: left"><span style="font-size: 10pt">Home care</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z86jOQNiggka" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">10,971,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zl1BpvekjHsi" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">9,033,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zqQkL2R3djz8" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">31,335,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVsh5wh4Vq08" style="width: 10%; text-align: right" title="Revenue"><span style="font-size: 10pt">27,721,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Institutional</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zRmkAT5v63h5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">440,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_z5lgkT0U2RD5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">392,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zDZJvfPHT1F7" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,420,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zlYFcN92AIYa" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,174,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Home care distributor</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zWdaUbftJc3l" style="text-align: right" title="Revenue"><span style="font-size: 10pt">501,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zFnnTkVGaiT5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">520,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zGLv1pAPQV54" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,391,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zzaPj6BkKZci" style="text-align: right" title="Revenue"><span style="font-size: 10pt">1,063,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">International</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zIYA14yIQGEc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">156,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zXfHm6g8UJQc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">196,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zaF7SL27pK04" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">309,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zCqWlakdq6r5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">432,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zd5l41CsTMj5" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">12,068,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331_zng3LTz2GCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">10,141,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zVPoLccoxd35" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">34,455,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331_zd3XEnTcWzD3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-size: 10pt">30,390,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">In the following table, net home care revenue is
disaggregated by payer type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine
    Months Ended March 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 47%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zH1XYS8w9Lya" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,787,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zsz8iLiK1zK4" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,358,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zfBVNpoRjc0g" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,706,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zMhoG4GeGNl8" style="width: 10%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,738,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zVwjODUXwiNe" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,822,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEBT6kF79IFa" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,027,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_z3dEZQq2uMa3" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,434,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zH9W63PDezOh" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,603,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicaid</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zmH6PG4boQd4" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z4eiQKE6bJ9i" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zOmfmtBqPkpj" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zfB4N5oepocj" style="text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">790,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zlyJTJjKAMrc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zDDGrVnM1117" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">275,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zEpSNMrXMyy8" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">577,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zO9SoJimqs8j" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">590,000</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z4T44Pxld2Vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,971,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zXvOELmvjwC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,033,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zMeVRJ4XZgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,335,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zvyDOZHiqHPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,721,000</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">The following table provides information about contract assets from contracts with customers:</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zWMBUzxObaea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Contract balances.</b> <span id="xdx_8BA_zTWSoVb7jQr1">The following table
provides information about contract assets from contracts with customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br/>
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br/>
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Increase
    (decrease)</span></td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Contract assets, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20220701__20230331_zojnsWRs8uDl" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets  beginning"><span style="font-size: 10pt">286,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20210701__20220630_zSJp3oDx3Dfg" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets, beginning"><span style="font-size: 10pt">393,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reclassification of contract assets to accounts receivable </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230331_zulTzlgwvoyb" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"><span style="font-size: 10pt">(1,107,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20210701__20220630_zcO5mEItPTre" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"><span style="font-size: 10pt">(833,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Contract assets recognized</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230331_zV7nM92BK2Tc" style="font-size: 10pt; text-align: right" title="Contract assets recognized"><span style="font-size: 10pt">1,372,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210701__20220630_zzmnkmPVAHWe" style="font-size: 10pt; text-align: right" title="Contract assets recognized"><span style="font-size: 10pt">784,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Increase (decrease) as a result of changes
    in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230331_zYT9RjztCYFj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"><span style="font-size: 10pt">19,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20210701__20220630_z60A9HmVzs8j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"><span style="font-size: 10pt">(58,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Contract assets, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230331_z7TEg7dvyzI2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"><span style="font-size: 10pt">570,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20210701__20220630_znjbSdw5tqM8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"><span style="font-size: 10pt">286,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849270962064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">The components of inventory were as follows</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ztm6QJuufMLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><span id="xdx_8BA_zGkVMdu5kD5d">The components of inventory were as follows</span>: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 9.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20230331_zAjqevD72dCk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220630_zFezRGXTIGY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">June
    30, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherInventorySupplies_iI_maINzW5z_maINzrcq_zsHRxqUaYAHi" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Parts inventory</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">2,908,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">2,672,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_maINzW5z_maINzrcq_z76eOK0OCXTd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Work in process</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">213,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_maINzW5z_maINzrcq_zg3MoyojxDv" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left"><span style="font-size: 10pt">Finished goods</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">280,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">469,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--OtherInventoryInTransit_iI_maINzW5z_maINzrcq_zjROX6X1J8Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Estimated inventory to be returned</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">263,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">228,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--InventoryValuationReserves_iNI_di_msINzW5z_msINzrcq_zPO8mebFeD1c" style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: Reserve for obsolescence</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(213,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(291,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iI_zICO24i8OXdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,451,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,178,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849265588176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesAndProductWarrantiesAbstract', window );"><strong>Guarantees and Product Warranties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Changes in the Company&#8217;s warranty reserve were as follows:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_z81p7xYdAUEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><span id="xdx_8BF_zFHwYYqtavx3">Changes in the Company&#8217;s warranty
reserve were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended <br/>
    March 31, 2023</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fiscal
    Year Ended <br/>
    June&#160;30, 2022</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; text-align: left"><span style="font-size: 10pt">Warranty reserve, beginning </span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230331_znWEmS9LRTn5" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"><span style="font-size: 10pt">1,256,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ProductWarrantyAccrual_iS_c20210701__20220630_zEzcXwsVIr97" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"><span style="font-size: 10pt">940,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Accrual for products sold </span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230331_zVZjpbza45Rl" style="font-size: 10pt; text-align: right" title="Accrual for products sold"><span style="font-size: 10pt">290,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20210701__20220630_z1R1172ED1Id" style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">494,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><span style="font-size: 10pt">Expenditures and costs
    incurred for warranty claims</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230331_z6CI4SCelsP1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expenditures and costs incurred for warranty claims"><span style="font-size: 10pt">(213,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20210701__20220630_zFvsEIt3Zcuj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(178,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Warranty reserve, ending</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230331_z3trpH4UvIl1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Warranty reserve, ending"><span style="font-size: 10pt">1,333,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ProductWarrantyAccrual_iE_c20210701__20220630_zhP5TRijSnI" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 10pt">1,256,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAndProductWarrantiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAndProductWarrantiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849269378768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option transactions during the nine months ended March 31, 2023 are summarized as follows:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2LBMDxTSnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zexP6TkyzPf">Stock option transactions during
the nine months ended March 31, 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 8pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"><span style="font-size: 10pt"><b>Number
                                         of Shares</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average
                                         </b><br/> <b>Exercise Price per</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;<b>Share</b>&#160;</span></p></td><td style="font-size: 8pt; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="width: 74%; padding-left: 0in"><span style="font-size: 10pt">Outstanding at June 30, 2022</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220701__20231231_zUk1cNxQRlW2" style="width: 10%; text-align: right" title="Options outstanding, beginning | shares"><span style="font-size: 10pt">502,084</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220701__20230331_zDELv2zhVc43" style="width: 10%; text-align: right" title="Options outstanding, beginning | $ / shares"><span style="font-size: 10pt">5.82</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20230331_zJHxA8gC1nq3" style="text-align: right" title="Granted"><span style="font-size: 10pt">104,325</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_zHX7AlfopaAi" style="text-align: right" title="Granted"><span style="font-size: 10pt">9.93</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Exercised</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20220701__20230331_z6E2KoU14aPb" style="text-align: right" title="Exercised"><span style="font-size: 10pt">(90,351</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_pid_uUSDPShares_c20220701__20230331_zq3XCSIew0Qe" style="text-align: right" title="Exercised"><span style="font-size: 10pt">1.82</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Cancelled or Forfeited   </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220701__20230331_zkgUtP23WzE1" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited"><span style="font-size: 10pt">(47,930</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_ziij5IOI2Yb8" style="text-align: right" title="Cancelled or Forfeited"><span style="font-size: 10pt">11.19</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Outstanding at March 31, 2023   </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20230331_zZdbeVZbk0Al" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending | shares"><span style="font-size: 10pt">468,128</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220701__20230331_zUnEMAzPClf8" style="text-align: right" title="Options outstanding, ending | shares"><span style="font-size: 10pt">6.96</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The following assumptions were used to estimate the fair value of stock options granted:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zbTnC3vjZCPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span id="xdx_8BB_zljBe1zRuSH1">The following assumptions were
used to estimate the fair value of stock options granted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended <br/> March 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended <br/> June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230331_zNriTIRbfnY8" title="Risk free interest rate - minimum">2.88</span> - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230331_z8PojxQwFNx9" title="Risk free interest rate - maximum">4.23</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210701__20220630_zBzqgbMF8p78" title="Risk free interest rate - minimum">0.89</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210701__20220630_zdGFnuw9iSwl" title="Risk free interest rate - maximum">2.52</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 69%; text-align: left">Expected term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220701__20230331_zyCtIt7J3IO5" title="Expected term (years)::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0849">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210701__20220630_z89Kw50kH0z2" title="::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0850">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(214,243,232)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230331_z5ONt5OVEGx" title="Expected volatility Minimum">53</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230331_zy6VX3coaKK3" title="Expected volatility Maximum">54</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210701__20220630_za2Zw3fbfi9d" title="Expected volatility - minimum">55</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210701__20220630_zCtfkkiMUtik" title="Expected volatility - maximum">64</span>%</span></td><td style="text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849264643248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Reporting (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="nump">$ 12,068,000<span></span>
</td>
<td class="nump">$ 10,141,000<span></span>
</td>
<td class="nump">$ 34,455,000<span></span>
</td>
<td class="nump">$ 30,390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted earnings per share</a></td>
<td class="nump">179,992<span></span>
</td>
<td class="nump">102,435<span></span>
</td>
<td class="nump">200,140<span></span>
</td>
<td class="nump">112,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=elmd_InternationalMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=elmd_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=elmd_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849258883616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In the following table, net revenues are disaggregated by market: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,068,000<span></span>
</td>
<td class="nump">$ 10,141,000<span></span>
</td>
<td class="nump">$ 34,455,000<span></span>
</td>
<td class="nump">$ 30,390,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareMember', window );">Home Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">10,971,000<span></span>
</td>
<td class="nump">9,033,000<span></span>
</td>
<td class="nump">31,335,000<span></span>
</td>
<td class="nump">27,721,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareMember', window );">Home Care [Member] | Commercial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">4,787,000<span></span>
</td>
<td class="nump">3,358,000<span></span>
</td>
<td class="nump">12,706,000<span></span>
</td>
<td class="nump">10,738,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareMember', window );">Home Care [Member] | Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">5,822,000<span></span>
</td>
<td class="nump">5,027,000<span></span>
</td>
<td class="nump">17,434,000<span></span>
</td>
<td class="nump">15,603,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareMember', window );">Home Care [Member] | Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareMember', window );">Home Care [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">234,000<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">577,000<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_InstitutionalMember', window );">Institutional [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">440,000<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
<td class="nump">1,420,000<span></span>
</td>
<td class="nump">1,174,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_HomeCareDistributorMember', window );">Home Care Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">501,000<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
<td class="nump">1,391,000<span></span>
</td>
<td class="nump">1,063,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=elmd_InternationalOneMember', window );">International One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elmd_HomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elmd_HomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_PayerTypeAxis=elmd_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_PayerTypeAxis=elmd_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_PayerTypeAxis=elmd_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_PayerTypeAxis=elmd_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_PayerTypeAxis=elmd_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_PayerTypeAxis=elmd_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_PayerTypeAxis=elmd_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_PayerTypeAxis=elmd_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elmd_InstitutionalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elmd_InstitutionalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elmd_HomeCareDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elmd_HomeCareDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=elmd_InternationalOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=elmd_InternationalOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849258844112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about contract assets from contracts with customers: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, beginning</a></td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 393,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Reclassification of contract assets to accounts receivable</a></td>
<td class="num">(1,107,000)<span></span>
</td>
<td class="num">(833,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract assets recognized</a></td>
<td class="nump">1,372,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, ending</a></td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849266535408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The components of inventory were as follows (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Parts inventory</a></td>
<td class="nump">$ 2,908,000<span></span>
</td>
<td class="nump">$ 2,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryInTransit', window );">Estimated inventory to be returned</a></td>
<td class="nump">263,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: Reserve for obsolescence</a></td>
<td class="num">(213,000)<span></span>
</td>
<td class="num">(291,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 3,451,000<span></span>
</td>
<td class="nump">$ 3,178,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849266535568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in the Company&#8217;s warranty reserve were as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesAndProductWarrantiesAbstract', window );"><strong>Guarantees and Product Warranties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Warranty reserve, beginning</a></td>
<td class="nump">$ 1,256,000<span></span>
</td>
<td class="nump">$ 940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Accrual for products sold</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Expenditures and costs incurred for warranty claims</a></td>
<td class="num">(213,000)<span></span>
</td>
<td class="num">(178,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Warranty reserve, ending</a></td>
<td class="nump">$ 1,333,000<span></span>
</td>
<td class="nump">$ 1,256,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAndProductWarrantiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAndProductWarrantiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849265049024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="nump">$ 576,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">16.40%<span></span>
</td>
<td class="nump">23.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Discrete current tax benefit - non-qualified stock options exercised</a></td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849260263168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_DebtInstrumentCovenantComplianceAmount', window );">Minimum tangible net worth to be maintained</a></td>
<td class="nump">$ 10,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of Credit, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Available borrowing capacity</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent', window );">Available borrowing capacity</a></td>
<td class="nump">5700.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">Dec. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent borrowing capacity of eligible accounts receivable percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_DebtInstrumentCovenantComplianceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent debt instrument covenant compliance amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_DebtInstrumentCovenantComplianceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849265008336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of share repurchased</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">14,568<span></span>
</td>
<td class="nump">24,551<span></span>
</td>
<td class="nump">55,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elmd_CapitalStockMember', window );">Capital Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=elmd_AuthorizedSharesUndesignatedStockMember', window );">Authorized Shares Undesignated Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elmd_CapitalStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elmd_CapitalStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=elmd_AuthorizedSharesUndesignatedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=elmd_AuthorizedSharesUndesignatedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849264211728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning | shares</a></td>
<td class="nump">502,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Options outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 5.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">104,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 9.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(90,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue', window );">Exercised</a></td>
<td class="nump">$ 1.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or Forfeited</a></td>
<td class="num">(47,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Cancelled or Forfeited</a></td>
<td class="nump">$ 11.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending | shares</a></td>
<td class="nump">468,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Options outstanding, ending | shares</a></td>
<td class="nump">$ 6.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent share based compensation arrangement by share based payment award options grants in period weighted average exercise date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>elmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849263416096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following assumptions were used to estimate the fair value of stock options granted: (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate - minimum</a></td>
<td class="nump">2.88%<span></span>
</td>
<td class="nump">0.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate - maximum</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility - minimum</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility - maximum</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139849266472048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">$ 506,000<span></span>
</td>
<td class="nump">$ 703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 1,802,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding exercisable</a></td>
<td class="nump">339,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 1,762,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 328,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 244,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued</a></td>
<td class="nump">32,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock - vested (shares)</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weight average fair value -vested restricted stock (per share)</a></td>
<td class="nump">$ 9.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock - unvested (shares)</a></td>
<td class="nump">57,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weight average fair value - unvested restricted stock (per share)</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=elmd_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=elmd_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>elmd230506_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:elmd="http://electromed.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="elmd-20230331.xsd" xlink:type="simple"/>
    <context id="From2022-07-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_InternationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">elmd:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_InternationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">elmd:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_InstitutionalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_InstitutionalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_InstitutionalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_InstitutionalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InstitutionalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_InternationalOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_InternationalOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_InternationalOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_InternationalOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:InternationalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HomeCareMember_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HomeCareMember_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_custom_HomeCareMember_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_custom_HomeCareMember_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="elmd:PayerTypeAxis">elmd:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">elmd:HomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-30_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CapitalStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elmd:CapitalStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AuthorizedSharesUndesignatedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">elmd:AuthorizedSharesUndesignatedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_us-gaap_EmployeeStockOptionMember_custom_EmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">elmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001488917</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-01to2023-03-31">0001488917</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-07-01to2023-03-31">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-07-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-07-01to2023-03-31">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:IncomeTaxReceivable
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2021-07-012022-03-31"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <elmd:LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="From2022-07-01to2023-03-31"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-012022-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-05-26_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="xdx2ixbrl0804"
      unitRef="Shares">3000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-07-01to2023-03-31" id="xdx2ixbrl0849">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0850">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0870">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl0888">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <dei:DocumentType contextRef="From2022-07-01to2023-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-07-01to2023-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-07-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-07-01to2023-03-31">001-34839</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-07-01to2023-03-31">Electromed,     Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-01to2023-03-31">MN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-01to2023-03-31">41-1732920</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-01to2023-03-31">500         Sixth Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-01to2023-03-31">New         Prague</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-01to2023-03-31">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-01to2023-03-31">56071</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-01to2023-03-31">952</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-01to2023-03-31">758-9299</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-07-01to2023-03-31">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-01to2023-03-31">ELMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-01to2023-03-31">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-07-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-07-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-07-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-07-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-01to2023-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-07-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-05-05" decimals="INF" unitRef="Shares">8561100</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6776000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">8153000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">45000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">45000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">22345000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">21052000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">570000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">286000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3451000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">3178000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1808000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1870000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxReceivable contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">219000</us-gaap:IncomeTaxReceivable>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">35169000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">34539000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5502000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">4568000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">604000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">599000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">60000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">120000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1506000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1538000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">42841000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41364000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1289000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1261000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2082000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">2742000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">51000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1333000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1256000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1713000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1840000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6417000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7150000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">30000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6447000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7191000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">13000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">13000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">8556600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">8556600</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">8475438</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">8475438</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">85000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">18548000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">18308000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">17760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">15780000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">36394000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">34173000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">42841000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41364000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">12068000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">10141000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">34455000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">30390000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">3012000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2398000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">8386000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">7066000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">9056000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">7743000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">26069000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">23324000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">7694000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">6544000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">22937000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">19806000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">166000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">336000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">618000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">1041000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">7860000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">6880000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">23555000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">20847000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">863000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">2514000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">2477000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">26000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">6000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">37000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">21000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">869000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">2551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">2498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">224000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">418000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">2133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">1922000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="Shares">8461531</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">8454504</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">8449623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="Shares">8485856</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="Shares">8710106</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">8744535</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">8694407</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="Shares">8762963</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">2133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">1922000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">370000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">368000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">52000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">105000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">506000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">703000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">32000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">1293000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">2582000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">284000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-98000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">264000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-9000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-105000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">519000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-270000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-443000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-111000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">550000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <elmd:AccruedCompensation
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">660000</elmd:AccruedCompensation>
    <elmd:AccruedCompensation
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">173000</elmd:AccruedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">316000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">53000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">1221000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">980000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">54000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">86000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1275000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-1066000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">305000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">70000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">153000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">962000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-418000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-1032000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">-2045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">8153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">11889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">655000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">1003000</us-gaap:IncomeTaxesPaid>
    <elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">136000</elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable>
    <elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">85000</elmd:PropertyAndEquipmentAcquisitionsInAccountsPayable>
    <elmd:IntangibleAssetAcquisitionsInAccountsPayable
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">6000</elmd:IntangibleAssetAcquisitionsInAccountsPayable>
    <elmd:IntangibleAssetAcquisitionsInAccountsPayable
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">9000</elmd:IntangibleAssetAcquisitionsInAccountsPayable>
    <elmd:LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">107000</elmd:LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities>
    <elmd:DemonstrationEquipmentReturnedToInventory
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">9000</elmd:DemonstrationEquipmentReturnedToInventory>
    <elmd:DemonstrationEquipmentReturnedToInventory
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">17000</elmd:DemonstrationEquipmentReturnedToInventory>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8533209</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">14922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">32416000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">439000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">439000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25900</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10530</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-64000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-64000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8569639</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">15361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">33041000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">838000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">838000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1387</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">55687</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">662000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">663000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8533339</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">15537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">33487000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">645000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24551</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">299000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">299000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8508788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18042000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">15883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">34010000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8475438</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18308000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">15780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">34173000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">81000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">27400</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-14166</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11760</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-60000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-60000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">95000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">95000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14568</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">145000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">145000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8485864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">15716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">34144000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">977000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012022-12-31"
      decimals="0"
      unitRef="USD">977000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3100</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-10-012022-12-31"
      decimals="0"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">221000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012022-12-31"
      decimals="0"
      unitRef="USD">221000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">800</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-10-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-10-012022-12-31"
      decimals="0"
      unitRef="USD">8000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8514164</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">16685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">35350000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">1075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1075000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">42436</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-245000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-245000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8556600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18548000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">17760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">36394000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zgZLgdNGfwwb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;Note 1. &lt;span id="xdx_82A_zmOQbaN18oHj"&gt;Interim Financial Reporting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Nature of business: &lt;/b&gt;Electromed, Inc.
(the &#x201c;Company&#x201d;) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest
Wall Oscillation (&#x201c;HFCWO&#x201d;) therapy in pulmonary care for patients of all ages. The Company markets its products in
the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The
Company also sells internationally, primarily through distributors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;International sales were $&lt;span id="xdx_90B_eus-gaap--Revenues_c20220701__20230331__srt--StatementGeographicalAxis__custom--InternationalMember_zRHEOsdnclIk" title="Net revenues"&gt;309,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Revenues_c20210701__20220331__srt--StatementGeographicalAxis__custom--InternationalMember_zRbLV67T5KQ7" title="Net revenues"&gt;432,000&lt;/span&gt;
for the nine months ended March 31, 2023 and 2022, respectively. Since its inception, the Company has operated in a single industry
segment: developing, manufacturing and marketing medical equipment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;Impacts of COVID-19 on the Company&#x2019;s
business:&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;The potential impact of the COVID-19 pandemic
and its effects on our operational and financial performance will depend in large part on future developments, which cannot be
reasonably estimated at this time. For a more detailed discussion, see &#x201c;Management&#x2019;s Discussion and Analysis of Financial
Condition and Results of Operations&#x201d; in Part I, Item 2 of this Quarterly Report on Form 10-Q.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Basis of presentation: &lt;/b&gt;The accompanying
unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting
principles (&#x201c;U.S. GAAP&#x201d;) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities
and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments
consisting of normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results
of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may
be achieved for the full year. The financial statements and related notes do not include all information and footnotes required
by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the
Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (&#x201c;fiscal 2022&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;A summary of the Company&#x2019;s significant accounting
policies follows:&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zAIyugA5IAf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_86C_zwAGO7ZjAZg2"&gt;Use of estimates.&lt;/span&gt; &lt;/b&gt;Management uses estimates
and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies
that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements
include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation
and warranty reserve.&lt;/p&gt;

&lt;p id="xdx_85E_zLK3gLpTtQ18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z8p7JCUBTdi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_86A_zanynNVgxi8d"&gt;Net income per common share.&lt;/span&gt; &lt;/b&gt;Net income
is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using
the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not
vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock
options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive.
Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were
&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zYrwOWEESbOd" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;179,992&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOv4v84jj4D8" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;102,435&lt;/span&gt; for the three months ended March 31, 2023 and 2022, respectively, and were &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zxrV5XaDJ7zl" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;200,140&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210701__20220331_zAV5NKvK0i5k" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;112,427&lt;/span&gt; for the nine
months ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p id="xdx_856_zi0rugzd0seg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz7WRCTqxvWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_861_z2NH1iOxi8ca"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;In June 2016, the Financial Accounting Board issued
Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&#160;&#x201c;Financial Instruments -- Credit Losses: Measurement of Credit
Losses on Financial Instruments&#x201d;,&#160;which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11,
and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including
trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It
is effective for interim and annual reporting periods in fiscal years beginning after December 15, 2022, with early adoption permitted.
The adoption of the standard is not expected to have a significant impact on the Company&#x2019;s consolidated results of operations
and financial condition.&lt;/p&gt;

&lt;p id="xdx_851_zkD3LR7Vi3Hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:Revenues
      contextRef="From2022-07-012023-03-31_custom_InternationalMember"
      decimals="0"
      unitRef="USD">309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-07-012022-03-31_custom_InternationalMember"
      decimals="0"
      unitRef="USD">432000</us-gaap:Revenues>
    <us-gaap:UseOfEstimates contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zAIyugA5IAf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_86C_zwAGO7ZjAZg2"&gt;Use of estimates.&lt;/span&gt; &lt;/b&gt;Management uses estimates
and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies
that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements
include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation
and warranty reserve.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z8p7JCUBTdi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_86A_zanynNVgxi8d"&gt;Net income per common share.&lt;/span&gt; &lt;/b&gt;Net income
is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using
the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not
vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock
options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive.
Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were
&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zYrwOWEESbOd" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;179,992&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOv4v84jj4D8" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;102,435&lt;/span&gt; for the three months ended March 31, 2023 and 2022, respectively, and were &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zxrV5XaDJ7zl" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;200,140&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210701__20220331_zAV5NKvK0i5k" title="Common stock equivalents excluded from calculation of diluted earnings per share"&gt;112,427&lt;/span&gt; for the nine
months ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="Shares">179992</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">102435</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">200140</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="Shares">112427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz7WRCTqxvWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;&lt;span id="xdx_861_z2NH1iOxi8ca"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;In June 2016, the Financial Accounting Board issued
Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&#160;&#x201c;Financial Instruments -- Credit Losses: Measurement of Credit
Losses on Financial Instruments&#x201d;,&#160;which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11,
and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including
trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It
is effective for interim and annual reporting periods in fiscal years beginning after December 15, 2022, with early adoption permitted.
The adoption of the standard is not expected to have a significant impact on the Company&#x2019;s consolidated results of operations
and financial condition.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_zGdbEaDPmYOg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;Note 2. &lt;span id="xdx_825_zveAcxBhmPA3"&gt;Revenues&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;Revenue is measured based on consideration specified
in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the
transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all
customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer,
as further described below under &lt;i&gt;Performance obligations and transaction price&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;Individual promised goods
and services in a contract are considered a performance obligation and accounted for separately if the individual good or service
is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available
to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes
multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated
standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance
obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs
under Accounting Standards Codification (&#x201c;ASC&#x201d;) 340-40, &#x201c;Other Assets and Deferred Costs&#x201d; (&#x201c;ASC 340&#x201d;),
or other applicable guidance are met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;The Company includes shipping and handling
fees in net revenues. Shipping and handling costs associated with the shipment of the Company&#x2019;s SmartVest&#xae; Airway Clearance
System (&#x201c;SmartVest System&#x201d;) after control has transferred to a customer are accounted for as a fulfillment cost and
are included in cost of revenues in the Condensed Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;The timing of revenue recognition, billings and
cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under &lt;i&gt;Accounts receivable&lt;/i&gt;
and &lt;i&gt;Contract assets&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLoifyJ7Myvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Disaggregation of revenues.&lt;/b&gt; &lt;span id="xdx_8B8_zbNN7XPeu6Id"&gt;In the following
table, net revenues are disaggregated by market:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Home care&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z86jOQNiggka" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;10,971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zl1BpvekjHsi" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;9,033,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zqQkL2R3djz8" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;31,335,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVsh5wh4Vq08" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;27,721,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Institutional&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zRmkAT5v63h5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;440,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_z5lgkT0U2RD5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;392,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zDZJvfPHT1F7" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,420,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zlYFcN92AIYa" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,174,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Home care distributor&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zWdaUbftJc3l" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;501,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zFnnTkVGaiT5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;520,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zGLv1pAPQV54" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,391,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zzaPj6BkKZci" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,063,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zIYA14yIQGEc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;156,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zXfHm6g8UJQc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;196,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zaF7SL27pK04" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;309,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zCqWlakdq6r5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;432,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zd5l41CsTMj5" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;12,068,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331_zng3LTz2GCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;10,141,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zVPoLccoxd35" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;34,455,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331_zd3XEnTcWzD3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;30,390,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;In the following table, net home care revenue is
disaggregated by payer type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 47%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zH1XYS8w9Lya" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,787,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zsz8iLiK1zK4" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zfBVNpoRjc0g" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,706,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zMhoG4GeGNl8" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,738,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zVwjODUXwiNe" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,822,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEBT6kF79IFa" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,027,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_z3dEZQq2uMa3" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17,434,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zH9W63PDezOh" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,603,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zmH6PG4boQd4" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;128,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z4eiQKE6bJ9i" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;373,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zOmfmtBqPkpj" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;618,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zfB4N5oepocj" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;790,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zlyJTJjKAMrc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;234,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zDDGrVnM1117" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;275,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zEpSNMrXMyy8" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;577,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zO9SoJimqs8j" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;590,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z4T44Pxld2Vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zXvOELmvjwC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,033,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zMeVRJ4XZgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,335,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zvyDOZHiqHPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,721,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A7_zLc5pPW1XhL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Revenues in the Company&#x2019;s home care, home
care distributor, and international markets are recognized at a point in time when control passes to the customer upon product
shipment or delivery. Revenues in the Company&#x2019;s institutional market include revenue recognized at a point in time upon shipment
or delivery as well as revenue recognized over time under operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;b&gt;Performance obligations and transaction price.&lt;/b&gt;
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account
under ASC 606, &#x201c;Revenue From Contracts With Customers&#x201d; (&#x201c;ASC 606&#x201d;). A contract&#x2019;s transaction price
is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue
when, or as, the performance obligation is satisfied. The Company&#x2019;s performance obligations and the timing or method of revenue
recognition in each of the Company&#x2019;s markets are discussed below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&lt;i&gt;Home care market&lt;/i&gt;.&lt;/b&gt; In the Company&#x2019;s
home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised
of three main components &#x2013; a generator, a vest and a connecting hose &#x2013; that are sold together as an integrated unit.
Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The Company makes available to its home care
patients limited post-sale services that are not material in the context of the contracts, either individually or taken together,
and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed
when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation:
the SmartVest System.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;Home care patients generally will rely on third-party
payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs
to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers&#x2019; reimbursement programs fall
into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright
sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest
System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or
(iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues
to use the SmartVest System.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;Regardless of the type of transaction, provided
criteria for an enforceable contract are met, it is the Company&#x2019;s long- standing business practice to regard all home care
agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government
or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature
installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly
less than expected if the contract is terminated due to changes in the patient&#x2019;s status, including insurance coverage, hospitalization,
death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System,
the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies.
As a result, the Company&#x2019;s product sales qualify for point in time revenue recognition. Control transfers to the patient,
and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks
and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further
discussed under &lt;i&gt;Accounts receivable&lt;/i&gt; and &lt;i&gt;Contract assets&lt;/i&gt; below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The Company&#x2019;s contractually stated transaction
prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government
programs. The transaction price for the Company&#x2019;s products may be further impacted by variable consideration. ASC 606 requires
the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value
of payments to be received from insurance payers based on historical experience and other available information, subject to the
constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include
(i) capped installment payments, which are subject to the third-party payer&#x2019;s termination due to changes in insurance coverage,
death or the patient&#x2019;s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility
amounts for deductibles, coinsurance, copays and other similar payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;Although estimates may be made on a contract-by-contract
basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable
consideration for portfolios of contracts. The Company&#x2019;s estimates of variable consideration consist of amounts it may receive
from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the
payment duration, changes to a patient&#x2019;s insurance status, changes in an insurance allowable, claims in appeals with Medicare
and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical
information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has
with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue
recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The
Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize
the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative
revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration
is included in the transaction price if, in the Company&#x2019;s judgment, it is probable that a significant future reversal of
cumulative revenue under the contract will not occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;For example, for contracts in which the Company
believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is
unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery
experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for
populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving
at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to
payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes
in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in
estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration
are generally not subject to the risk of significant revenue reversal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;For each type of variable consideration discussed
above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For
that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The Company often receives payment from third-party
payers for SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant
financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer
or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental
purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a
short period of time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&lt;i&gt;Home care distributors.&lt;/i&gt;&lt;/b&gt; Sales
to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based
rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor&#x2019;s
purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within
the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases
in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively
defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount
is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to
the distributor, as applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&lt;i&gt;Institutional market.&lt;/i&gt;&lt;/b&gt; The Company&#x2019;s
institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales
to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received
directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions
and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product
is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions
fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.95pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 18pt"&gt;&lt;span&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Outright sale &#x2013; Under these transactions, the Company sells its products for a prescribed
or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and
payment is made within normal credit terms, usually within thirty days.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 18pt"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;Wrap usage agreements &#x2013; Under these transactions, the Company
provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These
agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned
to the Company, where it can be refurbished and used again at a later date. Revenue for the consumable wraps is recognized when
control transfers to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;International market.&lt;/i&gt;&lt;/b&gt;
Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not
subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery
to the distributor, as applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;b&gt;Product warranty.&lt;/b&gt; The Company offers warranties
on its products. These warranties are assurance-type warranties not sold on a standalone basis or are otherwise considered immaterial
in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates
the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product
is sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;Accounts receivable.
&lt;/b&gt;The Company&#x2019;s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors.
Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid
and private insurance companies. Accounts receivable are carried at amounts estimated to be received from patients under reimbursement
arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines
the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#x2019;s
financial condition and credit history. Receivables are written off when deemed uncollectible.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;Contract assets. &lt;/b&gt;Contract
assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final
determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the
Company is dependent on a future event such as the patient meeting a deductible prior to the Company&#x2019;s claim being processed
by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the
Company&#x2019;s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive
payment is unconditional.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zWMBUzxObaea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;b&gt;Contract balances.&lt;/b&gt; &lt;span id="xdx_8BA_zTWSoVb7jQr1"&gt;The following table
provides information about contract assets from contracts with customers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended &lt;br/&gt;
    March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal
    Year Ended &lt;br/&gt;
    June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Increase
    (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Increase
    (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets, beginning &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20220701__20230331_zojnsWRs8uDl" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets  beginning"&gt;&lt;span style="font-size: 10pt"&gt;286,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20210701__20220630_zSJp3oDx3Dfg" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets, beginning"&gt;&lt;span style="font-size: 10pt"&gt;393,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reclassification of contract assets to accounts receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230331_zulTzlgwvoyb" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"&gt;&lt;span style="font-size: 10pt"&gt;(1,107,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20210701__20220630_zcO5mEItPTre" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"&gt;&lt;span style="font-size: 10pt"&gt;(833,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230331_zV7nM92BK2Tc" style="font-size: 10pt; text-align: right" title="Contract assets recognized"&gt;&lt;span style="font-size: 10pt"&gt;1,372,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210701__20220630_zzmnkmPVAHWe" style="font-size: 10pt; text-align: right" title="Contract assets recognized"&gt;&lt;span style="font-size: 10pt"&gt;784,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Increase (decrease) as a result of changes
    in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230331_zYT9RjztCYFj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"&gt;&lt;span style="font-size: 10pt"&gt;19,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20210701__20220630_z60A9HmVzs8j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"&gt;&lt;span style="font-size: 10pt"&gt;(58,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230331_z7TEg7dvyzI2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"&gt;&lt;span style="font-size: 10pt"&gt;570,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20210701__20220630_znjbSdw5tqM8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"&gt;&lt;span style="font-size: 10pt"&gt;286,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zLXTeaCb1Itj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;Incremental costs to
obtain a contract. &lt;/b&gt;Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs
that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin
on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment
or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred.
These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations.&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLoifyJ7Myvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Disaggregation of revenues.&lt;/b&gt; &lt;span id="xdx_8B8_zbNN7XPeu6Id"&gt;In the following
table, net revenues are disaggregated by market:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Home care&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z86jOQNiggka" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;10,971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zl1BpvekjHsi" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;9,033,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zqQkL2R3djz8" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;31,335,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVsh5wh4Vq08" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;27,721,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Institutional&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zRmkAT5v63h5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;440,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_z5lgkT0U2RD5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;392,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zDZJvfPHT1F7" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,420,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InstitutionalMember_zlYFcN92AIYa" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,174,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Home care distributor&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zWdaUbftJc3l" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;501,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zFnnTkVGaiT5" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;520,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zGLv1pAPQV54" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,391,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zzaPj6BkKZci" style="text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,063,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zIYA14yIQGEc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;156,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zXfHm6g8UJQc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;196,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zaF7SL27pK04" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;309,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--InternationalOneMember_zCqWlakdq6r5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;432,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zd5l41CsTMj5" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;12,068,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331_zng3LTz2GCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;10,141,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zVPoLccoxd35" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;34,455,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331_zd3XEnTcWzD3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;30,390,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;In the following table, net home care revenue is
disaggregated by payer type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 47%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zH1XYS8w9Lya" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,787,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zsz8iLiK1zK4" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zfBVNpoRjc0g" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,706,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zMhoG4GeGNl8" style="width: 10%; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,738,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zVwjODUXwiNe" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,822,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEBT6kF79IFa" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,027,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_z3dEZQq2uMa3" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17,434,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zH9W63PDezOh" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,603,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zmH6PG4boQd4" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;128,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z4eiQKE6bJ9i" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;373,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zOmfmtBqPkpj" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;618,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zfB4N5oepocj" style="text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;790,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zlyJTJjKAMrc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;234,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zDDGrVnM1117" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;275,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zEpSNMrXMyy8" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;577,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherMember_zO9SoJimqs8j" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;590,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z4T44Pxld2Vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zXvOELmvjwC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,033,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zMeVRJ4XZgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,335,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20220331__srt--ProductOrServiceAxis__custom--HomeCareMember_zvyDOZHiqHPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,721,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">10971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">9033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">31335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">27721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_InstitutionalMember"
      decimals="0"
      unitRef="USD">440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_InstitutionalMember"
      decimals="0"
      unitRef="USD">392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_InstitutionalMember"
      decimals="0"
      unitRef="USD">1420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_InstitutionalMember"
      decimals="0"
      unitRef="USD">1174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareDistributorMember"
      decimals="0"
      unitRef="USD">501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareDistributorMember"
      decimals="0"
      unitRef="USD">520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareDistributorMember"
      decimals="0"
      unitRef="USD">1391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareDistributorMember"
      decimals="0"
      unitRef="USD">1063000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_InternationalOneMember"
      decimals="0"
      unitRef="USD">156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_InternationalOneMember"
      decimals="0"
      unitRef="USD">196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_InternationalOneMember"
      decimals="0"
      unitRef="USD">309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_InternationalOneMember"
      decimals="0"
      unitRef="USD">432000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">12068000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">10141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">34455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">30390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_CommercialMember"
      decimals="0"
      unitRef="USD">4787000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_CommercialMember"
      decimals="0"
      unitRef="USD">3358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_CommercialMember"
      decimals="0"
      unitRef="USD">12706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_CommercialMember"
      decimals="0"
      unitRef="USD">10738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicareMember"
      decimals="0"
      unitRef="USD">5822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicareMember"
      decimals="0"
      unitRef="USD">5027000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicareMember"
      decimals="0"
      unitRef="USD">17434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicareMember"
      decimals="0"
      unitRef="USD">15603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_MedicaidMember"
      decimals="0"
      unitRef="USD">128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_MedicaidMember"
      decimals="0"
      unitRef="USD">373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_MedicaidMember"
      decimals="0"
      unitRef="USD">618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_MedicaidMember"
      decimals="0"
      unitRef="USD">790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember_custom_OtherMember"
      decimals="0"
      unitRef="USD">234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember_custom_OtherMember"
      decimals="0"
      unitRef="USD">275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember_custom_OtherMember"
      decimals="0"
      unitRef="USD">577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember_custom_OtherMember"
      decimals="0"
      unitRef="USD">590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">10971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">9033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012023-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">31335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012022-03-31_custom_HomeCareMember"
      decimals="0"
      unitRef="USD">27721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zWMBUzxObaea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;b&gt;Contract balances.&lt;/b&gt; &lt;span id="xdx_8BA_zTWSoVb7jQr1"&gt;The following table
provides information about contract assets from contracts with customers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended &lt;br/&gt;
    March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal
    Year Ended &lt;br/&gt;
    June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Increase
    (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Increase
    (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets, beginning &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20220701__20230331_zojnsWRs8uDl" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets  beginning"&gt;&lt;span style="font-size: 10pt"&gt;286,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_c20210701__20220630_zSJp3oDx3Dfg" style="width: 10%; font-size: 10pt; text-align: right" title="Contract assets, beginning"&gt;&lt;span style="font-size: 10pt"&gt;393,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reclassification of contract assets to accounts receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230331_zulTzlgwvoyb" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"&gt;&lt;span style="font-size: 10pt"&gt;(1,107,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20210701__20220630_zcO5mEItPTre" style="font-size: 10pt; text-align: right" title="Reclassification of contract assets to accounts receivable"&gt;&lt;span style="font-size: 10pt"&gt;(833,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230331_zV7nM92BK2Tc" style="font-size: 10pt; text-align: right" title="Contract assets recognized"&gt;&lt;span style="font-size: 10pt"&gt;1,372,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210701__20220630_zzmnkmPVAHWe" style="font-size: 10pt; text-align: right" title="Contract assets recognized"&gt;&lt;span style="font-size: 10pt"&gt;784,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Increase (decrease) as a result of changes
    in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230331_zYT9RjztCYFj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"&gt;&lt;span style="font-size: 10pt"&gt;19,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20210701__20220630_z60A9HmVzs8j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"&gt;&lt;span style="font-size: 10pt"&gt;(58,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230331_z7TEg7dvyzI2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"&gt;&lt;span style="font-size: 10pt"&gt;570,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20210701__20220630_znjbSdw5tqM8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Contract assets, ending"&gt;&lt;span style="font-size: 10pt"&gt;286,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">286000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">393000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1107000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="From2021-07-012022-06-30"
      decimals="0"
      unitRef="USD">-833000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">1372000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2021-07-012022-06-30"
      decimals="0"
      unitRef="USD">784000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">19000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="From2021-07-012022-06-30"
      decimals="0"
      unitRef="USD">-58000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">570000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">286000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zrBG6lEHYaP1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Note 3. &lt;span id="xdx_82C_z3esTlzgoW3c"&gt;Inventories&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ztm6QJuufMLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;span id="xdx_8BA_zGkVMdu5kD5d"&gt;The components of inventory were as follows&lt;/span&gt;: &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 9.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230331_zAjqevD72dCk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220630_zFezRGXTIGY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherInventorySupplies_iI_maINzW5z_maINzrcq_zsHRxqUaYAHi" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Parts inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,908,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,672,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_maINzW5z_maINzrcq_z76eOK0OCXTd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_maINzW5z_maINzrcq_zg3MoyojxDv" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;280,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;469,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherInventoryInTransit_iI_maINzW5z_maINzrcq_zjROX6X1J8Ti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Estimated inventory to be returned&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;263,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;228,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--InventoryValuationReserves_iNI_di_msINzW5z_msINzrcq_zPO8mebFeD1c" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Reserve for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(291,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryNet_iI_zICO24i8OXdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,451,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zuT5X7Q4dgM4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ztm6QJuufMLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&lt;span id="xdx_8BA_zGkVMdu5kD5d"&gt;The components of inventory were as follows&lt;/span&gt;: &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 9.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230331_zAjqevD72dCk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220630_zFezRGXTIGY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherInventorySupplies_iI_maINzW5z_maINzrcq_zsHRxqUaYAHi" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Parts inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,908,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,672,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_maINzW5z_maINzrcq_z76eOK0OCXTd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_maINzW5z_maINzrcq_zg3MoyojxDv" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;280,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;469,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherInventoryInTransit_iI_maINzW5z_maINzrcq_zjROX6X1J8Ti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Estimated inventory to be returned&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;263,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;228,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--InventoryValuationReserves_iNI_di_msINzW5z_msINzrcq_zPO8mebFeD1c" style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Reserve for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(291,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryNet_iI_zICO24i8OXdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,451,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherInventorySupplies contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2908000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">2672000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">213000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">100000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">280000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">469000</us-gaap:InventoryFinishedGoods>
    <us-gaap:OtherInventoryInTransit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">263000</us-gaap:OtherInventoryInTransit>
    <us-gaap:OtherInventoryInTransit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">228000</us-gaap:OtherInventoryInTransit>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">213000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">291000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3451000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">3178000</us-gaap:InventoryNet>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--ProductWarrantyDisclosureTextBlock_zPYKjjjq8wCb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Note 4. &lt;span id="xdx_825_zm7ErBxP5qcd"&gt;Warranty Reserve&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;The Company provides a lifetime warranty on
its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales
to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability
in the amount of such costs at the time the product is shipped. Factors that affect the Company&#x2019;s warranty reserve include
the number of units shipped, historical and anticipated rates of warranty claims, the product&#x2019;s useful life and cost per
claim. The Company periodically assesses the adequacy of its recorded warranty reserve and adjusts the amounts as necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_z81p7xYdAUEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;span id="xdx_8BF_zFHwYYqtavx3"&gt;Changes in the Company&#x2019;s warranty
reserve were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended &lt;br/&gt;
    March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal
    Year Ended &lt;br/&gt;
    June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Warranty reserve, beginning &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230331_znWEmS9LRTn5" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"&gt;&lt;span style="font-size: 10pt"&gt;1,256,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProductWarrantyAccrual_iS_c20210701__20220630_zEzcXwsVIr97" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"&gt;&lt;span style="font-size: 10pt"&gt;940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Accrual for products sold &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230331_zVZjpbza45Rl" style="font-size: 10pt; text-align: right" title="Accrual for products sold"&gt;&lt;span style="font-size: 10pt"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20210701__20220630_z1R1172ED1Id" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;494,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Expenditures and costs
    incurred for warranty claims&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230331_z6CI4SCelsP1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expenditures and costs incurred for warranty claims"&gt;&lt;span style="font-size: 10pt"&gt;(213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20210701__20220630_zFvsEIt3Zcuj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Warranty reserve, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230331_z3trpH4UvIl1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Warranty reserve, ending"&gt;&lt;span style="font-size: 10pt"&gt;1,333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProductWarrantyAccrual_iE_c20210701__20220630_zhP5TRijSnI" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,256,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zqlmEh3g1yFj" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_z81p7xYdAUEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;span id="xdx_8BF_zFHwYYqtavx3"&gt;Changes in the Company&#x2019;s warranty
reserve were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended &lt;br/&gt;
    March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal
    Year Ended &lt;br/&gt;
    June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Warranty reserve, beginning &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230331_znWEmS9LRTn5" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"&gt;&lt;span style="font-size: 10pt"&gt;1,256,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProductWarrantyAccrual_iS_c20210701__20220630_zEzcXwsVIr97" style="width: 10%; font-size: 10pt; text-align: right" title="Warranty reserve, beginning"&gt;&lt;span style="font-size: 10pt"&gt;940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Accrual for products sold &lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230331_zVZjpbza45Rl" style="font-size: 10pt; text-align: right" title="Accrual for products sold"&gt;&lt;span style="font-size: 10pt"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20210701__20220630_z1R1172ED1Id" style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;494,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Expenditures and costs
    incurred for warranty claims&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230331_z6CI4SCelsP1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expenditures and costs incurred for warranty claims"&gt;&lt;span style="font-size: 10pt"&gt;(213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20210701__20220630_zFvsEIt3Zcuj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Warranty reserve, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230331_z3trpH4UvIl1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Warranty reserve, ending"&gt;&lt;span style="font-size: 10pt"&gt;1,333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProductWarrantyAccrual_iE_c20210701__20220630_zhP5TRijSnI" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,256,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1256000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">940000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">290000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="From2021-07-012022-06-30"
      decimals="0"
      unitRef="USD">494000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">213000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="From2021-07-012022-06-30"
      decimals="0"
      unitRef="USD">178000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1333000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1256000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zEhE5mRpJIb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Note 5. &lt;span id="xdx_828_zGxgpa1ouBr5"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income tax expense was estimated at $&lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20230331_zfPhFpPGuhpk" title="Income tax expense"&gt;147,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20220701__20230331_zJllbYLgbAS5" title="Income tax expense"&gt;418,000&lt;/span&gt;, and the effective tax rate was &lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20230331_z6WC12it3x5e" title="Effective tax rate"&gt;12.0&lt;/span&gt;% and &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220701__20230331_zMdO0rdEw2q3" title="Effective tax rate"&gt;16.4&lt;/span&gt;% for the three and nine months ended March 31, 2023, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2023 includes a discrete current tax benefit of $&lt;span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20230101__20230331_zBBLtSTZxxa7" title="Discrete current tax benefit - non-qualified stock options exercised"&gt;176,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220701__20230331_zIix4EjDTQd7" title="Discrete current tax benefit - non-qualified stock options exercised"&gt;219,000&lt;/span&gt;, respectively, related to the exercise of stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income tax expense was estimated at $&lt;span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20220331_zp7JYiGqIw9b" title="Income tax expense"&gt;224,000&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210701__20220331_zg53vWkVMix9" title="Income tax expense"&gt;576,000&lt;/span&gt;, and the effective tax rate was &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20220331_ztjOKQWFZP98" title="Effective tax rate"&gt;25.8&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210701__20220331_zbSmcCmTpQH" title="Effective tax rate"&gt;23.1&lt;/span&gt;% for the three and nine months ended March 31, 2022, respectively.
Estimated income tax expense for the three and nine months ended March 31, 2022 includes a discrete current tax benefit of $&lt;span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20220101__20220331_zuYpzyve2tO1" title="Discrete current tax benefit - non-qualified stock options exercised"&gt;22,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c20210701__20220331_zA0vJnA3nYIi" title="Discrete current tax benefit - non-qualified stock options exercised"&gt;43,000&lt;/span&gt;, respectively, related to the exercise of stock options and other items.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company is subject to U.S. federal and state
income tax in multiple jurisdictions. With limited exceptions, years prior to the Company&#x2019;s fiscal year ended June 30, 2019
are no longer open to U.S. federal, state or local examinations by taxing authorities. The Company is not under any current income
tax examinations by any federal, state or local taxing authority. If any issues addressed in the Company&#x2019;s tax audits are
resolved in a manner not consistent with management&#x2019;s expectations, the Company could be required to adjust its provision
for income taxes in the period such resolution occurs.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">418000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      unitRef="Pure">0.120</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.164</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">176000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">219000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">224000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.258</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-07-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">22000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">43000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zlvGew50A74k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Note 6. &lt;span id="xdx_822_zTtz57LMREOd"&gt;Financing Arrangements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company has a credit facility that provides
for a $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3o5E1zjdVMl" title="Maximum borrowing capacity"&gt;2,500,000&lt;/span&gt; revolving line of credit. There was &lt;span id="xdx_90E_eus-gaap--LinesOfCreditCurrent_iI_do_c20230330__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5wvx3Wh5dIl"&gt;&lt;span id="xdx_90F_eus-gaap--LinesOfCreditCurrent_iI_do_c20220630__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zxWjK3EgGFad"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding principal balance on the line of credit as of March 31, 2023
or June 30, 2022. Interest on borrowings under the line of credit, if any, accrues at the prime rate (&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVCKA0YkE9S2" title="Interest rate"&gt;8.00&lt;/span&gt;% at March 31, 2023)
less &lt;span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220701__20230331_z1rgPYZCMzPj" title="Basis spread on rate"&gt;1.00&lt;/span&gt;% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $&lt;span id="xdx_903_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zndZE983dFja" title="Available borrowing capacity"&gt;2,500,000&lt;/span&gt;
or &lt;span id="xdx_90C_ecustom--BorrowingCapacityOfEligibleAccountsReceivablePercent_iI_uPure_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zy7VPEka9iq" title="Available borrowing capacity"&gt;57.00&lt;/span&gt;% of eligible accounts receivable and the line of credit expires on &lt;span id="xdx_90F_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20220701__20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zqNBIpjNNYse" title="Line of credit facility, expiration date"&gt;December 18, 2023&lt;/span&gt;, if not renewed before such date.
At March 31, 2023, the maximum $&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20230331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zlVkWyUABNTc" title="Available borrowing capacity"&gt;2,500,000&lt;/span&gt; was eligible for borrowing. Payment obligations under the line of credit, if any, are
secured by a security interest in substantially all of the tangible and intangible assets of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The documents governing
the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not
less than $&lt;span id="xdx_90E_ecustom--DebtInstrumentCovenantComplianceAmount_iI_uUSD_c20230331_zPrxef3Pynal" title="Minimum tangible net worth to be maintained"&gt;10,125,000&lt;/span&gt; and restrictions on the Company&#x2019;s ability to incur certain additional indebtedness or pay dividends.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2023-03-30_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2022-06-30_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">2500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <elmd:BorrowingCapacityOfEligibleAccountsReceivablePercent
      contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">57.00</elmd:BorrowingCapacityOfEligibleAccountsReceivablePercent>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="From2022-07-012023-03-31_us-gaap_RevolvingCreditFacilityMember">2023-12-18</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2023-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">2500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <elmd:DebtInstrumentCovenantComplianceAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10125000</elmd:DebtInstrumentCovenantComplianceAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKSISVZhDhK4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Note 7. &lt;span id="xdx_82B_z3i7lHEFjEBl"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Authorized
shares:&lt;/b&gt;&#160;The Company&#x2019;s Articles of Incorporation, as amended, have established&#160;&lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--CapitalStockMember_ztolrmB4gg33" title="Common stock, authorized"&gt;15,000,000&#160;&lt;/span&gt;authorized shares
of capital stock consisting of&#160;&lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaR19zCmm53e" title="Common stock, authorized"&gt;13,000,000&#160;&lt;/span&gt;shares of common stock, par value $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuodLQLa7cf1" title="Common stock, par value (in dollars per share)"&gt;0.01&lt;/span&gt;&#160;per share, and&#160;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__custom--AuthorizedSharesUndesignatedStockMember_zzJEq38i96E7" title="Common stock, authorized"&gt;2,000,000&lt;/span&gt;&#160;shares
of undesignated stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On
May 26, 2021, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) approved a stock repurchase authorization. Under
the authorization, the Company was originally able to repurchase up to $&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_dxL_uShares_c20220526__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zw2RweSZoxpg" title="Common stock, authorized::XDX::3000000"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;3.0&lt;/span&gt;&lt;/span&gt;&#160;million&#160;of shares of common stock through
May 26, 2022. On May 26, 2022, the Board removed the date limitation. As of March 31, 2023, a total of&#160;&lt;span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_uShares_c20220701__20230331_zthAU97Py7ik" title="Number of share repurchased"&gt;239,995&lt;/span&gt;&#160;shares
have been repurchased and retired under this authorization for a total cost of $&lt;span id="xdx_902_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_c20220701__20230331_z2HmskETELY5" title="Repurchase of common stock"&gt;2,725,000&lt;/span&gt;, or $11.36&#160;per share. Repurchased
shares have been retired and constitute authorized but unissued shares.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-03-31_custom_CapitalStockMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-03-31_custom_AuthorizedSharesUndesignatedStockMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">239995</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">2725000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zd2od0puKq63" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note 8. &lt;span id="xdx_82C_zRc74D7oLLlb"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s share-based compensation
plans are described in Note 8 to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for fiscal
2022. Share-based compensation expense was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220701__20230331_zxgLmDIDtxd" title="Share-based compensation expense"&gt;506,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210701__20220331_zPhPRUGcDif" title="Share-based compensation expense"&gt;703,000&lt;/span&gt; for the nine months ended March 31, 2023 and 2022, respectively.
This expense is included in selling, general and administrative expense in the Condensed Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock Options&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2LBMDxTSnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zexP6TkyzPf"&gt;Stock option transactions during
the nine months ended March 31, 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average
                                         &lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise Price per&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Share&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220701__20231231_zUk1cNxQRlW2" style="width: 10%; text-align: right" title="Options outstanding, beginning | shares"&gt;&lt;span style="font-size: 10pt"&gt;502,084&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220701__20230331_zDELv2zhVc43" style="width: 10%; text-align: right" title="Options outstanding, beginning | $ / shares"&gt;&lt;span style="font-size: 10pt"&gt;5.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20230331_zJHxA8gC1nq3" style="text-align: right" title="Granted"&gt;&lt;span style="font-size: 10pt"&gt;104,325&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_zHX7AlfopaAi" style="text-align: right" title="Granted"&gt;&lt;span style="font-size: 10pt"&gt;9.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20220701__20230331_z6E2KoU14aPb" style="text-align: right" title="Exercised"&gt;&lt;span style="font-size: 10pt"&gt;(90,351&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_pid_uUSDPShares_c20220701__20230331_zq3XCSIew0Qe" style="text-align: right" title="Exercised"&gt;&lt;span style="font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Cancelled or Forfeited   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220701__20230331_zkgUtP23WzE1" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(47,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_ziij5IOI2Yb8" style="text-align: right" title="Cancelled or Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;11.19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at March 31, 2023   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20230331_zZdbeVZbk0Al" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending | shares"&gt;&lt;span style="font-size: 10pt"&gt;468,128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220701__20230331_zUnEMAzPClf8" style="text-align: right" title="Options outstanding, ending | shares"&gt;&lt;span style="font-size: 10pt"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zTLxbcxo00x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"/&gt;





&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zbTnC3vjZCPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span id="xdx_8BB_zljBe1zRuSH1"&gt;The following assumptions were
used to estimate the fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended &lt;br/&gt; March 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year Ended &lt;br/&gt; June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230331_zNriTIRbfnY8" title="Risk free interest rate - minimum"&gt;2.88&lt;/span&gt; - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230331_z8PojxQwFNx9" title="Risk free interest rate - maximum"&gt;4.23&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210701__20220630_zBzqgbMF8p78" title="Risk free interest rate - minimum"&gt;0.89&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210701__20220630_zdGFnuw9iSwl" title="Risk free interest rate - maximum"&gt;2.52&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 69%; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220701__20230331_zyCtIt7J3IO5" title="Expected term (years)::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210701__20220630_z89Kw50kH0z2" title="::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230331_z5ONt5OVEGx" title="Expected volatility Minimum"&gt;53&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230331_zy6VX3coaKK3" title="Expected volatility Maximum"&gt;54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210701__20220630_za2Zw3fbfi9d" title="Expected volatility - minimum"&gt;55&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210701__20220630_zCtfkkiMUtik" title="Expected volatility - maximum"&gt;64&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A5_zstQvYouApKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;The intrinsic value of an option is the amount
by which the fair value of the underlying stock exceeds its exercise price. At March 31 2023, the weighted average remaining contractual
term for all outstanding stock options was &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5OwNa2skHy3" title="Weighted average contractual term outstanding stock options"&gt;5.9&lt;/span&gt; years and the aggregate intrinsic value of the options was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZT0TcgXtlw8" title="Options outstanding, intrinsic value"&gt;1,802,672&lt;/span&gt;. Outstanding
at March 31, 2023 were 468,128 stock options issued to employees, of which &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS3eSgcyRN1f" title="Outstanding exercisable"&gt;339,342&lt;/span&gt; were vested and exercisable and had an aggregate
intrinsic value of $&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6cDS4h9agHf" title="Options exercisable, intrinsic value"&gt;1,762,445&lt;/span&gt;. As of March 31, 2023, $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyGnMEFw0eNj" title="Unrecognized compensation expense"&gt;328,218&lt;/span&gt; of total unrecognized compensation expense related to stock options
is expected to be recognized over a weighted-average period of approximately &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEV2b3K2kx8" title="Weighted average period::XDX::P2Y2M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;2.0&lt;/span&gt;&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Restricted Stock&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;During the nine months ended March 31, 2023,
the Company issued restricted stock awards to employees totaling &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zeCJFOlGXgt" title="Restricted stock issued"&gt;32,400&lt;/span&gt; shares of common stock, with a weighted average vesting
term of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zTKOlXxVgeOi" title="Vesting period"&gt;2.7&lt;/span&gt; years and a weighted average fair value of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHGiuODpzcp7" title="Fair value on grant date"&gt;9.92&lt;/span&gt; per share, and to directors totaling &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zgJ4XkRlfM1b" title="Restricted stock - vested (shares)"&gt;21,000&lt;/span&gt; shares of common stock,
with a vesting term of six months and a weighted average fair value of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zaSHdLknxUj9" title="Weight average fair value -vested  restricted stock (per share)"&gt;9.86&lt;/span&gt; per share. There were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_uShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zCZ6paYeNclg" title="Restricted stock - unvested (shares)"&gt;57,818&lt;/span&gt; shares of unvested restricted
stock with a weighted average fair value of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_uUSDPShares_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zknYMC09m1Ce" title="Weight average fair value - unvested restricted stock (per share)"&gt;10.32&lt;/span&gt; per share outstanding as of March 31, 2023. As of March 31, 2023, $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs0U8Ka9X555" title="Unrecognized compensation expense"&gt;244,063&lt;/span&gt; of
total unrecognized compensation expense related to restricted stock awards is expected to be recognized over a weighted-average
period of approximately &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxL_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJswSXZSEDAb" title="Weighted average period::XDX::P1Y4M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;1.3&lt;/span&gt;&lt;/span&gt; years.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-01to2023-03-31"
      decimals="0"
      unitRef="USD">506000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012022-03-31"
      decimals="0"
      unitRef="USD">703000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2LBMDxTSnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zexP6TkyzPf"&gt;Stock option transactions during
the nine months ended March 31, 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.95pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-right: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average
                                         &lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise Price per&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Share&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="width: 74%; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220701__20231231_zUk1cNxQRlW2" style="width: 10%; text-align: right" title="Options outstanding, beginning | shares"&gt;&lt;span style="font-size: 10pt"&gt;502,084&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220701__20230331_zDELv2zhVc43" style="width: 10%; text-align: right" title="Options outstanding, beginning | $ / shares"&gt;&lt;span style="font-size: 10pt"&gt;5.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20230331_zJHxA8gC1nq3" style="text-align: right" title="Granted"&gt;&lt;span style="font-size: 10pt"&gt;104,325&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_zHX7AlfopaAi" style="text-align: right" title="Granted"&gt;&lt;span style="font-size: 10pt"&gt;9.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20220701__20230331_z6E2KoU14aPb" style="text-align: right" title="Exercised"&gt;&lt;span style="font-size: 10pt"&gt;(90,351&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue_pid_uUSDPShares_c20220701__20230331_zq3XCSIew0Qe" style="text-align: right" title="Exercised"&gt;&lt;span style="font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Cancelled or Forfeited   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220701__20230331_zkgUtP23WzE1" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(47,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220701__20230331_ziij5IOI2Yb8" style="text-align: right" title="Cancelled or Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;11.19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at March 31, 2023   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20230331_zZdbeVZbk0Al" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending | shares"&gt;&lt;span style="font-size: 10pt"&gt;468,128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220701__20230331_zUnEMAzPClf8" style="text-align: right" title="Options outstanding, ending | shares"&gt;&lt;span style="font-size: 10pt"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">502084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">5.82</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">104325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">90351</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <elmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">1.82</elmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">47930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">11.19</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">468128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">6.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zbTnC3vjZCPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span id="xdx_8BB_zljBe1zRuSH1"&gt;The following assumptions were
used to estimate the fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended &lt;br/&gt; March 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year Ended &lt;br/&gt; June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230331_zNriTIRbfnY8" title="Risk free interest rate - minimum"&gt;2.88&lt;/span&gt; - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230331_z8PojxQwFNx9" title="Risk free interest rate - maximum"&gt;4.23&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210701__20220630_zBzqgbMF8p78" title="Risk free interest rate - minimum"&gt;0.89&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210701__20220630_zdGFnuw9iSwl" title="Risk free interest rate - maximum"&gt;2.52&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 69%; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220701__20230331_zyCtIt7J3IO5" title="Expected term (years)::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210701__20220630_z89Kw50kH0z2" title="::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(214,243,232)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230331_z5ONt5OVEGx" title="Expected volatility Minimum"&gt;53&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230331_zy6VX3coaKK3" title="Expected volatility Maximum"&gt;54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210701__20220630_za2Zw3fbfi9d" title="Expected volatility - minimum"&gt;55&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210701__20220630_zCtfkkiMUtik" title="Expected volatility - maximum"&gt;64&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-07-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-07-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-07-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-07-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-07-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1802672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">339342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1762445</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">328218</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember"
      decimals="INF"
      unitRef="Shares">32400</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-07-012023-03-31_us-gaap_EmployeeStockOptionMember_custom_EmployeeMember">P2Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember"
      decimals="INF"
      unitRef="Shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-012023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember"
      decimals="INF"
      unitRef="USDPShares">9.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember"
      decimals="INF"
      unitRef="Shares">57818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember_custom_EmployeeMember"
      decimals="INF"
      unitRef="USDPShares">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">244063</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-07-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_ztNQUvbbFyO1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Note 9.&lt;span id="xdx_82D_zrjbfofoIPJa"&gt; Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;The Company is occasionally involved in claims
and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate
the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other
disposition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;On September 8, 2021, a state court putative
class action lawsuit was filed in Minnesota against the Company asserting injury resulting from the previously announced data breach
that impacted the Company&#x2019;s customer protected health information and employee personal information and seeking compensatory
damages, equitable relief, and attorneys&#x2019; fees and costs. On October 6, 2021, the proceeding was removed to the District
of Minnesota. The Company believes the plaintiff was not injured as a result of the data privacy incident and, as a result, the
claims are without merit. &lt;span style="background-color: white"&gt;Accordingly, on November 11, 2021, the Company moved to dismiss
the complaint in its entirety. Prior to the hearing on the motion to dismiss, the parties agreed in principle to settle the case.&#160;The
parties have executed a settlement agreement and submitted a motion to settle the class action in the near future. During January
2023, the settlement was preliminarily approved. The hearing for final approval is scheduled for June 5, 2023. If the court does
not grant the approval for settlement, the Company will continue to vigorously defend the lawsuit. At this time, the Company is
unable to determine the ultimate outcome or potential exposure to loss, if any.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6JAP2Y[$2BIMX\.CM$JM>&A53;Q>@=<[<A@J#I>+;+:OYL.S*OL/+:L)V"\
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ML_)72  3AZO$BL?6?CT06/G $Z^K"UJ*CXM[R[X?EP+Z$</#8ZKQ3B% ;BE
M[E'/CO*K^_[*/LW6U,C'5(/.QN82:B7^1FJS.PYY6B=+,VNXZV&_TZ74@1OY
M]5O$UILU0S/ZLJ74A'CFYCE?/BP^+99K1]DB9:O</5_K?>!F\"8D%',H=<Y[
M\.LJ7S[--[1<92N0,ZFUC+*W2\%]H<P.\/U<2KW?,#]0+&(/_P-02P,$%
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MZ75G*FE-F9U_OT[2- F"8+6XWW?(ELMP'.[+'6"-!JR1%^N;/!<-0(/"D#/
M>5LQ]()#$1,;1"LH-28S%8*JA0K1W.I-4T$!Z'5 YBR*YP#"F9_=RO$>9$+"
M*+9]<PCB(":3SL6#<['_0PBN)90K1">3+K:6CM/ 1FB+D2R9Q)<,^!(OO@_\
M'M)"R)(YL276HA ];(-SR.$TFT27#NA2+[IKR7:T+!![W)DZI=J4%GK+))3'
M;C-/QS6U,.$LR&SL+KG##W" /1NP9T<BFXN:(4T?]Q+;A3-SI-[2ANE=S5U.
MD*>2+ <WEEXW_A::5B=$>VEG0(P3AQ\.P2@.EY/QQL'(9L&1;($&1^JG-DM,
MS=M!RZ'G"&J)D[L">^/% ;$1.P2C.)G.;KS'O]B+^'W)@63/JW+#4,DUY7>E
MJ7Y=E*>!8PM/$D0.W+9<O/0$>N11[.6N]5_M#IS.A5[]$* #GRV&R?3&PR/Y
M83_[O6,;!OE:0$R?]Z"[O/5V#A#$@8/ZG(*A)P5&\L-^]NOVER>6-C-%)(L<
M-=@EB<,DF@8YDAB.3^J<_BSI;5F5>H(ML)<+?[1_^EG6#GT>B1'[F7%H2W;T
M::IT8YOW,,D<1<\IF.#I3S,R)/93),"4#:0Z)+KA2&KF(R=4F^9(D+FJG4,P
MC:8[(3P2(CZ9$7TQ_?]$USMB$VOLB?A(B-C/B%^IE)0#S?3+.YVP60Z'8>B(
MMD.0Q--]'1G9D/C9L"_2?7I4_IU+;(K#*7;@=0EFT731)B,7$C\7'C8:Q_ Z
M*##"J0.O+9CBV(-W;Y@\A00KP>_.-9/U4<0VV84.3G2(1=-)2T9*)'Y*[*)[
M#*/-<DD4N:)J"Z9XZ<$YTB&)O$QSLZ62;455,*E^0[]#$Z>?G%"]K/K#H_I/
MLG;H]$BOY-B06->"(Z5%_FV.SH*+ $.%E AF]H8AZ&F1,F&9(QR:2=?\=4]@
M(&KT%J:W?UGQ&F7S.$[F4#O:!CB;1VD\C\+L6;14RE2"=H1JM()NLRCYW1QZ
M#S-%?Z(RWPZ'-:W4QX:SX?QE;LK=CK4';Y7[D]@3:N9HI5QB\73FC'Q-CO!U
M492&_"#-S<QX7G*4TUT):>\$ZR#D+(X<XZ%3,@RF>S\R<C?Q<_=GIBD\@F&%
M2@[?PKTI'?-I=SQC(75(QNT4/H5TI&[BI^ZN?*B#S<FF-Z?-O&$2+ATCBDL2
MZOCTH1(9:9J<,KCN5;PVIT]V86D==DVTW2Y)=]N]V#NI-<?DL.7N2JY0Q3:@
M&ERD$ ;9G3QW-UKLVL/;6Z&UJ-O++:, W0C ^XT0^OG&G </Y__K_P!02P,$
M%     @ O("I5C9U-8C< @  \ <  !@   !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6RM55UKVS 4_2O"&R.%+G;LV"E=8FA3RC88A(9N#V,/BGT3B\J2)\E)
MMU^_*]DU2>OT Y:'6++O.?><*^EJNI/J3A< AMR77.B95QA3G?N^S@HHJ1[*
M"@1^64M54H-3M?%UI8#F#E1R/PR"Q"\I$UXZ=>\6*IW*VG F8*&(KLN2JC^7
MP.5NYHV\AQ<W;%,8^\)/IQ7=P!+,;;50./,[EIR5(#23@BA8S[R+T?E\8N-=
MP'<&.[TW)M;)2LH[._F2S[S "@(.F;$,%!];F /GE@AE_&XYO2ZE!>Z/']BO
MG7?TLJ(:YI+_8+DI9MZ91W)8TYJ;&[G[#*V?V/)EDFOW3W9-;!)Y)*NUD64+
M1@4E$\V3WK=UV .,QD< 80L(7PN(6D#DC#;*G*TK:F@Z57)'E(U&-CMPM7%H
M=,.$7<6E4?B5(<ZD<RER7!/(R27E5&1 EI9+D\&MH'7.#.0G9+"@"H0IP+",
M\A/RD=PNK\C@_<G4-ZC!,OE9F^^RR1<>R?>-JB&)1J<D#,*H!SY_'OZU%@@/
M'#P\A/OHO+,?=O9#QQ<=X5L::@ WI2%R3:Z9P HPRLE":N9VV<^+E38*]]JO
M/JL-][B?VYZ_<UW1#&8>'C -:@M>^N'=* D^]1G_3V0'98BZ,D3/L:<7629K
M@:NN( .VI2L.IX1R/.)N2V"S(+FL5V9=<SQX36Q?09HLB<MB^\<V'<=!$$S]
M[;[3EZ(.+(P["^-G+<QE6>*"X8')[DY)11794EX#&3"!VCFG2I,*L'\5N)=[
M-V[#/]F3%0R#T2/M+P0=2(\[Z?$;I-/:%%*QOY#WB6R8XKW\HRAPOT="7Q%X
M(#;IQ"9O$(OW@C94Y$QL^M0F3T2<Q7&2/!';$S>>Q./HK%_KI-,Z>8-6IG7=
M7]3)*V7VQ/7*]/?ZL;T+L>EMF-"$PQJ1P7""%*JY7YJ)D95KT2MIL.&[88%7
M,B@;@-_74IJ'B>WZW26?_@-02P,$%     @ O("I5M35ZKY[!0  ^QD  !@
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM65USHS84_2L:M]/9G<D&)$!
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M\S 4V%04LK)K TBX#?C+SA/(-3#&*CM_*SLB(9-9NG#G4=;"VO#:SM9TV&"
M_V.HLX$$IX'JT?4))-PG?&'56F9+JKS(@7BASB !FG!(<#;I[\%)UQJ0<&O@
MU8I%FVX':@70 HQQ"F"'>H4H#H#OF@5RN%G(62:9];?!;@T!L?I\/\3Q= J
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MD!@.2)<_S9E+0N,HYCP\'S=)68A435*IV>8;%F(X"UT>G3D(]S[-7=;HB,Y
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M7C+$<8& GJVT+SIZ@.[/9=_Y=VS!8T'D4Y<&&RPD)S[,6Q_@/*(YIH#2)K5
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M@R&9YM'6;)RNPD-IH1V>76&YQCN7C1? ^5+CAFDWWD#_<C[_%U!+ P04
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M^7%4GJM_=SV5/R?B( _M'AVP5W&T GNAD<D\)^D;=];]Z?ST!VX 88;F .9
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MR8WX"+F/9GQ:/DX4AK$.G*HMW <7;E1R+3B3>P+OC$$A(4S*P4?D&*%W(6D
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M\0%T7FBZZKWA$_0C??$74$L#!!0    ( +R J58:!L.FF@(  *4%   9
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ME4V@]8VDZ^P<NT$_F1=_ 5!+ P04    " "\@*E6OHLY9)@$  "V"0  &0
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M38RI,X3IE+GHR:#=D8@)Q-NQN@\&*A[HP)8&8<KGOFU]VK,GL(%2#<$)^ZM
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MH-HQTRZ,K%UK+Z2A0>',@B8S*AM _J649KNP!;I9G_X!4$L#!!0    ( +R
MJ58.*+.(N@(  "0&   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;(U5
MWV_:,!!^YZ\XI5/52JCY!2U0B 3=NNVA$VJW5=.T!Y,<Q*IC9[;3M/_];">D
M; *T%W(^WWWW?;;OF-9"/JD<4<-+P;B:>;G6Y<3W59IC0=2%*)&;G;60!=%F
M*3>^*B62S"45S(^"X-(O".5>,G6^I4RFHM*,<EQ*4%51$/FZ0";JF1=Z6\<]
MW>3:.OQD6I(-/J#^5BZE6?D=2D8+Y(H*#A+7,V\>3A8#&^\"OE.LU8X-5LE*
MB">[^)S-O, 20H:IM@C$?)[Q!AFS0(;&[Q;3ZTK:Q%U[BW[KM!LM*Z+P1K!'
MFNE\YHT\R'!-*J;O1?T)6SU#BY<*IMPOU$WL<.Q!6BDMBC;9,"@H;[[DI3V'
MG811<" A:A,BQ[LIY%B^)YHD4REJD#;:H%G#2779AASE]E(>M#2[U.3IY)%(
M2;A^A7M4*)\1SKZ2%4-U/O6U@;=!?MI"+1JHZ #4&.X$U[F"#SS#[.]\W]#J
MN$5;;HOH*. =D1<0AWV(@B@^@A=W6F.'%Q_ ^U@1JQ51 >$9+*7(JE1#>P34
MN'_.5TI+\U)^[9/?H _VH]ONF:B2I#CS3'NXP_22TY/P,K@^PGW0<1\<0T]N
M<L(WAB'EH'.$&U&4A+^>GHRB\.I:0;V]QK8RU"@1B(*U8*;OU&2?GJ,5]^OY
M3QJ]0S1Z7TR5WNX[@5NJ4L)Z/Y#(QM-[_$=,'U:XH9Q3OH%W$/:CX64_" )C
MCP>!M7KS-)458::,A+*Y5@5*L RBL8N P7C@(C^\F'&645W)]A6D0FG5HSRM
MI#1L+$)WF"DCM%!P%H6Q SF'L_!JU)A[6%K@EF(<QRW%-[K[7H&_T[D%RHV;
M3\J0JKANFKCS=B-PWG3^6W@S/TVWF$-2P'!M4H.+JZ$'LIE)S4*+TLV!E=!F
MJC@S-V,<I0TP^VLA]'9A"W1_#,D?4$L#!!0    ( +R J5:P^<ZR;0,  ",(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*56VV[;1A!]YU<,V**P
M 9EW*I(K"9#<I!<@J6"G#8JB#RMR*"Y,<IG=I63WZSN[E!DU4-F@?1'W,G/F
MS&5GM#@*^:A*1 U/==6HI5MJW=[ZOLI*K)GR1(L-W11"UDS35NY]U4IDN56J
M*S\*@JE?,]ZXJX4]V\K50G2ZX@UN):BNKIE\WF ECDLW=%\.[OF^U.; 7RU:
MML<'U+^T6TD[?T#)>8V-XJ(!B<7278>WF]3(6X%?.1[5V1J,)SLA'LWFQWSI
M!H805IAI@\#H<\ [K"H#1#0^GC#=P:11/%^_H+^QOI,O.Z;P3E0?>*[+I3MS
M(<>"=96^%\<?\.2/)9B)2ME?.)YD Q>R3FE1GY2)0<V;_LN>3G'X$H7HI!!9
MWKTAR_([IMEJ(<41I)$F-+.PKEIM(L<;DY0'+>F6DYY>/91,XLV&_,KA3M24
M:\5LN*[>LUV%ZGKA:S)CA/WL!+GI(:-_@)S#6]'H4L'K)L?\[_H^T1LX1B\<
M-]$HX%LF/8C#"41!%(_@Q8//L<6+O\#G+7NF$M.PEI(U>[3KW]<[I275RQ^7
MG.^QD\O8Y@W=JI9EN'3ID2B4!W17WWP53H-O1Y@G _-D#'WUH$7V"**U&2**
ME"Q;W KR3O)F#[I$:$@)ZCX%:%( %,"L'"((Y/WI$?(_Z98I*$1%KU/=7O)W
ME-%E?_^-IO,_:3KONGJ'TA$%V%PJ^&!?'^8WZP-*:B;.ZR>4&5<(6\DSA!9E
M+^K\W&FE69.;:#$-/W7$(@ZLR0C2()H$LP2^AM2;1<[W1)U (0R221RE=#SW
MYO& G</5/)C$:0C7=!4:C3O69-1AZ$I(H+91(#< 5\FKR3P.>KG0"^>?T_C,
M]60ZFX31C*2GWGP*(Y63#I63CE;.>XIX'SYK45%@VSXE1Z0X=\8;+0"5YM3J
MT!92P;B$ ZLZ!(JT.DNJ@GT?FHL5,\KD<L6,TW/^,SWGG:FR\WX$;[C*6 6_
M(9/]B7//U>--(1&!DQ)QTB"-D<B;S2#Q*!^!-YO3-HTH]RW-$\,&90U7SX2B
MKF$*TT\W!U%1"ZVX?H8TAC2!-(5I<C&)_EGCKE'N[7A2D(FNT7T/'TZ'";CN
M&_\G\7Y\4@7M.7E>84&J@?>*LB#[D=1OM&CM&-@)34/%+DN:XBB- -T70NB7
MC3$P_"]8_0502P,$%     @ O("I5MV5.K43 P  * H  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&ULK59=3]LP%/TK5C9-(&WDLX5V;21HBL8#"('8
M'J8]N,EM8^'8P79:]N]G.VE6VE"QT9?$'_><ZWML7]_1BHM'F0,H]%Q0)L=.
MKE0Y=%V9YE!@><)+8'IFSD6!E>Z*A2M+ 3BSH(*Z@>?UW0(3YL0C.W8KXA&O
M%"4,;@6255%@\?L"*%^-'=]9#]R11:[,@!N/2KR >U /Y:W0/;=ER4@!3!+.
MD(#YV#GWA].^L;<&WPFLY$8;F4AFG#^:SE4V=CRS(*"0*L. ]6\)$Z#4$.EE
M/#6<3NO2 #?;:_9+&[N.988E3#C]03*5CYTS!V4PQQ55=WSU#9IX>H8OY53:
M+UHUMIZ#TDHJ7C1@O8*"L/J/GQL=-@":IQL0-(!@&Q"] @@;0/A6#U$#B-[J
MH=< ;.AN';L5+L$*QR/!5T@8:\UF&E9]B]9Z$6;.R;T2>I9HG(JOF )!"G1)
M&&8IP13=0<F%(FR!CA)0F%");K 0V&SH,?J"'NX3=/3Q>.0J[=Z0N&GCZJ)V
M%;SB*D37G*E<HBG+(.O )_OQ@SUX5X?=QAZL8[\(]A)>8W&"0O\S"KP@[%C/
MY.WPH"N<]WF?_K?W%V*$[4$(+5_T"M^-SDD"EL JD%U[6Z/[%FV2SS+V Z]_
MYGG>R%UNBM9AZ/F1OV.8[!J&4=3K[1A..PR]<.!M&KX(.6I#CO:&/.%%H7.5
MOF/I(X*GBBPQ!:8D@N>45OJ,H;G@!4HQ32N*;5[C<Y016BD]!U@P?4LD*D'G
MW1P+Z)*M7D%O4XW3P6 0;(G68>8%4=C;DFS73+\'?K0M6 >;'T3!:;=<O5:N
MWEZY;*I@5@>=)GY>0S$#\:LKZ+T\YN4;RA*G,';TTR9!+,&)/WWP^][7KDMX
M2++DD&33 Y&]V(Q^NQG]=UW7O>A_W8)#DB7]CML\V+WTNV91&.Q>>7?CZ2M
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M%+&'H6EC\(!X<).;UEIB9[;[P;_'=M+0-EF98"]M[)QSKL^]SK7'&\8?Q1)
MHFV14S&QEE*6(]L6R1(*+'JL!*K>9(P76*HA7]BBY(!30RIRVW.<T"XPH58T
M-G.W/!JSE<P)A5N.Q*HH,/\UA9QM)I9K[2;NR&(I]80=C4N\@'N0#^4M5R.[
M44E) 5001A&';&)=NJ-9J/$&\(W 1NP](^UDSMBC'ERG$\O1"X(<$JD5L/I;
MPQ7DN192RWBJ-:TFI";N/^_4/QGORLL<"[AB^7>2RN7$&E@HA0RO<GG'-I^A
M]M/7>@G+A?E%FPH;#BV4K(1D14U6*R@(K?[QML[#'D'I=!.\FN =$X)G"'Y-
M\%\:(:@)P4LC]&N"L6Y7WDWB8BQQ-.9L@[A&*S7]8+)OV"I?A.I]<B^Y>DL4
M3T;7-&$%H*]X"P*=Q2 QR07Z@CG'NH+OT3EZN(_1V=OW8UNJ>)IE)[7VM-+V
MGM'VT0VC<BG0C*:0=O#CT_SA";ZM?#9FO9W9J7=2\ ;S'O+=#\AS/+]C/5<O
MIWM==OXO^NR?HQ\DPV\J[QL]_Z^51S$12<[$B@/Z<3D7DJO/]V=7O2O%H%M1
MM[21*'$"$TOU+ %\#5;T[HT;.A^[DOV:8O%KBLU>2>R@+$%3EN"4^JXL4I4%
MMNHT$-!5B$HC-!KZ*%A';G#A.,[87N^GN WSO* %B]NPP!VT8+,VK'\1[L,.
M#/<;P_V3AF=9!N:T,)Y5V^DT7&D,]F([/=<[LEN!A@<@KS\X<MN%<L/@R&RG
MEN]V>PT;K^%)K_I#XR!!=7;.@4IC>0X4,B)5IZ6,GC^M<$XR BE2O3]Y1*S4
M!ZI0FP%X0D1G'YV&[>UP6)DJ/VV8Y[5W0P?*';9W0QL6^.W-8.\=307PA;D3
M")2P%955KVIFFVO'I3EMC^:G[NC*[9B/U36ENE7\D:_N.*IA+HC*7 Z9"N7T
M+E1)>75OJ :2E>9@G#.ICEGSN%17+> :H-YGC,G=0 =H+F_1;U!+ P04
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M9T^"V( 5O7KA!L[;#N;]AGF_"SWZ7%89QT,K%64)IOV,+&"5,:9WP.^.G%7
M P.L+X!--' \9]0?VYL60H.&T.#?"'5OI I\>$BJ-_+:*04-I:"3T@=,I'JZ
M[RIWP5$,7*?O>X-VA\/&X?"Y#H='^L)>Z+>[&S7N1IWNWMV#B#/9[G!TI/ \
M=/R!V^XR;%R&SW<9'FET3^;0=?:7G=/I\I*R& L GE N"-[J2\A.Q+@&>J2Y
M/PQ]YP2%@_O6_5\4W.,8N#TW/,' VS/P_OYT@?EWGO4:]C D_6#D>J,3A/87
MI]MYNSV?D'\4H* 7!D_HV ?%L0"Q,D\ 26*^9JJJD\UH\\R85L5UO[QZHV#)
MP#M(DAR6:.KTAA@+497]JJ-X:4KM@BLLW*:9XE,)A%Z \TO.U:ZC'32/K^@/
M4$L#!!0    ( +R J5;6'&SJ^P(  .4(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;*U6VX[:,!#]%2N5JJW4)2%<-DLA$K!;M9560KN]/%1],,E
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M=PX>G$?QYIR*M[^=C'\#4$L#!!0    ( +R J5:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ O("I5D^4#5=3 P
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M4+92GN+8I?JN>;'>SUOO11[_ E!+ P04    " "\@*E6CWJT85T!   D$P
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=C-CH(P%(;A6R&] ,LY
M5=2)N)J-VXDW0+" D;_03D;O?@@N\".SF(WI69&6</J&Q1/"X<O6F;]VK:NN
MO8ON3=VZ5%7>]Q]:N[RR3>9676_;\4[1#4WFQ^50ZC[+;UEI-<=QHH?7&>IX
M>)T9G1^]_<_$KBBNN?WL\N_&MOZ/P?JG&VZNLM:KZ)P-I?6ITO=ZWG9ZNM!J
MG*RBTR55P^E"2H<.8@CB\$$&@DSXH#4$K<,';2!H$SXH@: D?- 6@K;A@W80
MM L?M(>@??@@BE'&6$#2 FL!6A-R30*\)@2;!(A-2#8),)L0;1*@-B';),!M
M0KA)@-R$=), NPGQ)@%Z,^K- O1FU)L%Z,V+CVT!>C/JS0+T9M2;!>C-J#<+
MT)M1;Q:@-Z/>+$!O1KU9@-Z,>K, O0WJ;03H;5!O\TZ]G7_4ULT]SS6>_TZJ
M_?BLG8^?EL_-Q4N8<-;P4^SX"U!+ P04    " "\@*E6[UO*"88!  #5$P
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M#_ZL^YLW^P102P$"% ,4    " "\@*E6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +R J5:@#W89
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( +R J5:97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ O("I5B%/-E_%!0  T!X
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M965T-2YX;6Q02P$"% ,4    " "\@*E6.^=D*,T+  #W;0  &
M    @('^(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MO("I5MMW%U,Q!0  10L  !@              ("! 3   'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +R J582YB=1*1,  '@U   8
M          " @6@U  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "\@*E6\*;(!J\"  #B!0  &               @(''2   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ O("I5DGS@63G P  K@@
M !D              ("!K$L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "\@*E6LQ;\!WD#  "E!P  &0              @('*3P
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +R J5:*X1'T
MK0(  -X%   9              " @7I3  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ O("I5AH&PZ:: @  I04  !D
M ("!7E8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "\
M@*E6OHLY9)@$  "V"0  &0              @($O60  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +R J5;3&#B%"04   $+   9
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M970Q.2YX;6Q02P$"% ,4    " "\@*E6L/G.LFT#   C"   &0
M    @($J<@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M +R J5;=E3JU$P,  "@*   9              " @<YU  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ O("I5BT&!Z^ !0  .BD  !D
M             ("!&'D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "\@*E6$.832U\#  !R"0  &0              @('/?@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +R J59KD!CGV0(
M $4(   9              " @66"  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ O("I5O_6*#7W @  'P@  !D              ("!
M=84  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "\@*E6
M H.^<0H#  #("0  &0              @(&CB   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( +R J58GTI,(\0,  /83   9
M      " @>2+  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ O("I5K4#[\-_!0  O3,  !D              ("!#)   'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "\@*E6DF7>ER(#  "("0
M&0              @('"E0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( +R J5;6'&SJ^P(  .4(   9              " @1N9  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ O("I5AK*G'(D
M!0  7AP  !D              ("!39P  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "\@*E6',4/H!X#  !($0  #0
M@ &HH0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +R J5:7BKL<P    !,"
M   +              "  ?&D  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +R
MJ59/E U74P,   \5   /              "  =JE  !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " "\@*E6CWJT85T!   D$P  &@              @ %:
MJ0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "\@*E6
M[UO*"88!  #5$P  $P              @ 'OJ@  6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     )P G (@*  "FK      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>109</ContextCount>
  <ElementCount>175</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Condensed Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Interim Financial Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/InterimFinancialReporting</Role>
      <ShortName>Interim Financial Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/WarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Financing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/FinancingArrangements</Role>
      <ShortName>Financing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Share-basedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Interim Financial Reporting (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/InterimFinancialReportingPolicies</Role>
      <ShortName>Interim Financial Reporting (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://electromed.com/role/Revenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://electromed.com/role/Inventories</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Warranty Reserve (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/WarrantyReserveTables</Role>
      <ShortName>Warranty Reserve (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://electromed.com/role/WarrantyReserve</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Share-basedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://electromed.com/role/Share-basedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Interim Financial Reporting (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/InterimFinancialReportingDetailsNarrative</Role>
      <ShortName>Interim Financial Reporting (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://electromed.com/role/InterimFinancialReportingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails</Role>
      <ShortName>In the following table, net revenues are disaggregated by market: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails</Role>
      <ShortName>The following table provides information about contract assets from contracts with customers: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - The components of inventory were as follows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails</Role>
      <ShortName>The components of inventory were as follows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Changes in the Company???s warranty reserve were as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails</Role>
      <ShortName>Changes in the Company???s warranty reserve were as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://electromed.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Financing Arrangements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/FinancingArrangementsDetailsNarrative</Role>
      <ShortName>Financing Arrangements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://electromed.com/role/FinancingArrangements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/CommonStockDetailsNarrative</Role>
      <ShortName>Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://electromed.com/role/CommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails</Role>
      <ShortName>Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>The following assumptions were used to estimate the fair value of stock options granted: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="elmd230506_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Share-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://electromed.com/role/Share-basedCompensationDetailsNarrative</Role>
      <ShortName>Share-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://electromed.com/role/Share-basedCompensationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockSharesAuthorized, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 -  elmd230506_10q.htm 106, 107, 108, 109, 110</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="elmd230506_10q.htm">elmd230506_10q.htm</File>
    <File>elmd-20230331.xsd</File>
    <File>elmd-20230331_cal.xml</File>
    <File>elmd-20230331_def.xml</File>
    <File>elmd-20230331_lab.xml</File>
    <File>elmd-20230331_pre.xml</File>
    <File>elmd230506_ex31-1.htm</File>
    <File>elmd230506_ex31-2.htm</File>
    <File>elmd230506_ex32-1.htm</File>
    <File>elmd230506_ex32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="497">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "elmd230506_10q.htm": {
   "axisCustom": 1,
   "axisStandard": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 497,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 109,
   "dts": {
    "calculationLink": {
     "local": [
      "elmd-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "elmd-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "elmd230506_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "elmd-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elmd-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "elmd-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 285,
   "entityCount": 1,
   "hidden": {
    "http://electromed.com/20230331": 1,
    "http://fasb.org/us-gaap/2022": 81,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 87
   },
   "keyCustom": 8,
   "keyStandard": 167,
   "memberCustom": 12,
   "memberStandard": 8,
   "nsprefix": "elmd",
   "nsuri": "http://electromed.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://electromed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Warranty Reserve",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://electromed.com/role/WarrantyReserve",
     "shortName": "Warranty Reserve",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://electromed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Financing Arrangements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://electromed.com/role/FinancingArrangements",
     "shortName": "Financing Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://electromed.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://electromed.com/role/Share-basedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://electromed.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Interim Financial Reporting (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://electromed.com/role/InterimFinancialReportingPolicies",
     "shortName": "Interim Financial Reporting (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://electromed.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://electromed.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Warranty Reserve (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://electromed.com/role/WarrantyReserveTables",
     "shortName": "Warranty Reserve (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://electromed.com/role/BalanceSheets",
     "shortName": "Condensed Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://electromed.com/role/Share-basedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Interim Financial Reporting (Details Narrative)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://electromed.com/role/InterimFinancialReportingDetailsNarrative",
     "shortName": "Interim Financial Reporting (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - In the following table, net revenues are disaggregated by market: (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails",
     "shortName": "In the following table, net revenues are disaggregated by market: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - The following table provides information about contract assets from contracts with customers: (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails",
     "shortName": "The following table provides information about contract assets from contracts with customers: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherInventorySupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - The components of inventory were as follows (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails",
     "shortName": "The components of inventory were as follows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherInventorySupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Changes in the Company\u2019s warranty reserve were as follows: (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails",
     "shortName": "Changes in the Company\u2019s warranty reserve were as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://electromed.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Financing Arrangements (Details Narrative)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://electromed.com/role/FinancingArrangementsDetailsNarrative",
     "shortName": "Financing Arrangements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Common Stock (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://electromed.com/role/CommonStockDetailsNarrative",
     "shortName": "Common Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails",
     "shortName": "Stock option transactions during the nine months ended March 31, 2023 are summarized as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://electromed.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails",
     "shortName": "The following assumptions were used to estimate the fair value of stock options granted: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Share-Based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://electromed.com/role/Share-basedCompensationDetailsNarrative",
     "shortName": "Share-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2021-07-012022-03-31_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://electromed.com/role/StatementsOfOperations",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2023-01-012023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://electromed.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://electromed.com/role/StatementsOfShareholdersEquity",
     "shortName": "Condensed Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2021-07-012021-09-30_us-gaap_RetainedEarningsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Interim Financial Reporting",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://electromed.com/role/InterimFinancialReporting",
     "shortName": "Interim Financial Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://electromed.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://electromed.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "elmd230506_10q.htm",
      "contextRef": "From2022-07-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 20,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r368",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://electromed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "elmd_AccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent accrued compensation.",
        "label": "Accrued Compensation",
        "negatedLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensation",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_AuthorizedSharesUndesignatedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for authorized shares undesignated stock member.",
        "label": "Authorized Shares Undesignated Stock [Member]"
       }
      }
     },
     "localname": "AuthorizedSharesUndesignatedStockMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent borrowing capacity of eligible accounts receivable percent.",
        "label": "Borrowing Capacity of Eligible Accounts Receivable Percent",
        "verboseLabel": "Available borrowing capacity"
       }
      }
     },
     "localname": "BorrowingCapacityOfEligibleAccountsReceivablePercent",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "elmd_CapitalStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for capital stock member.",
        "label": "Capital Stock [Member]"
       }
      }
     },
     "localname": "CapitalStockMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for commercial member.",
        "label": "Commercial [Member]"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_DebtInstrumentCovenantComplianceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent debt instrument covenant compliance amount.",
        "label": "Minimum tangible net worth to be maintained"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceAmount",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_DemonstrationEquipmentReturnedToInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent demonstration equipment returned to inventory.",
        "label": "Demonstration equipment returned to inventory"
       }
      }
     },
     "localname": "DemonstrationEquipmentReturnedToInventory",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for employee member.",
        "label": "Employee [Member]"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_HomeCareDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for home care distributor member.",
        "label": "Home Care Distributor [Member]"
       }
      }
     },
     "localname": "HomeCareDistributorMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_HomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for home care member.",
        "label": "Home Care [Member]"
       }
      }
     },
     "localname": "HomeCareMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_InstitutionalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for institutional member",
        "label": "Institutional [Member]"
       }
      }
     },
     "localname": "InstitutionalMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_IntangibleAssetAcquisitionsInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent intangible asset acquisitions in accounts payable.",
        "label": "Intangible asset acquisitions in accounts payable"
       }
      }
     },
     "localname": "IntangibleAssetAcquisitionsInAccountsPayable",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for international member.",
        "label": "International [Member]"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_InternationalOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for international one member.",
        "label": "International One [Member]"
       }
      }
     },
     "localname": "InternationalOneMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent lease assets obtained in exchange for new operating lease liabilities.",
        "label": "Lease assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "LeaseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for medicaid member.",
        "label": "Medicaid [Member]"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for medicare member.",
        "label": "Medicare [Member]"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other member.",
        "label": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_PayerTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for paper type axis.",
        "label": "Payer Type [Axis]"
       }
      }
     },
     "localname": "PayerTypeAxis",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "elmd_PayerTypeDomain": {
     "auth_ref": [],
     "localname": "PayerTypeDomain",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent property and equipment acquisitions in accounts payable.",
        "label": "Property and equipment acquisitions in accounts payable"
       }
      }
     },
     "localname": "PropertyAndEquipmentAcquisitionsInAccountsPayable",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "elmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent share based compensation arrangement by share based payment award options grants in period weighted average exercise date fair value.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerciseDateFairValue",
     "nsuri": "http://electromed.com/20230331",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r314",
      "r346",
      "r355",
      "r396",
      "r397",
      "r402",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r314",
      "r346",
      "r355",
      "r396",
      "r397",
      "r402",
      "r437"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r347",
      "r356",
      "r402"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r347",
      "r356",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r394",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable (net of allowances for doubtful accounts of $45,000)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r88",
      "r97"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r390",
      "r391",
      "r392",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r79",
      "r80",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r115",
      "r180",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r34",
      "r48",
      "r50"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of finite-life intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Common stock equivalents excluded from calculation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r96",
      "r111",
      "r129",
      "r165",
      "r168",
      "r172",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r298",
      "r300",
      "r306",
      "r354",
      "r399",
      "r400",
      "r434"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r107",
      "r117",
      "r129",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r298",
      "r300",
      "r306",
      "r354",
      "r399",
      "r400",
      "r434"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r109",
      "r338"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r30",
      "r36",
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r84"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Noncash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r129",
      "r147",
      "r148",
      "r150",
      "r152",
      "r156",
      "r157",
      "r181",
      "r187",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r208",
      "r209",
      "r212",
      "r216",
      "r223",
      "r306",
      "r337",
      "r377",
      "r386",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r91",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r185",
      "r186",
      "r327",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r390",
      "r391",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheetsParenthetical",
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheetsParenthetical",
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding",
        "periodEndLabel": "Balance at ending (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheetsParenthetical",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,556,600 and 8,475,438 shares issued and outstanding, as of March 31, 2023 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "The following table provides information about contract assets from contracts with customers:"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r225",
      "r226",
      "r237"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract assets",
        "periodEndLabel": "Contract assets, ending",
        "periodStartLabel": "Contract assets, beginning"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets",
      "http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.",
        "label": "Reclassification of contract assets to accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetReclassifiedToReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract assets recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingTableProvidesInformationAboutContractAssetsFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r25",
      "r129",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r306",
      "r399"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r127",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Financing Arrangements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Basis spread on rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r34",
      "r82",
      "r286",
      "r291",
      "r292",
      "r389"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r34",
      "r51"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r236",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "In the following table, net revenues are disaggregated by market:"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r244",
      "r271",
      "r272",
      "r274",
      "r278",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r124",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r147",
      "r150",
      "r151",
      "r152",
      "r154",
      "r304",
      "r305",
      "r316",
      "r319",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r124",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r150",
      "r151",
      "r152",
      "r154",
      "r304",
      "r305",
      "r316",
      "r319",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net income per common share."
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r105",
      "r120",
      "r121",
      "r122",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r155",
      "r182",
      "r224",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r303",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r49",
      "r315"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-life intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r24",
      "r129",
      "r165",
      "r167",
      "r171",
      "r173",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r306",
      "r342",
      "r399"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteesAndProductWarrantiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantees and Product Warranties [Abstract]"
       }
      }
     },
     "localname": "GuaranteesAndProductWarrantiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r22",
      "r85",
      "r92",
      "r103",
      "r165",
      "r167",
      "r171",
      "r173",
      "r317",
      "r342"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r283",
      "r284",
      "r285",
      "r289",
      "r293",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r143",
      "r144",
      "r164",
      "r281",
      "r290",
      "r294",
      "r320"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/IncomeTaxesDetailsNarrative",
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r95",
      "r378"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Discrete current tax benefit - non-qualified stock options exercised"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r31",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Taxes paid on stock options exercised on a net basis"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Income tax receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r116",
      "r339",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets",
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r47",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: Reserve for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r129",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r299",
      "r300",
      "r301",
      "r306",
      "r341",
      "r399",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r89",
      "r99",
      "r354",
      "r388",
      "r395",
      "r432"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r108",
      "r129",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r299",
      "r300",
      "r301",
      "r306",
      "r354",
      "r399",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.",
        "label": "Other long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r15",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Line of credit facility, expiration date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r15",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Available borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r15",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r2",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r35",
      "r93",
      "r102",
      "r106",
      "r118",
      "r119",
      "r122",
      "r129",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r149",
      "r165",
      "r167",
      "r171",
      "r173",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r305",
      "r306",
      "r342",
      "r399"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://electromed.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows",
      "http://electromed.com/role/StatementsOfOperations",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r171",
      "r173",
      "r342"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r39",
      "r45",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Interim Financial Reporting"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryInTransit": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.",
        "label": "Estimated inventory to be returned"
       }
      }
     },
     "localname": "OtherInventoryInTransit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Parts inventory"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid on net share settlement of stock option exercises"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Expenditures for finite-life intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Expenditures for property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r28",
      "r78"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r56",
      "r57",
      "r90"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Warranty reserve",
        "periodEndLabel": "Warranty reserve, ending",
        "periodStartLabel": "Warranty reserve, beginning"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets",
      "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "negatedLabel": "Expenditures and costs incurred for warranty claims"
       }
      }
     },
     "localname": "ProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.",
        "label": "Accrual for products sold"
       }
      }
     },
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Warranty Reserve"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/WarrantyReserve"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r52",
      "r100",
      "r318",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r81",
      "r104",
      "r436"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r71",
      "r98",
      "r324",
      "r325",
      "r354"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r105",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r182",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r303",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r166",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r235",
      "r236",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InFollowingTableNetRevenuesAreDisaggregatedByMarketDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r123",
      "r129",
      "r162",
      "r163",
      "r166",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r306",
      "r317",
      "r399"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Net revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative",
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "The components of inventory were as follows"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Changes in the Company\u2019s warranty reserve were as follows:"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/WarrantyReserveTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r241",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Stock option transactions during the nine months ended March 31, 2023 are summarized as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The following assumptions were used to estimate the fair value of stock options granted:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r112",
      "r113",
      "r114",
      "r156",
      "r208",
      "r209",
      "r210",
      "r212",
      "r216",
      "r221",
      "r223",
      "r343",
      "r377",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://electromed.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative",
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Fair value on grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Restricted stock - unvested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weight average fair value - unvested restricted stock (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weight average fair value -vested restricted stock (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Outstanding exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding, ending | shares",
        "periodStartLabel": "Options outstanding, beginning | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Restricted stock - vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Options exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Cancelled or Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending | shares",
        "periodStartLabel": "Options outstanding, beginning | $ / shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average contractual term outstanding stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r129",
      "r147",
      "r148",
      "r150",
      "r152",
      "r156",
      "r157",
      "r181",
      "r187",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r208",
      "r209",
      "r212",
      "r216",
      "r223",
      "r306",
      "r337",
      "r377",
      "r386",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r64",
      "r105",
      "r120",
      "r121",
      "r122",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r155",
      "r182",
      "r224",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r303",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r155",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Issuance of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Forfeiture of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock upon exercise of options (in shares)",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity",
      "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312023AreSummarizedAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Forfeiture of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Issuance of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Number of share repurchased",
        "negatedLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r46",
      "r354",
      "r388",
      "r395",
      "r432"
     ],
     "calculation": {
      "http://electromed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets",
      "http://electromed.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r128",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r224",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates."
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/InterimFinancialReportingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/FinancingArrangementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r146",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r145",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://electromed.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r364": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r365": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r366": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r368": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r369": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r371": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r372": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r373": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r374": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r376": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0000897101-23-000192-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000897101-23-000192-xbrl.zip
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MI!:D=#6_(D84$DD?!W:1GZX+W2W0S-1VL'1)NXYH]Y[>C(]R8_AMWD%H'B-
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MA_-%-0ED]6VE*=T&F0M+G@TI".OX=&]2L377:\ZBX"8$T358& ^!MC-:/QN
MU9K%'?#KWG[A_EN1DZN^/5N:HYN;%XMEB%\@S"7\IDU.99.^RG%:=0RX!N]*
M7]+C@W+B6GO?6'25TE>2=_Y:0O=J5?.M4NG6+R[L?OM RI ^)2Q2_; 9894P
M'%J-M W";B1AE<*LEK>[V=-V(G<Y8ZFMEDZKI[.(J*WG+1+U%5#TH4"!4QD
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M10 EK+;K1S^"Z'05(FGPC_HZD,D_?8KO69ICS84$M9AOTZ\".37_0QD0%#
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MJHQLHET-#%/=L<KI\80FBF#,R.<Y>ZJX(,\4N::R8Q&?3%*!&U)F^#L8;BA
M34G0BJ0X/ &N"%Y':7+ZM,9YB>DTSX\N1SZFIJ).FC[I,J,J0Q8YJ($AESM6
M15(5IHFP4"VY4U;P8^JX622 ,4DQM:>WT5/O!VB'FD+2KX'20AW;*4D,#*/T
MV&2KQ211%3T-O*W@;'&Q5 %MDM7ZA+,S55%%V87K1H/N:CXK!)H%N2+%&I/J
M^8I"K:B19*O6-=M8U3LY9A6_LY@=_'CZTLN#L3(.(.4)2ZCPB0JW\@>(KNZ"
M$^PLS=,*7Z0/.#G/*XHZI:90#!<]Q6Q*/DGF5H$AS<P:8(CF!'-*-:%TF*5+
MC-).J[%F,!@W\/,^T>XU3G<:69_\,L(=TDHI"(9-)G3JD$\@,^ ).\XF; PT
MWIW-.)D4?!+'#GS('KTT& I9(4HQ"HT"M42MOPU@FT"@-CJ*(1QKO4<-T94V
M^M! +,=%&BW2+*U27%(_C8=KW1=9@DG)?+;JV7+,ZZ[NDRQS*S6DDZLN&(LS
M$[#TT$.OSEUO'JK7%/#/2!0!B:5NX0<FA4!,= A$T$M#9-N\D(2!8G ZM<>(
M5]$SV]1R.P6>"H<X_U4#5IW\CB7!T,<(3WO:NQ;2P7ESNEIGQ3/&USAC@:3R
M6-#4VD'/)YN<JS$DEE4)#,=<D2KH1FKJB%,WG)V9[#YOY(:FBH'JEA,VJAGD
M/1LL,^R)S5(+@Z&4#:'A[ 2*[;HB15+'U8\1(5%.O4)6(^FY'9NPYXUQ ^#)
MEKA"$@QYC/"D9YD:*4118/(0GC=\G\MYIM-*>]^-=)O5-*)@N&/&I]F3;.:Q
M#)#'[4R@T-QQHTU@QECWGYP9,S[/!<H83NO;^RB_*/*["I/5"5Y4UF.1.04$
M8IACQ33,LVB#L6&S(:O-6D95#ID.5)K:JQ^,:!8F@35>1JL%B0;LNG-:\;NF
M[.I$P=,*X3S6T\*HX3=^VPI]'+>M%0=C<>P8Y3CM3H/O@H]T@K-+WM2G"\RL
M9O?HKUC^AB(_JBJ2+NJ*+35O"V916>!YD5$4=SQQ*RYM6^:[_HC?J\;[:*#Q
MI>1=?@',2-E+M:2+SA"/E :I+8S7$"4QW[99!7)JD(<R8+BE :8RO46.2I$I
MY(]OOGGS%JTC@AZ8#EI3SZ]D_#E ;]^SNUOL/^(OU%+7U7U!TM]P\C?TUX,_
M__DO!W^A/S+[_=>#/_W+GP_^]/ZOK6C*7E)(1!1\GX7D $7\7MCWM(GNT?NW
M!XCRY#V7^I]UCM'[-_PO[P[8=LP:\^3767CN'B4)3Q$095=1FISGQ]$ZK;2;
M>5IIKQO"9LBC[6"U*!A>F_%)IPJ=-&(7,@[3',5"(3B-KG$5I3E.3B.2LWQ0
M1W%<KVI^:'*"E^Q5<$T+N"CZ))=[188\LVN!H9PSU"G[6D6$&\W@I),]#F?7
M)+1/Z>87PEI,:_&IU]3ER%7#,%PU6X33AH%1L&+2-HE%@T4U1[36S1SN?H$D
MXE&;8N"L("=-?@$YBX'E@'Y>&5Y]M$VJ-_+<YA0 9G+=!+5#8HJ#/B.%.B%%
M<#H/%FA7$;DD/"%9PM=J5YCP5;M]::?7#+10ME5%LW;6J8&AJ3M6\PJ[7UM_
M1=<B29%E$2G[=3:$W"B3I*-'W3+?WC2R1B :ZJ!KZ#<5AT@[#48SW?H]&GC$
MTN<9=E,)2BU-CF$7>;CDLN<7'K.KV%-&X9W0B[_>ZFRS6NF@I!I#-O))B,*E
MT@B?F45B<S@X@434:)<6UG)>IY7VGQ%%"UG.BB*)@B&0&9\FPK?/X0LH6^\U
M?L!YK8T\Z'_VNT<[!C7>B16_@>'"!-"T\S_ABB[TA$CPWCXNRNIRV2#6&L>1
MC-\I1@%O/+$,!, P0(5*GD1*GGD2#!4^DJ(LKTBQU)[<C"1\TD !;4B"P<^P
M-C5E8%,6< FTYB+!&7!)U_$1BUQJ4L;9<K8;Y+U&[-M@CV+V=<)@C(<-H13@
MVLIWZ?J"$^D&\PB?CSBGT+*C/#E*5FF>LFJP((BF8KI#)T=EK\=YLRHT.N)S
MT@1#OEEPI5 MH7R [H0Z/XN)1@4$I^8U+C&+UZ%5.Z$S;U;P3&%F1EIT_#K"
M#O#'WK%! 0SM7%#*T0E"A[,LZ;6"4TPRX*Z&/O"TZ31=PG*P=/#4Q\0%O)FR
MJX#8$KB@WJ"MJD/)('R1H2H9TXL!Y8P$4.]9B?1:P=G2ADP+Y WG3<G8=>)^
M=_G,H,?;?&I9,!.5!:"\T2?$&P+!2 _9\_Z,=I2XK%)3EC=T+_+R UX6! \2
M%IP^4?^M($F:1^29/4M=JF/YC;NC>_JB_QWKO3:=O.N]E\_!LLG[KZAJ%[9)
MFKC@1<-*H=A5M#$Q'^B*2K\QIY4.DM]>#5F9XWXL"LC*F_ 9\K4T?F5P^E!V
M6QW*B8Q/JBCA#0DR$H!EJE30],8E.!/:H/\VRNM#5*:Q95_7HN,UVY@+_%&F
M,9,"& /C@E)C9KI8N^]@<FM.C0%PR9E#L+FCX0S_#1Q/3M*LKK2Q35KID%R9
M0#:QI1$%RY<Q/BFCN/@U.&=^Q.G=/05R]$!7 '?X4[U:8'*YE +]7.:S#<OR
MR;>MJCMDXT8%@>'J-NBE9'A-68>1*(REYN1A>^).]R#X,_Q,.JO>NV@[P.S>
MFM5>V4P!+8H2FU8,FX"'.9%K:M+,&:YA\;-+ 4!56Q4=R*HKXH70U0(?JA_1
MQ=A>+MGSXF=9\6@+:S*K^+U%;@<_OD^NEP<SQSN E )+ND#I8HGX*_%<"U+8
M-'O,F0*[(L5#FN#DP_/GDJ5\[HX0CUCZ%W&]V<R^30KRO'>W844G&WPS2P'#
MWXVA2Q' /9'9J0?JCYO[(DR\AK-!^PY2YRAP =Z?/4K^JRY%[L#;XAJSODDS
M/*K&;;$;R[*?3_G- [6_QAHGD=K]=\ ,D3U63DY?U7T*505+;R ^QL(@NO/6
M@O];S(SANODB6CP/@K6B[G/A%^HG>$UKD?(S:4W[CD7\OH<H@QN_@-C_#H:.
M"E#R*X>]2' &'*U8:LO?.)C+Y?3=6-V8LRAY-:).%1B90Z,&&"8YP91,U$")
MK2Z6IN=]@Y.O/?#!R?'@G2'=0DLC['4%:P0\6KLJ)<&0RPA/F;/V<,&D1P]"
M@8D/D1Z:=0HSLFH%??S7'G9D48&V$><&]V4\"4SK0# =#R=8_._ FVPRH-H3
M%C@7X#GJ;6;%)H%PCMI@#.%LR-*VQSW]-Y94.1_Z^'Q^Y5=Y!LG\POO[<FWE
MY&[.#:52#<M5?67,+)7U_/#S6\'/'-_QQQEGT52+V2$='T >LB!I-LI^3*O[
M8[K*IK:><$_7N4$,)81EI;5J9G)JU>%SU 9=3B(AY*&L3^0:G></.*<?TK]E
M8]$)2T4%?#/Y!@KPZ2:#E8-..PF Y+HBF*7%;R]_\J>^G"NO5@Y+-U.%S+Q3
M:<(GH 'UE(F-:'=U5[S&(=ZLA&K\)@^6SW95.CT87N*D&FXN8J,$>/VB1FJX
MY3-,TPSD0J>Y2BR/AWC7U?[BX*:%@:*HL<*S>*LLZ>60V01?N^YI7AT7Z5MV
M_QXPSE8)(_'[-^_?O^5$9G]IGTDW;&SKQ7R0SP:2T4HG V4FMN!3,()W_G /
M.[BU<X^_V3J !VIDU7815>#N4\[#K0KF<8H>@,I<ML8J=Q$C:"P( ),=*NK
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M/-4%V"U.> UGNECT%21_YY+<17GS*/9QD9=%EB;B^EB>7%&$[%:#>&6[N;1
M5S9M0(<M+<*.RO8Y9>RT.894WTG!8*:57=9F.EZ&91^@4>G\BL*P?#85=5]
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M<RQ/]T55P#IT4I7L#IU))3#%+ Z=7AXRR>R>7,LR *[<"5Y4SM9*)^R316;
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M:<.5566PS+-=.I@]&N#,+1]#8;*I*5HO!9:8M@,7,OW 0;^F:!'B^.R)/V:
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M5W*;4VBR4C 6@>4YIK*!SC#X6[?B3Z)/JW'?$9W]-P>'A? 'JMWJZ=B</\E
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ML97U%'DT_EM)L+#F;*IJ,U@V^NV0RKM#JOU^(67([>UO+Z@,PYEO+ZAD-&^
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M7%Q]"T'8>0A"M\@#\.G'X'$'/BR1%/)9+)C,-?W@S\8R[4@#7UI5YSEC6J6
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M3C%%$6LQ.YF%F,[#5.G+6"53'; #GRZ@MVBS0P1\\M;PQN5L<S7[M!J!VI6
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MUX:R(LQ6-<CBK(!LFLYU547K7LO0Z6_T*X(".$U6U/*0%901*SF/OH!J<WG
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MQM?H++-_SU0!4@J,([_,KI8;-[I39>A2F[W!Q_#!/I>F)# W-V@(ZV@RZS6
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MP)FM$G4P(5KRB)52Q@<IH@TG1/\+,6\+/DKBOS/GA>Q8^T*@F9%F16$ O^4
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MR DG&1@.S9HMZ3>=?QJ^L!QL#SHRDBQAIT_@"-/7;H'^:K)'DQ=N_!DAL2@
M@AU>VOL[NZ+(]"-VCA9M7LUU3._J,.HF1$.<Z+A5'6=S^TY-P=E$:1?=JFB7
MB3$\5U>Y;A>0%<<@/L&WT 3Z]XP^6_'5J.VDFV-,(QE?$G2&/F<VH%?C%_TZ
M"</SF'<>YRY*L8!TXM\/K/)"-"3PSUR_V$>_+Z<0K-90>P"^6("B_MK$HX5%
M**U8A$>=5>"#XK0%QK*B.1L'O39]N,[7?^8HRK=QZ,O*B-7^/1/>M<N>+(N
ME31%!TY68V5,B,W%?";[Q=6&. G69$R^\-<BYH</!!+.%)'L'Y]*K4ZU=?^;
M:%6;C5:':#ZUVD^E>H?H- @8M'1@8$)0#-%H$53V;_X?HG&S&$?G6Y58!#:+
MF*94[L#G"*K(9 P%$\+ [?IK_^;-A("SSEA/$Z#GUB+V&UDAM"$@7BW!$T;.
MCP 2#WAB%</9%0PW\<-58XW"&<&#4O];IOHSQ\ZR@2"81T5[\+TASTZG@%6
MY 3DI8&=74&-Q T)ADH1J%E7- <O=BJ7/R>SR[+?.&N@.G$TMH?0[PNYEU>]
M68655 $M V]27M_[#:;%O$K4#SY(Y=5G1=51>ZV.RE1?F=W4UTIPV%OVG4)2
M:9U6J=ZN8<65Z+2 =)HVAX.EU/H0:(0]&[C_WYH<;'O$>2AJ*,M@[S)$<3F)
MQDFUH$/9!16MFA$W G3?Z_+YI6TH*XJ',A5/%:]TH1?@',:+TTX*)R/J$XT>
MRZ.;7 "A]&J?:"612C.9 E.,U((4-P8&J_9D8Z2VNARRRYK"/L&7V9CAP+.Z
M)L_=Y]S&<&QU&.C5W4(T3TI]'LWOX/;C.-)7PL@M563@K04&Z(Y0Z*.C8@%G
MG+_^>7ENDT^C9[H7&,Z7^SV[JHJ T^#[@$\9W*Q)W+F77%),@]+J.\MI!**-
MD/O$@EJ"58GV&'"H'( G!"@8327*0^P._^-$5(PG4^$@D\EQT7"GR90I[#J7
MK"4JDX\K,XI9FE$0N+("_4%\91W>]%.6=1@"3\LR[S+!*H/KW]7[ GC^F0_"
M<TVK@$/E7QH8*_(;FGG+48N'<<(81I DH,H:ZS()B=59Z!9B9/[:QMB5Q2@/
M7O(A,;#99^BP[S6SW(?#G-WD0,R86AZT6N/&PR PQ>HR@+.K#)6F\@Q=I$FO
M$HVC7L5 ):#++:-#?(AG71%47N"PVPT5K6 '-7Y,&;"2,,._.R<('7-[49!2
M.V^=M\\)LRI/(9;%ACQ51X,0K32V)3[#Z\XOO9M5!13*OGZR<ZR(/Q,D)$.C
M)F97/7*SI$=*/*\ 537_01O/*9<@9#)L]>A*?7*?"4R'.'1^=I4ER46PT89F
M9DB4WH"DPYCJI]=%O\!BE9!DD'.201G^V% Z\D1REH#R+KQ*_-VW^_O@M/A:
MUV=7D#$+!C85=J #%[:GML2U9N-8E3:4)O01H-IT<4UH\+-3'/2$W/MS=*Z)
M\P W^"2$#7!KI2TKRBMT7\0)F:NJRW@Y.&6T#^BK3N!HRE!*XA]A[.ZU9INO
M<O%F7"C]&0:-^Z7>H>K)D7EJ@XYQ%GD<W1>3/N2JC!4(:F',B@1X!YRN"6\H
M5(3F'Z@Q<U2@' @DB&.+3X\UV5/8.==C3>V_W>8V,B0E!;#NL_FW]/[\WOS=
M^R7T YC-]O[.KHI9VF7V_F-R<V78&7/8]S+D?G,H2QOSL'3SI=G7.]IKSG_X
MO!CZ:I]G5_EL(5VDB^YIV*C#IN4*A1QSGMNUG,R8V(NTU/_];X&F\E]4V(@(
MQHAX0L+4IU!()>JH.X*% H4,]:X(]DI$4ZOK!T&U3 K0FVI#E:L(F@!?53 7
M@ )X8JPKJHZR=)H,WS>B2HK^N_</U,R?/Z%5GA*G708['$="#UYK%%;>A:&#
MRKM8.L*4Y)2B>_A8%6<=4>]5.S_&WRA280+0$:M]&NM,LF3P#V^Z2A'_(<])
M"LY5A7AC15=GW7,>C8YE'LV_/,T%R%6QDJ98.PJ+<-Z>CGJRZ)(^>_C=^$'7
MOCVU@PA]ESH\NZK>/U02D7D2V?7*3*R^<T-6&@#W%:7^CZ>;ZF^^FLW1@465
M /:Z'E ZC0G&TK_;58/1)=PI).?^OGS,>5&LAE!8 5AN2'#HB+&811'F_"*,
M"?:W^D_,QF>MU6$& A,N!'0 )D,!?K+P$H[6^SF[0@>.<2B!WIL2W!! 13)"
MQ;.3(<#9=.3@*(NERK\IZ)X/697H"R)TCEA1A-^B2B?D,[WJ O*8H*/4 ^8#
ML-&YT\2@Y+M1.@1YBAJV>5S69$3>%/H:50P1//P6P@,].E8 !S!8*/KS)UQ^
MIQ)_PP;AG"=4'4I#'<IHQ=2JM-&&K+8Z^@F[/$PT1N-EDXA_4@0K\<3?]#\$
M(K('-0?\OO<,24#/XT?A2W 8GS^9#:&R+Q6/ @^3536B2!(\.U7/U[1B:2FM
M4M85!;YL5(HA,Z.QFJXZ:\>?K[\D6;_+EG-!^"J;^C^[^HTVZ#JK/;,8EZC+
MQ+RP+3 D'AC:2.!0UB-!TP#_^1,PJ@\DI,/%*0&@/I\2-:0U6 XG9BJLQAH%
M1"O(GS>R%#N@K:=$ALR::_^Z:"SIM-,=XF]$>?X+S=#GY@/:4% _?X(S8HQJ
M -SF 1'0-# &/$<W4/]9AVYA94%[S@?$!A-)+KN+"@^_<O?94I'W;]C7%ZJ=
M^M\$W<^?3AB[GS\)*L$2(FP"$"P'8T*T81\*%TE303K-\5,"LBGM^(4Z@J"'
MW2B6;H"2&D$V3I$*AZU!K8=&.R &BCS1AA"JQM?GD!J !\>#OB#ATD><V43)
M!)K\XC9"_#7UQ7ILZP-KXYN/P'H0J7'SX97!$BM/"I(Q-V'@EJ8MRV0W1^?A
MX20N,?WNM1+YOU9S3N1YCLZB/(IKS("WS=P[0V Q)P/9L&,.,\NL#;.0.3?*
MX#:.LN1E?&$[_<Y+[?OF!BT&1%KB[PLJ;GL_%F6Q2AE*:" K4Y>%\-&K]EAZ
M>\^-7H*+*7'G&!.<V;G3>N72Z&!TZ:1IMWA9SK%0T-6]%AS:KBI_<U4"?N]:
M5P4)J"[.ZXOPIW;WZQO3;!?#W$+F,)[MV\>"+Y=>G5_A]5!U-FQK EM>S;7>
MNL4OE8UWG 77XY]?^>N':G$JAKI]9L/ MN^@B4*"(<7UT,WK.[A3EB#10HNC
M%RA@)P6%H$O1"PY9H'*19!QQZ*KABD$I&7OI'+:C0'<.=29.4>\3 ?:- "3!
MT<M(%;P)*E96$BMQ BLBLXT*0M'#Z+PNGE5X&*>@N@V!=ULK8?YF_W%TJT[.
M#2>P%ZX.H?MFB?#SI[^A8+ S;-1V;W8U8> %0QB+,5N"L#;J:./\;63>;LC9
MZZ10#J2(>,O\M8\'6;RMYBV^8N] X0)B@OYRRVR;.12\QH-7=XSSVAJZAF<&
MG")=H=8="WQ7-[[!(F+(+'1C9I/F[U;O=W]V^VNQ)?4&![1PQJSE:3;T<;8D
MQ\4YAUGX9UEVDC[B98T'G  -Y!EA_J#^>U:KWYP1Z&@SW(1UZEPAE<U1*1AK
M6%*TAC<7HW&4&T*Q;:,&WJ.!P ]'#*6 %KV@?K#6NZSU+W1D(GH[1<@+4M V
M"'-*<**LXL1KS[3C*.?ZP$Z)K+%]-KB(+.1U9:/EV!V_9ELJ<EQ*LAW/%NWQ
M:\');YG;J,\OL(%7'4@<(N4+89PAK5ZBCDQ;]87X@5!Z23#&^+!'L<Y(BU>W
M"D0DLV"574IH?6Q-4#G'S:(.!P0NZA)6W1#C7,'5@8TA>>F> MB7= _ 20])
M8,4).U67!Y4+?4QV88=TS)[K1L15+13T*7:D^Q;('O(3P#MR>^;G5Q!&7OWS
M)[3-%.IAPC@)J1?XZ7KNXPI#HVWD@Z^TUF(T%Q*R5^*V06TY$@EKJS3+/^LJ
M;!=:KOGGF@(T;H@^0]WL>"R20_K#?+^863_#R/%@A2V/899"NVQN5;F$1AG2
M*0J( "N?M;),CV?L2AK%O9FS*S0G]\E@[;[WPV&TCHFG]3<=1_*5)88*\E/^
MER6AK_M&X=G7++4Z1 WG>RFHVF]J]5*]7"O=$]"W:;0>2AWSG,BO%^PN2\MK
M8W<OVMZ'IOUY&L:XUG-V9LK.+@$:2Z"F :C>SJ'FM^+$^<5F:G@LIT*CBEE0
M19]#OU."LP81,Z^(K @JIQLG"*!UAI+$BE-5P.[K@@=E&;JUFO5,"ZBZJ.%'
M&F-@3,TPF1,>=S(+[C#GR-ZA((7%2Z*(4/B!:/V.^ 1=>1W%":4>]/4)=# 7
MT(B6H+Z$2'P^-.*S"^(SYTC$T.,054QX4Y$YP.OX>.O0*"N<DHI9X6UN69TO
M]'FC\ZW:2G1YR+H\OZ3+[\$ ZC",:5QN$#M0>Z*I8*.I=([5#G'#XDL4CY*>
MXI)E>I)L=>IM5C2S,:^ZH$WMM55(.ST9"153H$=)/44N69X*Z+/8I#Z-41T-
MD 19L5%]E!122^;E ?KL4*Y] ,5I,Z5'29G-4\R>$PV</:])1H(2ND(ATE0,
MC2:;GY@[)ZKO0Z$GA.KQ+I-B._TVTN@^D)XR6>;<^S'B&U)Y=)*U.X*L7>8\
MOWD_&EI@683T1HK"+:S__&G)%PSC%.^=SW_V<)2WK_.Z/9US!SFV-8.SGH\B
MS5.='0[.S9PSYOX.TQ\T/&[CX66)T7:)H</H'9( MM>1[OJZX=SNP$[^V[:A
M^.@STAO/FN]=H?0#D-#R_34K0HE 3V(( #)/0:>@?9V7OFF^6(NM# RW*>@3
MS8I]Z=>8?JKJ$&J$JH_@&*;XD<L%R(@TX48R\?>3Q.J\H '^'R\'ZWO/"UN6
M>:-5=SK(9K6&SC/\++?$PCJU4LJW&(G]:'B+HYEBP58>(&:_O0^;G5I-Z*^R
M9<O6,L_#=>+#ZE'(H?+C<)S.='%)1HXAN[-QOS7^,\@*S=)+E)S^KL, @B$Q
MH^FP&;UU*2'JR>)!6OY8X31>FXH);M"NL8,##=N9Z"*M.6)1>9%Y760Z75)5
MJ#E+/539Q&E=X;H[R[Y6Q<:;^*-/<V>;9?R%Z$$P#Q19EWBD864%QC:#WM\T
ME4G1&29%,_0_KN7$GAEE#'$SHQR88]QHXHRO+:M5WAN,TVB<1)U;$[6YAV8A
M<9*",I_\*3.#"3=J9/(^9/YS*&C O6Y\QZEF4&:.DTBD[U_ZUS;IEUEU6))X
M] _*'+ZQ(O+82UJ95114%8J#:X@&NM8=L:7R[$ZO=V?DK]=BLUC_?B/08:J"
M'6*E_.H!.8@3SA>W(%)Q3I1#/X %T<Z*>Y> ;<L*OX\&G:; ?_8?Z.I^?ZN0
MP+$4T;I#V!-4W"H2UZM)72L225L](K[--Y?*YW,ITK$8<6^1.7%XD_>1X&%_
M/-!I,I=F2+]X**2H+',H/&Q3J"6C1EYM 0Y GL" MPXT:X?LBA[-#55Q.,A5
M'NHOL3"OS@K3HHA0YB01?TL []-G15&>H%C;V //RWI/Z^OSG0)X1>H_JS74
M%3N[K 9N9*5BOKW.PCG_:F89M;$KOE:_D1_NAJ_?H4>JH>,N(,+6!YM:C-)Y
MD.M;S3+[CM ,_%Z&MWUZFIT!-K=M-NW431A:-NSA[3GI,UF7&>]<GVZ=)N=7
M(P2EN8,W+COKZ4T:*0P@T72*<956$%0'P<>/+-\]9R)-I<@L':E\G8SNC3V*
M0958< P_!6U8UE5H,(&"(T1WVYL%+ GY18,WYM QC,>XQ:218)="WP\,? ]2
M#T._9?-DHMSB+N-]=5PAZ(!SOZBB)KU!2F5E"LE>U60ORO>;!IA4?W7\:++]
MHP@G966-%U=B?7@0VZ47AD9B4IDLE>BDV(AS3^7#I*A\X>#JIV13/TT%C%F!
MK[Z/T0)[2>)Q!=_2RL&J5J)O[P9/DWOHEF:/P[\R:22 0:11-VO<*<29BPZ)
MYV7.  ]X"$//4:D"&>W$2*3L0\I[JC\HY8@][&WA);H8;P0Z[/LBQ%Y5=\^/
MPL]BX2U[7XS'2JECQ8:;KX:H(S3VW98T]<]J[X4S.U7"!#EGPNG1H^^P!J50
M<G!4,> 9Y BGX)74AT>/?2\W.G$N+;RGAP+/ _@,U$RT\-Y31))$!P&GE_9R
M1R14)UV9=2LG064D':@F-5--0GTY>]/$[NSMX>';$PLFMS^%&!03;7<1K0T@
M'5ECQ<0?7$M!A^WY,=D4E0M:I26NWQX"W3?&S:2R3+0"W::YFHH\ABIHVA19
M28/>+BIJ&*/:<B/G1M46ZJLVJU8'?/FZ7RS&PMM#T:LQ>!RU FOD*4("6@+G
MRTVB#66)()4EHUTA2\2[BWCWK45(97.'3]#9RVANT&GKX%YX WQ-TEAI(,#
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M]JE?KKNS:P'\N1MGY.]R1$6PH64LT<'OAEMMC,&X?-7\B- 0IY+8U,MD#0V
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MB("X8 N(JZPB066K-H'2'K(*N&95@5NZ96HT?'J>O'Y_'/;I* )C;XO=Q!A
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MX%%*=C98#/A"=*9CR(:2PO8$[@M1A\K&8%)=1IRA[2]=6&^A;Q9,_GH!&>?
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MC>'GI"+)V6N2$Z_/"$W0$&4V1O7F!R[]#14)OB-$720QY@F(OYQ+:#=OQ=]
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MQ9W(Y<)1!5 4E<KGCC^ *AS]&7*%HT_2%N*;I/5*00BW"Y>VV"RGVX4+V<*
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M&[6A(NN0D[R #E3OZ9JLJ,%Y5 ? ;,U.*Z&R(FQK B#G_[,\H8ODM4V1M2!
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MQHI\8XA8:,1P2&(.T'H7QR$C%EK&'F+L4(!:B2<L4]W7(;.F,'@Q@@97*"A
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ML>:;Q=%8EW35XCD(1=7RRJP];.A5_(ZQDPW;[YX,50WZE</XY 51UPQ0S7N
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M;P;)!P8":UJPW0 _D48:$=L&[<$B#<Q258=2N70U:I=.NI_[[I?FSVQ4!XE
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M' D\>NQPS-,!("CS U!E8<?P4]\!*4'8 SMS27@;2,QV7/4@)  &9+M$ZN:
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M%@4PL8$6.F)[7F_@B!R,B"-3.D" 7H@N&DP]@!V#16I]I U[K)1*4SI\5Z@
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M/VOJEIX5BXD+::%-!VP8L@LMW/_;O:O1Y?<+[UNS=OW9+W)*2<M#G8RX.)?
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M\W8,&DQ$O?Q^#6PQ&)/K?#513GYK!S96EZ.4BY AJAD5 X.HT)HV2=7AFF<
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M29CW/VI[3LOKZ7OVTT3F!<5&QHBNBI!&OE%>(Z:OUD9:2H1(JW;SA4AE//>
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M/LS_O],:/C\>5U(KBG'>R>CMZ%>[>7)4[]6>"U>*52DOFON;CJ*%?#TU])#
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M&<:-_/@0Z(.KD7_=;'DM[_C\@_[JC:;LF*S<V)Y7,@IZ#3&?RU@41_,,0P^
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M=5@1&UX9';QKO2^NV#(39X>SP@@G@LOKLW3L6+H#9HSMLES' Q F"+&&G#]
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M3YD# W&_U^-BO?? K+0CGYO7#K7]#C;@^8Z5=6>! <*=U6AYM/='^]_/P@V
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M>2=@)-L&FJ<M$2&@;8.L0"J?SC6UUZ'N&3($A6O )Y#PF?5U*-2#CC/V&NG
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M.\5ZOD)5?<TWIS:6]JHX+?TO6B:[*N3+D5-IUJ9J8E-$3=M;1$Z\F46OZ+?
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M+%"%#OG3VTC)L2<:0A;OKGAUQ0,+=YOI 9%0QO^VU=E:\%2_1@@\^"6CQBC
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MF5-%B^UNY(UH6?KI(( ?_@M02P,$%     @ O8"I5N";P(-C!P  7"   !4
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MT%3 ME;5YF45F,O?!+3+'P@,VN5O"OX+4$L#!!0    ( +V J5:@5@B$40<
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M 9O27;Q:WM+N33TOW0JH_;2RO\(/F^WBTT?IY\YO;:PEA9^ I@*VL:H6+ZO
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M8C0FL+VL6CJM*N;ZVZ-5?XC@ETGU[?([4$L#!!0    ( +V J5;3CM67*@0
M )4,   5    96QM9#(S,#4P-E]E>#,R+3(N:'1M[5=A;^(X$/U>J?]ACM6B
M5DH@@:6Z D4*$!8D"BQ)==>/)G' .L=)'=.6_?4W3@BP;?>JN]-J/]P)"8@]
M&;]Y[WF<=,?^[;1W?M8=N\Y0__H3?^KVNO7B%P?JY4Q_/KS'7_WI+L#S[Z?N
M325*A&J#;:6J;MNMC^"SF&8PHT^P3&(BC&+  (]*%G4@)G+-1!LL_-B-5'5
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M,S,Q7V-A;"YX;6Q02P$"% ,4    " "]@*E6 (C+6X@2  !K\@  %0
M        @ %V%P  96QM9"TR,#(S,#,S,5]D968N>&UL4$L! A0#%     @
MO8"I5H;A*0B'.P  +DT# !4              ( !,2H  &5L;60M,C R,S S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( +V J596U@+B*2<  *-H @ 5
M      "  >ME  !E;&UD+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    " "]
M@*E6#2[&UA7G  #75PD $@              @ %'C0  96QM9#(S,#4P-E\Q
M,'$N:'1M4$L! A0#%     @ O8"I5N";P(-C!P  7"   !4
M ( !C'0! &5L;60R,S U,#9?97@S,2TQ+FAT;5!+ 0(4 Q0    ( +V J5:@
M5@B$40<  $,@   5              "  2)\ 0!E;&UD,C,P-3 V7V5X,S$M
M,BYH=&U02P$"% ,4    " "]@*E6,7:N ST$  #$#   %0
M@ &F@P$ 96QM9#(S,#4P-E]E>#,R+3$N:'1M4$L! A0#%     @ O8"I5M..
MU9<J!   E0P  !4              ( !%H@! &5L;60R,S U,#9?97@S,BTR
:+FAT;5!+!08     "@ * )<"  !SC $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
